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Myelinated axons are crucial for rapid information transmission within the central nervous 
system (CNS). Myelin injury is a common feature of white matter (WM) pathology in a number 
of disease states, including ischemic stroke. Myelin disruption can lead to a complete failure 
in saltatory action potential conduction, resulting in devastating neurological deficits. 
However, the fundamental mechanism of ischemic myelin injury is controversial. Glutamate-
mediated excitotoxicity is now recognised as a crucial event in the development of ischemic 
WM pathology. This thesis investigates the potential mechanisms of glutamate release in 
central WM and examines the hypothesis that NMDA receptor over-activation mediates 
ischemic myelin damage. Using glutamate biosensor microelectrodes and FM-dye imaging, I 
show that axonal depolarisation in the adult corpus callosum evokes rapid vesicular docking 
in axons, capable of elevating extracellular glutamate concentration. My findings show that 
vesicular fusion occurs under the myelin sheath in myelinated axons, which supports the 
existence of a novel synapse between the axon and overlaying myelin. Simulation of ischemia 
triggered an early and robust rise in optic nerve extracellular glutamate levels. Unexpectedly, 
a significant component of ischemic glutamate release also originated from axonal vesicular 
fusion. Together, these findings show that the axon-myelin synapse represents a significant 
site of excitotoxic injury during ischemia. Resolving prior conflicting results, I show that NMDA 
receptor antagonists prevent myelin degradation and improve functional recovery when 
applied for sufficient time to penetrate the sheath. Finally, I identify a fluorescent myelin stain 
(QNZ-46) which is a negative allosteric modulator of NR2C/D-containing NMDA receptors. 
QNZ-46 selectively accumulates in myelinated WM regions of the CNS following systemic 
administration, and is retained following wash-out. As a result, QNZ-46 provides persistent 
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1.1: White Matter 
 
The mammalian central nervous system (CNS) is divided into two distinct regions; grey matter 
(GM) and white matter (WM). GM regions, such as the neocortex, are primarily populated by 
neuronal cell bodies, dendrites and glial cells. Conventional neuronal synapses are abundant 
in discrete regions of GM and therefore, it plays an essential role in information processing, 
learning and memory (Bakiri, Burzomato et al. 2009). WM consists of a collection of compact 
axonal bundles and supporting glia. WM tracts form the connections between distinct GM 
regions and are essentially responsible for information transmission within the CNS, relaying 
electrical signals between different neuronal networks.  They are typically grouped together 
in a source-destination dependant manner, forming groups of association, commissural and 
projection fibres. These connect cortical areas within the same hemisphere, between 
hemispheres and to the brainstem/spinal cord, respectively (Wakana, Jiang et al. 2004). 
Although topographically segregated, there are no distinct barriers separating the two regions 
(Goldberg and Ransom 2003). In fact, WM tracts are known to run within subcortical GM 
regions such as the basal ganglia and thalamus (Filley 2012). Interestingly, WM occupies 
approximately 50% of the adult brain by volume and is estimated to consume between 30 
and 43.8% of the brain’s total energy supply at rest (Filley 1998, Zhang and Sejnowski 2000, 
Matute 2011, Harris and Attwell 2012).  
 
1.1.1: The Axon 
 
Information transmission along WM tracts is accomplished by axons. Axons are long 
cylindrical processes extending from the axon hillock of neuronal cell bodies and projecting 
to distant target regions. They occupy approximately 44% of the available space in human 
WM (Beiu, Madappuram et al. 2011). Neurofilaments and microtubules are the major 
structural components of the axonal cytoskeleton, running parallel along the longitudinal axis 
to maintain a cylindrical shape. Microtubule tracks also play an important role in intra-axonal 
transport. Anterograde and retrograde axonal transport is essential for the supply of newly 
synthesised proteins and lipids to the distant synapse, and the clearance of misfolded or 
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damaged proteins, respectively (Chevalier-Larsen and Holzbaur 2006). While organelles such 
as mitochondria and smooth endoplasmic reticulum (ER) are present throughout the axon, 
they generally contain fewer organelles than neuronal cell bodies, lacking both Golgi 
apparatus and rough ER (Waxman and Kocsis 1995). The axon is surrounded by the axonal 
membrane, or axolemma, which is structurally similar to the plasma membrane found at the 
cell body (Waxman and Kocsis 1995). The function of the axon is to propagate an electrical 
impulse known as the action potential (AP).  
 
1.1.1.1: Resting Membrane Potential  
 
In quiescent axons, the resting membrane potential (Vm) is approximately -65mV due to an 
unequal distribution of charged ions across the axolemma (Waxman and Kocsis 1995). The 
resting Vm is largely maintained by the activity of the Na+/K+-ATPase, an energy-dependant 
ion pump, responsible for maintaining a gradient of positively charged Na+ and K+ ions across 
the axolemma (Wright 2004, Filley 2012). The Na+/K+-ATPase extrudes intracellular Na+ ([Na+]i) 
in exchange for extracellular K+ ([K+]e) in a 3:2 ratio. Thus, it maintains a low axoplasmic 
concentration of Na+ and a high concentration of [K+]i.  
The negative resting Vm is a consequence of a surplus of negatively charged intracellular ions, 
relative to the extracellular side of the axolemma (Wright 2004). At rest, the axolemma is 
slightly permeable to K+ ions (through K2P-channels (Renigunta, Schlichthorl et al. 2015)), 
leading to a net efflux of positively charged K+ ions which drives the resting Vm closer to 
equilibrium potential for K+ (EK, approximately -90mV). The equilibrium potential for an ion 
(Eion) is the theoretical membrane potential where there is no net flow of the ion across the 
membrane, assuming the membrane is selectively permeable to this ion. For the case of K+, it 
is where the movement of K+ ions down their concentration gradient out of the cell 
(diffusional force) is equal to the movement of positively charged K+ ions into the more 
negatively charged intracellular domain (electrical force) (Barnett and Larkman 2007). The 
theoretical Eion can be calculated using the Nernst equation; 
Eion= RT/zionF In [ion]o/[ion]I, 
4 
 
where R=gas constant, T=temperature in °K, F=Faraday constant and Z= valence of the ion. 
Reviewed by (Barnett and Larkman 2007).  
However, the resting Vm does not reside at Ek as the axonal membrane is also slightly 
permeable to other ions such as Ca2+, Cl- and Na+. Depolarising inward currents from either 
Ca2+ or Na+ will contribute to the less negative resting Vm of -65mV. The resting Vm can be 
calculated using the Goldman-Hodgkin-Katz equation based on the relative membrane 
permeability for Na+, K+ and Cl- ions (Goldman 1943, Hodgkin et al. 1952). 
 
1.1.1.2: The Action Potential (AP) 
 
Neurons are excitable cells and their capacity to relay rapid signals along the axon cylinder is 
accomplished via the propagation of APs. An AP is characterised by the rapid depolarisation 
and subsequent repolarisation of the axonal Vm. This rapid change of Vm is based on the flow 
of ionic current across the axolemma (Wright 2004, Filley 2012).  
When a neuron receives sufficient stimulation to depolarise the resting Vm by ~20mV 
(threshold value), it leads to the initiation of an AP. If the initial stimulus does not cause the 
Vm to surpass this threshold value, an AP will not pursue. This is referred to as an ‘all-or-
nothing’ event. Single synaptic events are typically incapable of pushing the Vm to its threshold. 
However, either spatial or temporal summation of synaptic inputs may be sufficient (Stuart, 
Spruston et al. 1997). Once the threshold is surpassed, it leads to the opening of voltage-gated 
Na+ channels (VGNCs), allowing an influx of depolarising Na+ ions, driving the Vm close to ENa 
(+60mV). This is referred to as the rising or depolarising phase of an AP. 
However, this depolarisation does not quite reach ENa due to a combination of rapid 
inactivation of VGNCs (preventing further Na+ influx) and the delayed activation of voltage-
gated K+ channels (VGKCs). Compared to VGNCs, the gating of VGKCs requires a much larger 
depolarisation (Barnett and Larkman 2007). As VGKCs open, the subsequent efflux of K+ ions 
repolarises the membrane potential back towards resting Vm. Similar to their delayed 
activation, VGKCs are also slow to inactivate, leading to an after-hyperpolarisation where the 
membrane potential will temporarily overshoot to approximately -80mV (see Fig. 1.1) 





Fig. 1.1: The action potential.  
A schematic representation of the different phases of an action potential. Taken from (Barnett and 
Larkman 2007).  
 
AP propagation along an axon is unidirectional. Depolarisation of the axolemma will 
depolarise adjacent regions of axolemma typically travelling away from the neuronal cell body 
towards the end terminal or synapse (Barnett and Larkman 2007). Once an AP occurs, the 
membrane experiences a ‘refractory period’ which prevents an AP returning back towards 
the neuronal cell body. Na+ channel inactivation prevents any further Na+ influx and thus 
ensures that only Na+ channels ahead of the AP will activate. In addition, the K+ channel 
mediated after-hyperpolarisation also increases the input stimulus required to reach 
threshold (Barnett and Larkman 2007). By the time Na+ have returned to their resting state 
and when resting Vm has been restored, the AP will have travelled along the axon and so any 




1.1.1.3: Mode of Action Potential conduction and Myelin Sheath 
 
The mode of AP conduction is dependent on presence of a myelin sheath, an ensheathing 
lipid layer which insulates the axon cylinder. During the first half of gestation, all central axons 
lack myelin sheath. While many axons are myelinated during development, a significant 
population remain unmyelinated in the mature CNS. AP conduction in unmyelinated axons 
travels progressively along the axon in a wave-like manner (Fig. 1.2). Unmyelinated AP 
conduction is facilitated by the expression of a low density of Nav1.2 Na+ channels (2/µm2), 
evenly distributed along the axolemma (Waxman, Black et al. 1989). This mode of conduction 
is relatively slow due to the high capacitance of unmyelinated axons (Waxman, Black et al. 
1989). The bare axolemma is exposed to the extracellular space and therefore, separates 
charged ions on either side of the membrane.  However, the axolemma itself is relatively thin, 
which leads to an accumulation of charged ions along the membrane. This stored electrical 
charge is referred to as capacitance, which hinders AP conduction, reducing AP conductance 
velocity. As a result, AP propagation in unmyelinated axons is typically slow and continuous.  
In the mature CNS, many central axons are ensheathed by multiple insulating wraps of myelin 
sheath. Myelin has a very high proportion of lipid and has a water content of about 40% in 
situ. While cell membranes typically have a higher ratio of protein to lipid, myelin on the other 
hand, has a dry weight of approximately 70% lipid. Cholesterol and cerebrosides are the most 
abundant lipids found in myelin, respectively accounting for 40% and 20% of total myelin lipid 
content (Quarles, Macklin et al. 2006, Filley 2012). Myelin also expresses a variety of 
structural proteins responsible for compacting its various layers, including myelin-associated 
glycoprotein (MAG), proteolipid protein (PLP) and myelin basic protein (MBP) (Filley 2012). 
The ensheathing myelin layer is separated from the axolemma by a narrow region known as 
the periaxonal space (approximately 20nm). Each subsequent wrap of myelin is separated by 
very thin spaces of cytoplasm, typically measuring 4-5nm wide (Blaurock 1981). Myelin 
thickness is defined by the number of myelin wraps around an axon and their compactness 
(Velumian and Samoilova 2014). It is quantified by a g-ratio, which is the ratio of the axon 
diameter to the diameter of the axon plus the myelin sheath. Generally speaking, it is directly 
proportional to axon size, with larger axons having thicker myelin (Waxman and Sims 1984). 
Myelin is typically thinner on central axons when compared those in the peripheral nervous 
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system (PNS). For example, the typical g-ratio of mature PNS axons is 0.6, while the CNS has 
a typical g-ratio of 0.75 (Waxman and Sims 1984). For several mammalian species, as brain 
size increases, the fraction of axons which are myelinated also increase (Wang, Shultz et al. 
2008). Similarly, the overall percentage volume of WM in the brain also increases with size 
(Beiu, Madappuram et al. 2011).  
Myelination typically begins late in the final trimester during human foetal development and 
continues well into adulthood. It is carried out by oligodendrocytes in the CNS (or Schwann 
cells in the PNS). Prior to the onset of myelination, many axons undergo a programme of 
radial expansion in preparation for contact with oligodendrocyte processes (Alix, Zammit et 
al. 2012). Increasing axonal diameter decreases internal resistance, which in itself increases 
AP conduction velocity. Myelination is carried out in segments along the axon, covering ~99% 
of the axon cylinder, starting less than 100µm away from the neuronal cell body and 
continuing right up to the synaptic terminal (Stys 2005, Back 2014, Velumian and Samoilova 
2014). However, in the optic nerve axon, myelin typically begins millimetres from the retinal 
ganglion cells in order to prevent light scattering which would occur if myelin was present 
(Doyle, Simon et al. 2008, Velumian and Samoilova 2014). The unmyelinated region between 
the axon hillock and the beginning of myelin is termed the axon initial segment (AIS) and is 
characterised by a high density of voltage-gated channels (Kole and Stuart 2012). The 
segments of myelin sheath are separated by a narrow gap, known as the node of Ranvier, 
which expose the axolemma to the extracellular space (approximately 1µm wide). Directly 
adjacent the node is the paranodal domain which contains a tight axo-myelin junction 
(paranodal junction) and has a high expression of adhesion proteins such as contactin and 
Caspr (Rios, Melendez-Vasquez et al. 2000). The distance between each node is proportional 
to the diameter of the axon (Waxman and Sims 1984). The wraps of insulating myelin between 
each node of Ranvier increase electrical resistance and decrease capacitance. High electrical 
resistance prevents the loss of current across the axolemma and thus, promotes AP 
movement along the axon. Capacitance is inversely proportional to the thickness of the 
membrane separating two conductors. So by increasing the thickness of the membrane (with 
myelin), it also lowers the capacitance by increasing the distance between the two conductors. 
This decreases the stored charge on either side of the axolemma. Therefore, the increased 
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resistance and decrease in capacitance provided by myelin facilitates the rapid and passive 
conduction of an AP to the next node.  
During myelination, the expression of Nav1.2 Na+ channels along the unmyelinated axolemma 
is replaced by clusters of Nav1.6 Na+ channels which form at the node of Ranvier. The high 
density of Nav1.6 channels restricts inward Na+ currents to less than 1% of the axon surface 
(Waxman, Craner et al. 2004, Nave 2010). For this reason, myelinated APs propagate via 
saltatory or ‘jumping’ conduction between nodes (Fig. 1.2). While saltatory conduction is 
much faster, it is also much more energy efficient when compared to unmyelinated axons 
(Stys 2011). The restoration of ionic gradients (by Na+/K+-ATPase, also found at the node) is 
restricted to small areas along the axon, dramatically reducing the energy demand (Nave 
2010). Unlike Na+ channels, K+ channels are typically dispersed within the juxtaparanodal 
region of the axon, concealed underneath the myelin sheath (Doyle, Simon et al. 2008, Baltan, 
Carmichael et al. 2014). This restricts the involvement K+ channels during AP conduction, seen 
with the lack of an after-hyperpolarisation in myelinated axons. The K+ channels under myelin 




Fig. 1.2: Action potential conduction.  
Schematic representation of AP conduction in myelinated and unmyelinated axons. Myelinated AP 
propagation is via saltatory conduction, where the AP ‘jumps’ between the node of Ranvier. In 
contrast, unmyelinated AP conduction is continuous as it propagates along the entire axolemma. 
Taken from ‘Encyclopaedia Britannica Online- Node of Ranvier’. 
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1.1.2: Glial Cells 
 
Aside from axons, WM contains a number of glial cells including fibrous astrocytes, 
oligodendrocytes, NG2 glia and microglia (Goldberg and Ransom 2003).  Axons are highly 
dependent on a close interaction with these glial cells, which actually outnumber the amount 
of neurons in the mammalian CNS. The word glia originates from the Greek word for ‘glue’ as 
they were initially considered to act as a scaffold for supporting neurons. However, it is now 
well known that they play a much more important role within the CNS (Nave 2010). The 
intimate interaction between axons and their neighbouring glial cells is essential for the 




The term oligodendrocyte originates from the Greek words for few (oligo), branches (dendro) 
and cell (cyte) and was initially introduced by Pio Del Rio-Hortega in 1928 (Verkhratsky and 
Butt 2007). Similar to Schwann cells in the PNS, oligodendrocytes are highly specialised glial 
cells, primarily responsible for the production of myelin, which enwraps axon cylinders. 
However, they also play an important role in supporting the long term integrity of axons, as 
well as stimulating the growth of axon diameter (Nave 2010). Contrary to the origination of 
their name, a single oligodendrocyte can send out many processes which account for 
segments on up to 60 neighbouring axons (Doyle, Simon et al. 2008).  
Oligodendrocytes develop from proliferating oligodendrocyte precursor cells (OPCs) which 
migrate from the ventricular zones of the CNS (Barres and Raff 1994). From here, a 
combination of chemorepellent and chemotactic signals guide their migration along axons 
and radial glia to their final destinations (Sugimoto, Taniguchi et al. 2001). OPC development 
into mature, myelin-forming oligodendrocytes involves a series of developmental stages 
which can be defined by the presence of a number of cell surface markers (stage-specific 
antibodies), including NG2, A2B5, O4, O1 and MBP (Fig.1.3) (Zhang 2001). In addition to the 
sequential expression of cell markers, they undergo a morphological transformation from 
bipolar progenitors to myelinating oligodendrocytes bearing multiple processes (Zhang 2001). 
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Oligodendrocytes are the last cell type to develop in WM and they carry out the majority of 
myelination post-natally (Miller 2002). 
 
 
Fig. 1.3: Oligodendrocyte development.  
Oligodendrocyte lineage showing the variety of cell makers expressed during different periods of 




Astrocytes are the most abundant type of glial cell in the CNS (Lundgaard, Osorio et al. 2014). 
They play a crucial role in the maintenance of homeostatic conditions, including pH regulation, 
neurotransmitter re-uptake, free radical scavenging and extracellular K+ buffering (Butt and 
Ransom 1993, Ransom 2003). In addition, they also play an important role in the maintenance 
of the blood brain barrier (BBB), as their end-feet processes cover approximately 90% of the 
cerebral vasculature (Lundgaard, Osorio et al. 2014).  
Unlike the protoplasmic type found in GM, WM astrocytes are predominantly fibrous, having 
a relatively small cell body with extensive long processes which extend out from the body and 
run along nerve fibres (Shannon, Salter et al. 2007). In addition to maintaining homeostatic 
conditions, fibrous astrocytes have shown to be an important source of energy reserve for 
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neighbouring axons. Astrocytes contain stores of glycogen which can be converted to lactate 
and subsequently shuttled to axons by MCT transporters during periods of high energy 
demand and/or energy deprivation (Ransom and Fern 1997, Wender, Brown et al. 2000, Fern 
2015). Mature GFAP-expressing astrocytes are first observed in WM regions around the same 
time that OPCs begin migrating (Lundgaard, Osorio et al. 2014). Astrocytes may play a role in 
guiding OPC migration and development as they are the primary producer of platelet-derived 
growth factor (PDGF), and PDGFα receptor signalling is known to inhibit oligodendrocyte 




Microglia are the resident immune cell within the CNS. Unlike neurons and macroglia 
(astrocytes and oligodendrocytes) which originate in the embryonic germ layer (the 
neuroectoderm), microglia enter the CNS from the circulating vasculature (Allen and Barres 
2009). Microglia have a ubiquitous distribution throughout the CNS, accounting for 
approximately 5-20% of total cells in the mouse brain  (Streit 2000). Their main function is to 
scavenge and engulf debris, damaged cells and infection. Under pathological conditions, 
microglia become activated or ‘reactive’ which induces an increase in mobility, a change in 
morphology and an upregulation of monocyte-macrophage molecules (Streit 2000). They are 
also proposed to play a role in synaptic remodelling, by removing unnecessary synaptic 
connections (Allen and Barres 2009). Interestingly, microglia communicate with the systemic 
immune system. For example, systemic infections can lead to the metabolic upregulation of 
microglia in the CNS (Dantzer, Bluthe et al. 1998, Perry and Teeling 2013). 
 
1.1.2.4: NG2+ Glia/OPCs 
 
The fourth glial cell type within the CNS is known as NG2 glia, based on their expression of 
NG2 chondroitin sulfate. NG2 glia have a stellate morphology, similar to astrocytes but are 
often referred to as oligodendrocyte precursor cells (OPC) as they regularly differentiate into 
oligodendrocytes. During development, a sub-population of NG2+ OPCs remain 
undifferentiated, accounting for a significant population in the adult CNS (Dawson, Polito et 
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al. 2003). Interestingly, NG2+ glia account for 8-9% of the total cell population in WM, but 
only 2-3% in GM (Verkhratsky, Butt et al.  2015). OPCs are the principle proliferative cell type 
in the mature CNS (Dawson, Polito et al. 2003). There is evidence to suggest that NG2+ cells 
generate oligodendrocytes following demyelination, suggesting that they act primarily as a 
reservoir of new oligodendrocytes (Polito and Reynolds 2005, Tripathi, Rivers et al. 2010). 
Aside from regenerating oligodendrocytes in the mature CNS, they form close synaptic-like 
contacts with nodes of Ranvier and receive direct synaptic input from neuronal cells which 
suggests that they may also have a functional role under physiological conditions (Butt, 
Duncan et al. 1999, Kukley, Capetillo-Zarate et al. 2007, Ziskin, Nishiyama et al. 2007). 
 
1.1.3: Model WM tracts:  
 
1.1.3.1: The isolated Optic Nerve (ON) 
 
Throughout this project, the isolated rodent optic nerve (ON) is used as a model WM tract. 
Extensive use of the ON has provided invaluable insight into both physiological and 
pathological interactions between glial cells and axons in WM. The ON is an extruded central 
WM tract, essentially responsible for transmitting visual information from the eye to the brain 
(Drance and Anderson 1995). This information transmission is facilitated by several hundred 
thousand axons which project from retinal ganglion cells to the optic chiasm at the base of 
the brain. Many axons cross over at the optic chiasm and carry on as the optic tract, 
eventually terminating at the superior colliculus (or optic tectum) in the mid-brain (Raff 1989).  
The ON offers a variety of advantages over alternative WM tracts. An important feature of 
the ON is the lack of intrinsic neuronal cell bodies, which eliminates any complications or 
interferences, associated with neighbouring GM regions. The ON contains a variety of 
supporting glial cells, namely oligodendrocytes, astrocytes, NG-2+ cells and microglia, so any 
cell bodies in the ON must be those of glia (Butt, Pugh et al. 2004). The lack of neuronal cell 
bodies allows for the study of physiological and pathological axo-glial interactions in WM (Butt, 
Pugh et al. 2004). In addition, it ensures that any recordings from the ON (e.g. extracellular 
glutamate) are purely of WM origin. The intact nerve is relatively simple to isolate and due to 
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the surrounding connective sheath, the cellular components remain bundled together and so 
it can be treated like an individual fibre. The isolated nerve can be maintained for several 
hours with minimal structural/functional loss, allowing for investigations over relatively long 
periods (Dong and Hare 2005). The functional homogeneity and structure of the ON allows 
for reliable electrophysiological recordings i.e. compound action potential recordings. This 
permits the study of a variety of nerve conduction properties including conduction velocity 
and functional recovery following an insult e.g. ischemia, anoxia, aglycemia.    
The structural anatomy of the rat ON (RON) has been well characterised, both during 
development and in mature rodents. The RON originates from the optic stalk, an extension of 
the neural tube (Raff 1989). By embryonic day 14-16 (E14-16), the first axons begin to invade 
the optic stalk, originating from newly developed retinal ganglion cells (Sefton, Horsburgh et 
al. 1985). By birth (P0), a period which developmentally correlates with mid-term human WM, 
the number of axons in the rat ON reaches between 240,000 and 275,000 (Crespo, O'Leary et 
al. 1985, Sefton, Horsburgh et al. 1985). At this age, all axons are unmyelinated and have a 
diameter of <0.3µm (Sefton, Horsburgh et al. 1985), where AP propagation is mediated by a 
low density of NaVs distributed along the axolemma, with a conduction velocity of 0.2m/s 
(Foster, Connors et al. 1982, Waxman, Black et al. 1989). The RON contains two macroglial 
cell types; fibrous astrocytes and oligodendrocytes. Of the two, astrocytes represent the vast 
majority of glial cells in the ON at birth (Butt and Ransom 1993, Mi and Barres 1999). They are 
known to populate the optic stalk from E16, emerging from the retina-end and forming a 
perivascular, glial limiting membrane around the periphery of the nerve (C. Raff and H. Miller 
1984, Small, Riddle et al. 1987). On the other hand, the first OPCs begin to emerge after P2 
from the chiasm-end of the nerve (Raff 1989). 
From early-mid gestation onwards, axons undergo selective deletion or pruning, which can 
reduce the number of WM axons by over half. Over the course of the first week and a half 
after birth, the number of RON axons dramatically declines to a more stable figure of 100,000 
(Crespo, O'Leary et al. 1985). Prior to the initiation of myelination, the small pre-myelinated 
axons undergo a programme of radial expansion, where they increase in diameter (up to 3-
fold) in preparation for contact with glial processes and ensheathment (Alix and Fern 2009). 
While OPCs appear at P2, the first post-mitotic, immature oligodendrocytes begin to emerge 
at P6, when their processes begin to navigate along pre-myelinated axons. Immature 
14 
 
oligodendrocytes extend a much higher number of processes compared to their more mature 
phenotype (typically 30 v 16 processes, respectively), which correlates to the high number of 
unmyelinated axons present in younger ONs (Butt and Ransom 1993). The first detectable 
wraps of myelin are observed between P6-P8 (Foster, Connors et al. 1982). By P10, only ~2% 
of axons are myelinated (Alix, Zammit et al. 2012). In addition, the first clusters of NaVs on 
axons begin to emerge between P9-P10, consistent with the redistribution of Na+ channels to 
future nodes of Ranvier (Rasband and Shrager 2000). At this age, the ratio of astrocytes to 
oligodendrocytes is 50:50 (Wilke, Thomas et al. 2004). Myelination proceeds rapidly and by 
P28, approximately 85% of all axons with the nerve are myelinated (Foster, Connors et al. 
1982). However, myelination continues up until ~P90, when 100% of RON axons are 
myelinated, analogous to a continuous increase in the number of oligodendrocytes into 
adulthood, where they eventually become the most abundant glial cell in the ON (Vaughn 
1969). During this developmental period, the AP conduction velocity sharply increases from 
0.2m/s at birth (P0), reaching 30 m/s in the fully-myelinated mature RON, a 150-fold increase 
(Foster, Connors et al. 1982).  
The isolated ON is an ex vivo model and therefore should closely reflect any interactions or 
injury mechanisms which occur in vivo. Exposing the ON to modelled ischemia has provided 
invaluable information about the injury mechanisms involved in WM. Despite this, it is not 
without limitations. As mentioned previously, there are no physical barriers separating GM 
and WM regions in the CNS. While the absence of surrounding GM in the ON preparation 
ensures recordings are of pure WM origin, it also excludes any potential interactions with 
surrounding GM regions which are likely to have an influence in vivo.  
 
1.1.3.2: Corpus Callosum (CC) 
 
In addition to the ON, the corpus callosum (CC) was also used as a model WM tract during 
this project. The CC is the primary commissural WM tract in the brain, responsible for 
connecting the left and right cerebral hemispheres. It is the largest white matter tract in the 
mammalian brain, composed of between 200 and 250 million axonal projections in humans 
(Fitsiori, Nguyen et al. 2011). Although the majority of axons connect to homologous regions 
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in the opposite hemisphere, some axons project diagonally to contralateral association 
regions while some extend down through the CC from the supracallosal gyrus on the upper 
surface of the CC to the fornix, located on the under surface of the CC (Moody, Bell et al. 
1988). The CC is classified into 3 spatial regions; the genu located anteriorly, the splenium 
found at the posterior region of the CC and the body, which is found in between these two 
structures.     
Compared to the RON, developmental changes which occur in the rat CC are not as well 
characterised. The number of axons nearly triples from birth to P5 reaching approximately 
11.4 million in the rat, but unlike the ON, this number is maintained until at least P60 in adult 
rats (Gravel, Sasseville et al. 1990). The first wraps of myelin sheath do not appear until P12 
(Bjartmar, 1994). In addition, the mature CC consists of a mix of both myelinated and 
unmyelinated axons. Unlike the ON, the development of the CC is not homogenous across all 
regions (Luders, Thompson et al. 2010). Coronal brain slices, including the corpus callosum, 
have been previously used as a model WM as they have some advantages over isolated 
preparations such as the ON. While the ON excludes the cell body from which the axons 
originate, the whole CC slice includes the entire cell, including the cell body (Tekkok and 
Goldberg 2001). In addition, it also contains a mixed population of both myelinated and 
unmyelinated axons. Finally, intact brain slices include the surrounding GM which will likely 













Glutamate is the principle excitatory neurotransmitter in the mammalian CNS (Nedergaard, 
Takano et al. 2002). The excitatory actions of glutamate have been acknowledged since the 
mid-twentieth century when early studies found that the application of glutamate directly 
onto the motor cortex induced clonic-type convulsions in dogs and apes (Hayashi 1952). The 
vast majority (~90%) of excitatory neurons in the CNS are glutamatergic (Danbolt 2001). 
Glutamatergic signalling is associated with a variety of physiological processes including 
plasticity, learning and memory (Anderson and Swanson 2000, Danbolt 2001, Stys and Lipton 
2007). In addition, more recent findings suggest that it is a key mediator of neuronal and glial 
cell development; regulating migration, proliferation, differentiation, synapse formation and 
myelination (Danbolt 2001, Lujan, Shigemoto et al. 2005, Lundgaard, Luzhynskaya et al. 2013).  
Glutamate has a ubiquitous distribution throughout the brain and spinal cord. However, the 
actions of glutamate are not restricted to the CNS. Studies have shown that glutamate 
receptors are expressed in non-neuronal peripheral tissue including the heart, lungs, kidneys, 
bone marrow, ovary, testis and endocrine cells (Patton, Genever et al. 1998, Gill, Pulido et al. 
1999, Gill and Pulido 2001). However, knowledge of the distinct functions of glutamatergic 
signalling in peripheral tissues is sparse (Nedergaard, Takano et al. 2002). For the relevance 




1.2.1.1: De novo synthesis 
 
Glutamate is a non-essential amino acid meaning that it is not a dietary requirement. It can 
be synthesised de novo though our own metabolism. Glutamate is unable to cross the blood 
brain barrier (BBB) and therefore, must be synthesised from local precursors within the CNS. 
Glucose is a major energy substrate in the brain. Glycolysis is an essential anaerobic 
biochemical pathway which converts a 6-carbon glucose molecule into two 3-carbon pyruvate 
molecules. The de novo synthesis of glutamate takes place in astrocytes due to the presence 
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of pyruvate carboxylase (PC), an enzyme which catalyses the production of oxaloacetate from 
pyruvate. In addition, pyruvate can also be metabolised to acetyl CoA by pyruvate 
dehydrogenase (PDH) (Schousboe, Scafidi et al. 2014). Both oxaloacetate and acetyl CoA enter 
the tricarboxylic acid cycle (TCA cycle) where they subsequently condense to form a net 
production of the intermediate, α-ketoglutarate. α-ketoglutarate is converted to glutamate 
via aspartate aminotransferase (ATT) (Westergaard, Drejer et al. 1996, Pardo, Contreras et al. 
2013). While PC is abundant in astrocytes, neurons lack significant expression and therefore, 
lack the ability to synthesise large amounts of glutamate from glucose (Shank, Bennett et al. 
1985). In astrocytes, glutamate is converted to glutamine (by the energy requiring enzyme, 
glutamine synthase), released into the ECS and taken up by neighbouring neurons, where it 
can be converted back to glutamate (Nedergaard, Takano et al. 2002) (See Fig. 1.4).  
 
1.2.1.2: Pyruvate-Recycling Pathway 
 
The de novo synthesis of glutamate is estimated to account for only 25-30% of the glutamate 
neurotransmitter pool (Schousboe, Bak et al. 2013). Alternatively, glutamate is taken up by a 
range of excitatory amino acid transporters (EAATS; see Section 1.2.2.1) and can enter the 
‘pyruvate-recycling pathway’ where it is converted back into pyruvate again. Once taken up 
by astrocytes, glutamate is metabolised back into α-ketoglutarate by glutamate 
dehydrogenase (GDH). α-ketoglutarate dehydrogenase (KGDH) subsequently catalyses the 
oxidative decarboxylation of α-ketoglutarate to succinyl Co-A, which continues in the TCA 
cycle to form malate. Malate is then converted back into pyruvate via malic enzyme (ME). 
Pyruvate can be re-synthesised into glutamate, as required (Anderson and Swanson 2000, 





Fig. 1.4: Glutamate Biosynthesis.  
A schematic representation outlining the de novo synthesis of glutamate from glucose (blue: essential 
enzymes) and the re-uptake of extracellular glutamate which enters the pyruvate-recycling pathway 
(red: essential enzymes). Taken from (Schousboe, Scafidi et al. 2014). 
 
1.2.1.2: Glutamate-glutamine cycle 
 
The glutamate-glutamine cycle is the major pathway by which glutamate is recycled in the 
CNS. This process requires an intimate relationship between neurons and astrocytes. Similar 
to the pyruvate-recycling pathway, once glutamate is released into the extracellular space, it 
is rapidly taken by EAATs located on astrocytes. Glutamate is then quickly converted into 
glutamine via glutamine synthase (GS), an enzyme which is absent in neurons (Chen and 
Swanson 2003). Glutamine is non-toxic, does not activate glutamate receptors and is the most 
common precursor of glutamate in the CNS. Glutamine can be shuttled out of astrocytes into 
the extracellular space by system-N transporters (SN1) and subsequently taken up from the 
extracellular space by glutamine specific, sodium-coupled amino acid transporters (SATs) 
located on neuronal membranes (Danbolt 2001, Chen and Swanson 2003). The up-taken 
glutamine is the main precursor of neuronal glutamate synthesis, as it can then be directly 
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converted back into glutamate via the mitochondrial enzyme, glutaminase (Danbolt 2001). 
Glutamate is then actively repackaged into vesicles (see section 1.2.2.2). Not only are 
astrocytes essential in the synthesis of glutamate, but they also play a vital role in the control 
of extracellular and intracellular glutamate concentrations. 
 
1.2.2: Glutamate Transporters 
 
1.2.2.1: Excitatory amino acid transporters (EAATs) 
 
An essential characteristic of glutamatergic signalling is the maintenance of low resting 
extracellular concentrations. As mentioned, glutamate is abundant throughout the CNS 
however, the majority is kept within cells. Under physiological conditions, extracellular 
glutamate concentrations ([Glut]e) are kept in the low micro-molar range, typically 1-4µM. In 
contrast, intracellular concentrations are over a thousand-fold higher (in the millimolar range, 
~1-10mM), forming a steep concentration gradient (Danbolt 2001, Chen and Swanson 2003, 
Cavelier and Attwell 2007). The maintenance of low [Glut]e is predominantly due to glutamate 
uptake via a range of glutamate transporters, also referred to as excitatory amino acid 
transporters (EAATs). Synaptically released glutamate is rapidly removed by EAATs, with a 
time constant of approximately 1ms (Vyklicky, Korinek et al. 2014). 
EAATs are thermodynamically-driven proteins which are located on the surface of cells 
throughout the CNS (Amara and Fontana 2002). The uptake of glutamate, against its 
concentration gradient, is predominantly driven by the steep Na+ gradient across the plasma 
membrane (Sherwin and Fern 2005, Grewer, Gameiro et al. 2008). Thus, EAATs are secondary 
active transporters, using ionic gradients as a source of free energy for this process. The 
inward movement of glutamate is coupled with a net inward movement of between 2 and 3 
Na+ ions (depending on transporter subtype) with one H+ ion, accompanied by the counter 
transport of one K+ ion (Danbolt 2001, Amara and Fontana 2002, Grewer, Gameiro et al. 2008). 
Thus, EAATs are referred to as symporters. The stoichiometry of this process gives way to a 
net inward movement of positive charge. The electrogenic nature of this transport is further 
driven by a negative membrane potential across the plasma membrane (Amara and Fontana 
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2002, Grewer, Gameiro et al. 2008). This movement of ions is followed by the work of the 
Na+/K+ ATPase pump (sodium-pump) to restore the physiological Na+-gradient and regain the 
resting Vm (Anderson and Swanson 2000). As discussed, glutamate taken up by astrocytes can 
either enter the pyruvate-recycling pathway or the glutamate-glutamine cycle. However, 
glutamate is also directly taken up by neurons, where it is packaged into vesicles (see below, 
section 1.2.2.2).  
To date, 5 pharmacologically distinct Na+-dependent glutamate transporter genes have been 
identified and cloned, known as EAAT1-5 in humans (Amara and Fontana 2002, Baud, Haynes 
et al. 2004). As it stands, EAAT-1 and EAAT-2 are the predominant glial transporters, EAAT-3 
is a neuronal transporter, EAAT-4 is also a neuronal transporter but is restricted to GABAergic 
Purkinje cell neurons in the cerebellum, while EAAT-5 is restricted to bipolar cells and rod 
photoreceptors in the retina (Domercq, Sánchez-Gómez et al. 1999). However, they are all 
polypeptides which share about 50%-60% amino acid sequence similarity (Salter and Fern 
2005). The non-human homologues of EAAT1-3 are referred to as GLAST (glutamate-
aspartate transporter), GLT-1 (glial-type glutamate transporter) and EAAC-1 (excitatory amino 
acid carrier 1), respectively (Bridges and Esslinger 2005). Although these transporters are 
located on various cell types, astrocyte uptake is quantitatively most important (Anderson 
and Swanson 2000). GLAST and GLT-1 are abundantly distributed on astroglial membranes 
(Chaudhry, Lehre et al. 1995). Furthermore, these two-subtypes are the dominant regulators 
of glutamate uptake in the CNS (Rothstein, Dykes-Hoberg et al. 1996, Amara and Fontana 
2002).  
Similar to GM, EAATs regulate [Glut]e in WM. GLAST, GLT-1 and EAAC-1 are the major 
glutamate transporters found in the rodent ON (Domercq, Sánchez-Gómez et al. 1999). EAAC-
1 (originally thought to be an exclusive neuronal transporter) was seen to be the major EAAT 
sub-type expressed on axons and oligodendrocytes (Arranz, Hussein et al. 2008). Conversely, 
EAAC-1 contributes to more l-glutamate ([3H]-labelled) uptake than either of the other EAATs 
in developing oligodendrocyte cultures (derived from the P7 rat CC) (DeSilva, Kabakov et al. 
2009). EAAT expression appears to be developmentally regulated, as GLT-1 expression is 
down-regulated as immature oligodendrocytes develop into mature myelin-producing 
oligodendrocytes in vivo (DeSilva, Kabakov et al. 2009). Similarly, another study also reported 
a strong expression of EAAT2 in developing oligodendrocytes in the 32-week gestational age 
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in human, whereas, expression was undetectable in 7 month olds (Desilva, Kinney et al. 2007). 
In contrast, the expression of EAAT1 and EAAT3 is constant throughout (Desilva, Kinney et al. 
2007). Consistent with a high expression of EAATs during development, P14-P17 
oligodendrocytes are capable of accumulating high levels of d-aspartate during exogenous 
perfusion (Arranz, Hussein et al. 2008). While GLT-1 is reportedly downregulated during 
development, Baltan et al. (2008) demonstrated that astrocytic GLT-1 expression increases in 
older mouse ONs (12 month old).  
 
1.2.2.2: Vesicular Glutamate Transporters (VGLUTs) 
 
While EAATs regulate [Glut]e, vesicular glutamate transporters (VGLUTs) are responsible for 
regulating intracellular glutamate concentrations in neurons ([Glut]i). The cytoplasmic 
concentration of neuronal glutamate can reach ~10mM. However, vesicular concentrations 
are typically several-fold higher, reaching concentrations of ~100mM (Cavelier and Attwell 
2007). VGLUTs are vesicular-bound proteins which sequester cytoplasmic glutamate inside 
vesicles. Like EAATs, VGLUTs can also be classified into distinct subgroups; VGLUT1, VGLUT2 
and VGLUT3. However, there are several major differences between the two groups of 
transporters. While EAATs have a very high affinity for glutamate, with a Km between 4 and 
40µM, VGLUTs have a much lower affinity, with a Km of approximately 1mM (Shigeri, Seal et 
al. 2004). Unlike EAATs, VGLUTs are not Na+-dependant transporters. VGLUT-mediated 
transport of glutamate is largely dependent on the activity of V-type H+-ATPase, an ATP-
dependant vesicular H+ pump located on the vesicular membrane. The V-type H+-ATPase is 
responsible for forming and maintaining a high concentration of protons inside the vesicular 
lumen, thus generating a proton gradient and an acidic environment inside vesicles (pH 5-5.5) 
(Cavelier and Attwell 2007). Furthermore, the proton gradient also forms an internal positive 
membrane gradient (approximately +50mV) across the vesicle (Beyenbach and Wieczorek 
2006, Cavelier and Attwell 2007). It is this electrical transmembrane gradient, rather than the 
pH gradient, which drives the transport of negatively-charged glutamate by VGLUTs (Fremeau 




1.2.2.3: Glutamate-Cystine Antiporter 
 
EAATs and VGLUTs represent the two major glutamate transporters within the CNS. However, 
it must be noted that the CNS expresses a number of proteins capable of glutamate transport. 
For example, the glutamate-cystine antiporter is an electroneutral exchanger which uses the 
glutamate transmembrane gradient to transport cystine into the cell. Unlike EAATs, the 
glutamate-cystine exchanger is Na+-independent and transports glutamate out of the cell 
(Danbolt 2001, Bridges, Natale et al. 2012). This will be further discussed in section 4.1.3.5. 
 
1.2.3: Glutamate Receptors  
 
Excitatory neurotransmission is facilitated by a range of glutamate receptors located on the 
surface of neuronal and glial cells throughout the CNS. Thanks to the development of 
molecular biology and cloning, glutamate receptors can be broadly divided into two distinct 
families; ionotropic and metabotropic receptors. Ionotropic glutamate receptors (iGluRs) are 
ligand-gated ion channels which mediate rapid synaptic signalling, allowing the direct influx 
of ions such Na2+, Cl- and Ca2+ in response to agonist binding. On the other hand, metabotropic 
glutamate receptors (mGluRs) are G-protein coupled receptors and act via second messenger 
signalling pathways (Niswender and Conn 2010). While iGluRs mediate rapid glutamatergic 
signalling, mGluRs are commonly referred to as neuromodulatory glutamate receptors 
(Niswender and Conn 2010).  
 
1.2.3.1: Ionotropic Glutamate Receptors (iGluR) 
 
iGluRs are large, cation-specific ion channels which share a common tetrameric structure (i.e. 
made up of four protein sub-units). Each heterogeneous sub-class is composed of a variable 
combination of distinct receptor subunits (Fig. 1.5). Each receptor is composed of four 
hydrophobic subunits intercalated within the plasma membrane; including 4 transmembrane 
domains,  one re-entrant pore loop, an extracellular N-terminus (expressing a ligand binding 
domain) and intracellular C-terminus (Paoletti and Neyton 2007). The variable subunit 
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composition for each receptor subtype heavily influences the receptors permeability to Na+, 
K+ and Ca2+ ions, electrophysiological properties and therefore, their functional properties. 
Changes in iGluR expression is particularly evident during development (Lujan, Shigemoto et 
al. 2005). Agonist binding induces a conformational change causing the channel to open. This 
allows the movement of charged ions through the transmembrane pore and causes a change 
in membrane potential referred to as an excitatory post synaptic potential (EPSP) (Platt 2007). 
iGluRs are ubiquitously distributed throughout the mammalian CNS, with evidence of 
functional expression on axons as well as astroglia, oligodendrocytes, NG-2 cells and even 
myelin itself (David, Yamada et al. 1996, Micu, Jiang et al. 2006, Ouardouz, Coderre et al. 2009, 
Ouardouz, Coderre et al. 2009, Li, Xiao et al. 2013). 
Although all iGluRs share a common structure, they are classically sub-divided into three 
major subtypes based on their subunit composition and pharmacological characteristics; 
NMDA (N-methyl D-aspartate), AMPA (α-amino-3-hydroxy- 5-methyl-4-isoxazolepropionic 
acid) and kainate receptors (Ozawa, Kamiya et al. 1998). However, AMPA and kainate 
receptors are now regularly classified as ‘non-NMDA receptors’ as neither agonist (AMPA nor 
kainate) clearly distinguishes the receptors, since both agonists are capable of activating both 
receptors (Ozawa, Kamiya et al. 1998). AMPA receptors are assembled from a combination of 
GluR1-4 subunits, while kainate receptors contains a combination of GluR5-7 and KA1-2 
(Traynelis, Wollmuth et al. 2010) (Fig 1.5). Non-NMDA receptors have a much lower affinity 
for endogenous glutamate compared to NMDA receptors (Dingledine, Borges et al. 1999, Platt 
2007). They display very rapid gating kinetics and so, generate the early component of 
excitatory post synaptic currents (EPSC). Equally, they undergo rapid desensitisation (within 
100ms), time-limiting the flow of ions (Dingledine, Borges et al. 1999, Platt 2007). Non-NMDA 
receptors are relatively permeable to monovalent cations, such as Na+ and K+, but are typically 
Ca2+ impermeable (Platt 2007). However, it must be noted that receptors which lack the Ca2+-
impermeable GluR2 subunit allow Ca2+ influx (Dean, Fraser et al. 2005). NMDA receptors are 
composed of a combination of 4 distinct sub-units from three families; NR1, NR2 and NR3 (Fig. 
1.5). Interestingly, NMDA receptors have a voltage-dependant Mg2+ block, which can be 
relieved following sufficient depolarisation of the cell membrane. This can be provided by 






Fig 1.5: Classification of glutamate receptor class, sub-classes and subunit composition.  
Glutamate receptors can be broadly divided into ionotropic and metabotropic receptors. Ionotropic 
receptors are further divided into AMPA, kainate and NMDA receptors. Metabotropic receptors are 
divided into group I, group II and group III. Each receptor is composed of a variable combination of 
distinct subunits.  
 
1.2.3.2: Metabotropic Glutamate Receptors (mGluR) 
 
mGluRs are G-protein coupled receptors which are responsible for the modulation of slow 
excitatory transmission. They consist of a dimer of two 7–transmembrane domains which 
when activated, initiate an intracellular cascade of events. mGluRs relay information though 
the activation of intermediate molecules known as G-proteins. G-proteins are intracellularly 
bound to mGluR and are composed of α, β and γ subunits. In its inactivated state, the α 
subunit is linked to GDP (guanine diphosphate) (Niswender and Conn 2010). However, the 
binding of an extracellular agonist to the receptor causes the exchange of GDP for GTP 
(guanine triphosphate), and the disassociation of the α subunit from the trimeric complex. 
The β, γ dimer and the GTP-bound α subunit are then free to activate a variety of downstream 
targets such ion channels or effectors, capable of mediating intracellular secondary 
messengers (Niswender and Conn 2010).   
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mGluRs are divided in three sub-types (Group I,II and III) based on their intracellular signalling 
mechanisms and pharmacology. Group 1 mGluRs are coupled to phospholipase C which 
classically leads to Ca2+ immobilisation. Whereas group II and III, directly regulate ion channels 
through the inhibition of adenylate cyclase (Niswender and Conn 2010). Within these groups, 




Under a variety of pathological conditions, the excessive release of endogenous glutamate 
and/or the failure of EAATs can have detremential effects. Elevated extracellular glutamate 
concentrations ([Glut]e) can lead to the sustained activation of iGluRs, a phenomenon known 
as excitotoxicity. Excitotoxicity is defined as the pathological process of cell death resulting 
from the toxic actions of excitatory amino acids (Dong, Wang et al. 2009), or simply as “an 
exaggeration of the excitatory effect” (Olney, Rhee et al. 1974). This mechanism underlies the 
progression of a growing number of acute and chronic neurological disease states (Wang and 
Qin 2010). These include stroke, traumatic brain injury, hypoglycaemia, spinal cord injury, 
Alzheimer’s and Parkinson’s disease (Blandini, Porter et al. 1996, Reisberg , Doody  et al. 2003, 
Xu, Hughes et al. 2004, Yi and Hazell 2006, Doyle, Simon et al. 2008, Alix and Fern 2009, Yang, 
Hamner et al. 2014).  
The toxic actions of glutamate were first reported in 1957 by D.R. Lucas and J.P. Newhouse, 
who noticed that systemic injections of sodium l-glutamate induced cell death in the inner 
layer of the retina in mice (Lucas and Newhouse 1957). The term ‘excitotoxicity’, was later 
coined by John Olney in 1969 who confirmed the neurotoxic actions of glutamate after finding 
that subcutaneous injections also induced acute neuronal necrosis in a variety of regions in 
the CNS (Olney 1969). However, excitotoxic damage is not confined to neurons. Since then, a 
variety of studies have demonstrated the vulnerability of oligodendroglia to excitotoxicity 
(Fern and Moller 2000, Deng, Rosenberg et al. 2003, Xu, Hughes et al. 2004, Káradóttir, 
Cavelier et al. 2005, Salter and Fern 2005, Hamilton, Hubbard et al. 2009). There is also 
evidence of glutamate-receptor mediated injury to astrocytes, microglia and NG-2 cells (David, 
Yamada et al. 1996, Kingham, Cuzner et al. 1999, Hamilton, Hubbard et al. 2009).  
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Elevated concentrations of extracellular excitatory amino acids, such as glutamate and 
aspartate, promote the over-activation of iGluRs. This ultimately gates the post-synaptic 
receptor ion channel allowing an excessive influx of a range of extracellular ions including Na+, 
Cl- and Ca2+. Na+ influx through the ion channel (combined with K+ efflux) meadiates the 
excessive depolaraisation of the post synaptic membrane (Dong, Wang et al. 2009). In 
addition, the accumulation of Na+ and Cl- ions contribute to rapid cellular swelling and osmotic 
disruption, a common feature of excitotoxicity (Olney, Price et al. 1986, Choi 1987). While the 
removal of extracellular Na+ or Cl- ions can prevent  early neuronal cell swelling, it has no 
effect on the inevitable cell death which occurs after prolonged periods sustained receptor 
activation (Choi 1987). The rise in intracellular Ca2+ concentration ([Ca2+]i) is recognised as the 
central mediator of excitotoxic cell death (Choi 1985, Choi 1987). Under physiological 
conditions, [Ca2+]i is kept low due to the activity of a varity of mechanisms, including the Ca2+-
ATPase and the Na+-Ca2+ exchanger (NCX). However, under certain pathological conditions, 
the failure of these homeostatic mechanisms combined with the excessive influx of Ca2+ 
through iGluRs allow [Ca2+]i to reach toxic levels. High [Ca2+]i triggers a cascade of events, 
including the activation of a variety of deleterious, Ca2+-dependant enzymes capable of 
causing apoptotic and necrotic cell death (Szydlowska and Tymianski 2010). The activation of 
lipases, proteases, phospahatases and endonucleases promote the degradation of cell 
organelles, cytoskeletal/membrane disruption and toxic downstream events (Szydlowska and 
Tymianski 2010). The excitotoxic rise in [Ca2+]i is largely considered a consequence of direct 
entry through iGluRs. The activation of Ca2+-permeable NMDA receptors and/or 
AMPA/Kainate receptors (particularly GluR2-lacking receptors) can elevate cystolic free Ca2+, 
a process which is exacerbated under certain patholgical conditions. For example, the toxic 
rise in [Ca2+]i in oligodendrocyte cell bodies during ischemia is largely facilitated through the 
activation of AMPA/kainate receptors (Fern 1998, Deng, Rosenberg et al. 2003, Wilke, 
Thomas et al. 2004, Salter and Fern 2005). Interestingly, NMDA receptors are known to permit 
a much larger Ca2+ influx (Mayer and Westbrook 1987) and therfore, have a greater potential 
in mediating the detrimental rise in [Ca2+]i (Salter and Fern 2005, Micu, Jiang et al. 2006, 
Szydlowska and Tymianski 2010). However, it must be noted that AMPA/kainate receptor 
activation is known to mediate WM damage in the absence of extracellular Ca2+, indicating 
that receptor activation may be sufficient to induce Ca2+ release from intracellular stores or 
that [Na+]i accumulation alone may mediate cell death (Baltan, Besancon et al. 2008). As 
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cystosolic Na+ and Ca2+ increases, alternative mechanisms are known to contribute to 
excitotoxic-induced Ca2+ overload. For example, excessive membrane depolarisation can 
activate voltage-gated Ca2+ channels (Lee, Zipfel et al. 1999). Similarily the sodium-calcium 
exchanger (NCX), which normally extrudes [Ca2+]i in exchange for Na+, is known to operate in 
reverse contributing to the initial rise in [Ca2+]i observed following acute exposure to 
excitotoxins (Hoyt, Arden et al. 1998).  
Mitochondria can sequester cytosolic Ca2+, which depolarises the mitochondrial membrane 
potential (Δψm). Excitotoxic Ca2+ influx can promote mitochondrial overload which can lead 
to the opening of the permeability transition pore (PTP) on the inner mitochondrial 
membrane. Under such conditions, the PTP sequentially begins to release Ca2+ back into the 
cytosol, along with apoptotic mediators like cytochrome-c (Nicholls and Budd 1998, Nicholls 
and Ward 2000, Szydlowska and Tymianski 2010). Mitochondrial Ca2+ accumulation also leads 
to the generation of excessive reactive oxygen species (ROS), like nitric oxide (NO), which can 
cause damage to cellular nucleic acids and promote mitochondrial dysfunction (Szydlowska 
and Tymianski 2010).  
The involvement of metabotropic glutamate receptors in excitotoxicity is still somewhat 
controversial. There is evidence to suggest that prolonged activation of mGluRs (particularly 
group 1) reduces neuronal susceptability to NMDA-mediated excitotoxicity in both 
organotypic hippocampal  and cortical culture (Koh, Palmer et al. 1991, Bruno, Copani et al. 
1994, Baskys, Bayazitov et al. 2005). This is also the case for oligodendrocyte cultures exposed 
to ischemic conditions, an effect was was suggested to be a result of preventing intrecellular 
glutathione loss and inhibiting the build-up of ROS (Deng, Wang et al. 2004). On the otherhand, 
other studies have found them to exaccerbate axonal injury  by promoting intracellular Ca2+ 









1.3.1: White Matter Ischemia 
 
The human brain represents approximately 2% of the total body mass, yet consumes 20% of 
the body’s total energy production at rest (Engl and Attwell 2015). The majority of cerebral 
ATP (adenosine triphosphate) is generated through a combination of glycolysis (in the cytosol) 
and oxidative phosphorylation (in the mitochondria). Thus, the brain requires a continuous 
supply of the essential substrates required for cellular respiration, specifically O2 and glucose. 
To achieve this, the brain receives nearly a quarter of our total cardiac output (Flynn, 
MacWalter et al. 2008), consuming ~20% of total oxygen intake and ~25% of circulating 
glucose (Harper and Jennett 1990, Doyle, Simon et al. 2008). Cerebral ischemia is defined as 
the inadequate supply of essential nutrients to the brain, which occurs through the cessation 
of blood flow. An insufficient supply of O2 and glucose ultimately leads to depleted levels of 
cellular ATP which can have catastrophic consequences.  
On the basis of O2 consumption, WM has a lower metabolic rate when compared to cerebral 
GM (Nishizaki, Yamauchi et al. 1988). Consequently, it receives a lower blood supply. For 
example, while GM regions typically receives a blood flow of 50ml/100mg/min-1, WM receives 
30ml/100mg/min-1 (Mohr, Grotta et al. 2011). As a result, WM has a higher infarction 
threshold (Pantoni, Garcia et al. 1996, Tekkok and Ransom 2004). Even so, prolonged periods 
of ischemia can result in extensive WM damage. Due to the high density of packing within 
WM tracts, the formation of an infarct severely disrupts signal transmission and neuronal 
circuits, which will inevitably lead to devastating clinical impairments. Ischemic WM injury can 
lead to the reduced conductance velocity of WM axons or in severe cases, a complete block 
in action potential conduction. To date, a variety of neuroprotective compounds have shown 
promise in rodent stroke models but have failed in clinical trials (Song, Woodbury et al. 2014). 
While their failure is likely multifactorial, the under-appreciation of WM injury in stroke is 
now considered a primary reason. WM constitutes about 14% of total brain volume in the 
rodents, whereas, it occupies about 50% in humans (Song, Woodbury et al. 2014). Many 
studies have focused on GM protection, inadvertently neglecting WM. Considering the high 
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percentage of WM in the human brain, it comes as no surprise that stroke is rarely confined 
to GM (Goldberg and Ransom 2003). The occlusion of large intracranial arteries will affect 
both grey and white matter regions. Ischemic WM damage is now recognised as a major 
component of cerebral ischemia (Sozmen, Hinman et al. 2012). In fact, approximately 95% of 
all ischemic stroke patients exhibit some degree of WM injury (Ho, Reutens et al. 2005, Wang, 
Liu et al. 2016). Interestingly, WM damage occupies an average of 42% of the total infarct 
volume (Ho, Reutens et al. 2005). Furthermore, up to 30% of ischemic strokes predominantly 
involve subcortical WM infarcts due to the occlusion of penetrating arteries which supply 
deep WM regions (Rosenzweig and Carmichael 2013). In addition, the injury mechanisms 
which operate under ischemic conditions are distinct from those which contribute the GM 
damage, which may explain the lack of clinical benefits to date. There are a number of ways 




Stroke is a devastating disease which occurs approximately 150,000 times every year in the 
UK alone (Writing Group, Roger et al. 2012). Despite major advances in recent years, it is 
currently the 4th leading cause of death in the UK (Hackett, Yang et al. 2010, Lerdal, Bakken 
et al. 2011). However, according to the World Health Organisation (WHO), it is the 2nd largest 
cause of mortality worldwide, accounting for approximately 6.7 million deaths every year 
(WHO, 2014). In addition, it is the leading cause of long-term disability, with nearly half of all 
stroke survivors suffering from physical and/or mental impairments (Ovbiagele and Nguyen-
Huynh 2011). This accounts for a wide range of disabilities including speech, walking, co-
ordination, swallowing and vision to name but a few. Furthermore, the burden of the disease 
is set to double worldwide by 2030 due to an ageing population (Feigin, Forouzanfar et al. 
2014). While age is the single largest risk factor for stroke, other factors include smoking, 
excess alcohol, obesity, diabetes and high blood pressure (Scarborough, Bhatnagar et al. 
2011). 
It is estimated that approximately 30% of all stroke survivors experience a recurrent stroke 
(Mohan, Wolfe et al. 2011). In fact, it is estimated that recurrent strokes account for 25-33% 
of total cases (Stroke Association, Stroke statistics 2016). A study by Lee et al. found that of 
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patients who experienced a stroke, 24% had a second cerebrovascular event within 5 years 
(Lee, Shafe et al. 2011). Recurrent strokes are typically more severe, with approximately 16% 
being fatal within 56 days of the initial stroke (Lee, Shafe et al. 2011). Unfortunately, current 
treatments for acute stroke are relatively limited. Therefore, there is an urgent need for 
effective interventions in order to minimise irreversible damage.  
There are two distinct types of cerebral stroke; haemorrhagic and ischemic. A haemorrhagic 
stroke involves the rupture of a weakened blood vessel and a subsequent bleed which occurs 
either within the brain (an intracerebral haemorrhage), or on the surface of the brain (a 
subarachnoid haemorrhage) (Gomes and Wachsman 2013). It results in the accumulation of 
blood, increasing pressure in the surrounding tissue and disruption normal blood flow. 
Haemorrhagic strokes are typically more severe than ischemic stroke, but only account for 
approximately 10-15% of all cases (Gomes and Wachsman 2013). The remaining 85-90% of 
cases are ischemic. Ischemic strokes involve the occlusion of a major artery or blood vessel 
within the brain which obstructs blood flow, and therefore, restricts the supply of essential 
nutrients. This is a consequence of clot formation within the artery, either via a thrombosis 
or an embolism. The degree of cell death depends on the severity and the duration of the 
ischemic insult (Doyle, Simon et al. 2008). Ischemic strokes typically lead to the formation of 
an infarct, which is a region of severe tissue damage within the brain (Doyle, Simon et al. 
2008). The infarct core is characterised by rapid focal necrosis and irreversible damage. 
However, the surrounding area, known as the penumbra, can remain functionally viable for a 
short period due to the collateral blood supply (Gomes and Wachsman 2013). However, the 
collateral supply is incapable of supporting this region indefinitely, and so, cells within the 
penumbra will succumb to apoptosis/necrosis unless the blood supply is restored. This region 
is the most clinically salvageable area and therefore, is the focus of much research.  
 
1.3.1.2: Periventricular White Matter Injury and Cerebral Palsy 
 
Selective WM injury in the developing brain is the most common pathological substrate 
associated with a range of neurological disorders, including cerebral palsy (Khwaja and Volpe 
2008). WM pathology in the neonatal brain was first reported by Virchow in 1867, who 
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described the ‘softening’ of developing WM (Jin, Londono et al. 2015). Some years later in 
1962, Banker & Laroche described the necrosis of WM regions adjacent the lateral ventricles 
(Banker and Larroche 1962). While research into the etiology of immature WM pathology is 
still ongoing, ischemia is currently considered the most common predisposing factor related 
to this pattern of injury (Back 2014). Interestingly, ischemic insults to the early developing 
CNS selectively damage WM structures, while sparing GM regions (Fern 2011). As a result, 
ischemia regularly leads to the development of a selective pattern of injury known as 
periventricular white matter injury (PWMI).  
As the name suggests, PWMI is found deep in developing WM adjacent the lateral ventricles 
(Shannon, Salter et al. 2007). The hallmark characteristic of PWMI is the death of developing 
oligodendrocytes. However, irreversible injury to pre-myelinated axons, diffuse gliosis and 
enlarged ventricles is also evident. Severe cases involve ischemic-type lesions, known as 
periventricular leukomalacia (PVL), which display a focal necrotic core, surrounded by areas 
of diffuse injury, characterised by the selective loss of developing oligodendrocytes (Banker 
and Larroche 1962, Volpe 2001). Pre-term infants are the largest patient cohort who suffer 
PWMI, with the high-risk period being those born between weeks 23 and 32 of gestation. It 
is apparent in approximately 50% of pre-term infants born before 32 weeks and/or under 
1500g birth-weight (Khwaja and Volpe 2008). Advances in neonatal care have dramatically 
improved the survival rate of pre-term infants, yet there has been no significant reduction in 
the incidence of this debilitating WM injury (Alix and Fern 2009). Infants who develop PWMI, 
regularly exhibit problems such as seizures, sensory/cognitive deficits and/or motor 
disabilities, including cerebral palsy (CP). CP is a non-progressive disorder which accounts for 
a wide range of incurable motor and sensory impairment syndromes, which manifest at a 
young age, and continue unabated throughout a lifetime (Volpe 2001). It is the most common 
human birth disorder, with a prevalence of 1 in every 400 live births (Kuban  and Leviton 1994). 
This translates to approximately 1800 new cases of CP every year in the UK alone 
(cerebralpalsy.org.uk). PWMI is the leading cause of CP in surviving premature infants (Salter 
and Fern 2008). It is estimated that between 60-100% of CP cases, show signs of PWMI 
(Anderson and Swanson 2000). However, at the moment there are not effective treatments 
or prophylactic remedies for dealing with this. 
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This raises the question as to why the developing brain would be deprived of blood, and what 
makes WM so susceptible? The propensity for PWMI is closely associated with an incomplete 
vascular supply at this age (Volpe 2001, Khwaja and Volpe 2008). Focal necrotic lesions in PVL 
are typically located in the arterial end zones of long penetrating vessels. The distal end zones 
of penetrating arteries are not fully developed during the early-mid gestational period of 
human development, which leaves deep WM regions particularly susceptible to periods of 
prolonged ischemia if blood flow decreases. In addition, blood flow to WM regions in the 
developing brain is surprisingly low, ranging from 1.6 to 3ml. 100 g-1.min-1, which is 
approximately 25% of what GM regions receive at this age (Khwaja and Volpe 2008). 
Therefore, the margin by which cerebral blood flow (CBF) can drop before injury begins to 
occur is minimal (Volpe 2001). There is also evidence to suggest that that immature infants 
show an impaired autoregulation of CBF during periods of low blood pressure (Khwaja and 
Volpe 2008). This is likely related to the absence of muscles in penetrating arteries (Kuban 
and Gilles 1985). A second cohort of full-term infants suffer birth-asphyxia, which is the 
temporary interruption of oxygen availability during birth (Morales, Bustamante et al. 2011). 
This may can occur from a prolapsed umbilical cord before birth, delivery complications or 
underdeveloped lungs (cerebralpalsysymptoms.com). In addition, genetic factors, such as 
congenital heart disease (CHD), may also leave infants susceptible to prolonged periods of 





Fig 1.6: Cerebral blood supply and 
periventricular white matter injury.  
Schematic representation of a coronal 
section through the cerebrum. The left 
hemisphere indicates the cerebral 
vascular supply, including long and short 
penetrating arteries. The right 
hemisphere indicates the location of 
both focal necrotic regions (black) and 
the diffuse penumbra region (grey) seen 
with PVL. Note the location of focal 
regions adjacent the lateral ventricles 
(centre). The outer overlaying grey 
shading depicts grey matter, whereas the 
under-laying white region depicts white 




1.3.1.3: Cardiac arrest, vascular dementia and spinal cord injury 
 
As discussed, stoke and PWMI regularly lead to the formation of focal ischemic lesions. 
However, global cerebral ischemia, which encompasses the entire brain, can also occur when 
blood flow to the brain is completely stopped. This is regularly a consequence of cardiac arrest. 
Ischemic heart disease is the leading cause of death worldwide, accounting for approximately 
8.76 million deaths per year (WHO, 2014). Furthermore, approximately 40% of patients who 
survive cardiac arrest are left in a vegetative state (Madl, Kramer et al. 2000). Cerebral 
ischemia is considered the leading cause of disability and death following cardiac arrest 
(Mangus, Huang et al. 2014). The cessation of systemic circulation during cardiac arrest leaves 
the cerebrum susceptible to global ischemic brain injury. If blood supply in not restored 
quickly, this ultimately leads to extensive neuronal and glial damage.  
Vascular dementia is the second leading cause of dementia, after Alzehimers’ disease. It 
currently affects approximately 150,000 people in the UK. Interestingly, approximately 20% 
of patients who survive a stroke will develop vascular dementia. Subcortical vascular 
dementia is typically caused by cerebrovascular disease, such as hypertensive small vessel 
disease (Strub 2003). It typically arises from the development of thick walled arteries, and stiff 
and twisted blood vessels which ultimately reduce blood supply. It is the most common form 
of vascular dementia and predominantly occurs in people over the age of 65 (Alzehimers 
Society, Vascular dementia).  
A reported 2.5 million people are currently living with spinal cord injury, with that number 
increasing by approximately 130,000 every year (Thuret, Moon et al. 2006). Similar to stroke, 
it is a major debilitating pathology. The primary insult typically arises from physical trauma. 
However, secondary injury is regularly observed due to vascular and biochemical events 
which occur following the initial insult (Oyinbo 2011). The vascular mechanisms of secondary 
injury include impaired autoregulation of blood flow, systemic hypotension and ischemia-
reperfusion. A reduction in blood flow immediately after the primary trauma can contribute 




1.3.2: Pathophysiological events during WM Ischemia  
 
1.3.2.1: Early events: Ischemic depolarisation 
 
Depleted levels of ATP during ischemia initiate a deleterious cascade of events which 
ultimately lead to cell death if the blood supply is not restored. ATP is utilised by a variety of 
energy-dependant proteins and pumps involved in maintaining homeostatic conditions. A 
significant fraction of cerebral ATP is used by the Na+/K+ ATPase to maintain ionic gradients 
within the CNS. It is estimated that the Na+/K+ ATPase consumes up to 50% of the brains 
energy levels (Attwell and Laughlin 2001). The Na+ and K+ gradients between the intracellular 
compartment and extracellular space, power a variety of homeostatic transporters, including 
several Na+-coupled transport systems such as the sodium-calcium exchanger (NCX) and 
excitatory amino acid transporters (EAATs). As mentioned in section 1.1.1.2, these ionic 
gradients are also essential for action potential conduction in WM.  
During ischemia, cellular ATP levels are consumed within a matter of minutes which leads to 
the failure of a variety of ATP-dependant pumps, including the Na+/K+ ATPase. The failure of 
the Na+/K+ ATPase and the gating of ATP-sensitive K+ channels cause a dramatic rise in [K+]e 
(Ransom, Walz et al. 1992, Sun and Feng 2013), accompanied by a depolarising shift in 
membrane potential, which subsequently gates a number of voltage-dependant channels 
(Stys 1998, Alix 2006). Na+ influx proceeds through the opening of non-inactivating voltage-
gated Na+ channels (VGNCs) (Malek, Adorante et al. 2005, Stys 2005). While axons are 
incapable of AP conduction following the collapse of Na+/K+ gradients, the early loss in 
excitability does not directly lead to irreversible injury. It is under these conditions which a 
variety of deleterious events occur.  
In an effort to maintain sufficient levels of ATP, astrocytic glycogen stores may be utilized via 
an increase in anaerobic metabolism. However, the amount of ATP produced by anaerobic 
respiration alone is minimal. It leads an accumulation of extracellular lactic acid and an acid 
shift in extracellular pH (~0.31 drop) (acidosis) (Ransom, Walz et al. 1992). In addition, the 
high intracellular levels of Na+ also promote the reverse operation of the Na+-H+ antiporter, 
further acidifying the intracellular compartment (Stys 1998).  
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1.3.2.2: Axonal Ionic Injury Mechanisms: ‘Ca2+ dyshomeostasis’ 
 
The collapse of cellular Na+ and K+ gradients predisposes a variety of mechanisms which 
mediate irreversible cell injury and death in WM. Ca2+ is a major intracellular second 
messenger in neurons and glia. Intracellular Ca2+ signalling is dependent on the maintenance 
of low cytosolic concentrations in quiescent cells (Alberdi, Ruiz et al. 2014). While extracellular 
Ca2+ concentrations ([Ca2+]e) are approximatly 2mM, intracellular Ca2+ concentrations ([Ca2+]i) 
are maintained in the nanomolar range (typically <150nM) by several proteins, including the 
Ca2+-ATPase which sequesters Ca2+ into intracellular stores and Na+/Ca2+ exchanger, which 
extrudes Ca2+ across the plasma membrane. In addition, numerous cytosolic, Ca2+-binding 
proteins (or ‘Ca2+ buffers’) serve as chelators of free Ca2+ ions, which modulates the temporal 
and spatial transient rises in cytosolic Ca2+ (Schwaller 2010). Examples of Ca2+ buffers include 
calretinin, calbindin-D9k/-D28k and parvalbumins.  
During ischemia, the failure of these mechanisms combined with the excessive influx of [Ca2+]e 
across the plasma membrane and/or the release of Ca2+ ions from intracellular stores, leads 
to toxic elevations in cytosolic Ca2+. As previously mentioned in section 1.2.4, Ca2+ overload 
promotes several toxic downstream events, including the activation of a variety of deleterious 
Ca2+-dependant enzymes e.g. protease and lipases (Marcoli, Bonfanti et al. 2004, Montana, 
Ni et al. 2004, Káradóttir, Cavelier et al. 2005). Ca2+ overload is recognised at the central 
deleterious event in ischemic WM.  
Numerous studies have shown that irreversible WM injury is a Ca2+-dependant process. 
However, the source and pathway of cytosolic Ca2+ is somewhat controversial. The influx of 
[Ca2+]e is a major mediator of anoxic injury in the myelinated ON (Stys, Ransom et al. 1990, 
LoPachin and Stys 1995). Studies have shown that the degree of anoxic injury is directly 
proportion to the concentration of [Ca2+]e, with complete protection seen with 0mM Ca2+  
(plus the calcium chelator, EGTA) (Stys, Ransom et al. 1990). Furthermore, anoxia leads to a 
sustained decrease in extracellular Ca2+ levels by approximately 0.42mM, consistent with the 
influx of extracellular ions (Brown, Westenbroek et al. 2001). In contrast, Ouardouz et al. 
found that the ischemic rise in axonal Ca2+ in the dorsal column predominantly originates from 
intracellular stores (Ouardouz, Nikolaeva et al. 2003). In fact, Ca2+ free solutions are known to 
exacerbate injury in older WM tracts (optic nerve) (Baltan, Besancon et al. 2008). Nikolaeva 
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et al. reported that the chemical ischemia-induced rise in ON axonal Ca2+ is only abolished 
when [Ca2+]e was omitted, and IP3/ryanodine receptors on intracellular stores were 
simultaneously blocked (Nikolaeva, Mukherjee et al. 2005). Therefore, it is plausible that Ca2+ 
dyshomeostasis during ischemia occurs via multiple pathways.  
 
1.3.2.2a: Reversal of the Na+/Ca2+ Exchanger (NCX) 
 
Interestingly, Na+ influx through non-inactivating VGNCs is also necessary for irreversible 
anoxic injury in the RON (Stys, Waxman et al. 1992). Axoplasmic Na+ levels gradually rise over 
the course of 60 minutes of anoxia, increasing by approximately 5-fold, reaching 
concentrations near 100mM (LoPachin and Stys 1995, Stys, Lehning et al. 1997). Na+ channel 
blockade (with either TTX or STX) or Na+ replacement (with either Cl- or Li+) significantly 
improves post-anoxic compound action potential (CAP) recovery in the myelinated RON (Stys, 
Waxman et al. 1992, Brown, Westenbroek et al. 2001).  A major mechanism for coupling the 
fluxes of both Ca2+ and Na+ ions is the NCX. The NCX is an transmembrane antiporter which 
usually extrudes [Ca2+]i ions from a cell in exchange for [Na+]e ions. However, the accumulation 
of [Na+]i combined with a positive shift in membrane potential favours the reverse operation 
of the NCX and thus, promotes transport of Ca2+ into a cell. Pharmacological inhibition of the 
NCX is highly protective, resulting in a significant improvement in CAP recovery post-anoxia 
(Stys, Waxman et al. 1992, Li, Jiang et al. 2000). Likewise, inhibition of the NCX (with bepridil) 
also prevents a significant component of the anoxia-induced drop in [Ca2+]e during anoxia 
(Brown, Westenbroek et al. 2001). Therefore, a primary route of axonal Ca2+ influx during 
anoxia is through the reversal of the NCX. 
 
1.3.2.2b: Voltage-Gated Ca2+ Channel (VGCCs) activation 
 
An early study by Stys et al., found that the application of a range of non-specific Ca2+ channel 
blockers (Mn2+, Co2+ and La3+) had no significant effect on ON functional recovery following 
anoxia (Stys, Ransom et al. 1990). However, it was suggested that any potential protection 
may have been clouded by the toxic effect of applying inorganic ions (Stys 1998). Therefore, 
the involvement of voltage-gated Ca2+ channels (VGCCs) was re-examined some years later 
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due to a lack of appropriate controls. More recent studies using non-toxic L-type VGCC 
antagonists (nifedipine, diltiazem and verapamil) found a significant improvement in CAP 
recovery post-anoxia (Fern, Ransom et al. 1995). Furthermore, the co-application of N-type 
channel antagonist, SNX-124, with diltiazem added further protection post-anoxia suggesting 
that multiple sub-types of VGCCs mediate a toxic rise in [Ca2+]i (Fern, Ransom et al. 1995). 
Similar to NCX inhibition (with bepridil), inhibiting L-type VGCCs (with diltiazem) also reduced 
the drop in [Ca2+]e levels in the adult RON during anoxia (Brown, Westenbroek et al. 2001). 
Thus, a combination of influx through VGCCs and the NCX contribute to the toxic Ca2+ rise in 
myelinated axons.   
Moreover, Ca2+ influx through VGCCs mediate the ischemic injury of developing pre-
myelinated axons. Diffuse expression of VGCCs along the axolemma of pre-myelinated axons 
is known to contribute to AP conduction during development (Alix, Dolphin et al. 2008). 
However, the expansion of central pre-myelinated axons prior to the initiation of myelination 
is accompanied by the formation of clustered Ca2+ channels (P- and Q- type) which populate 
future nodes of Ranvier (Flynn, MacWalter et al. 2008, Alix, Zammit et al. 2012). Interestingly, 
these large diameter central axons are particularly susceptible to ischemic injury, which is 
mediated via Ca2+ influx through these VGCCs (Alix, Zammit et al. 2012). 
 
1.3.2.2c: Mobilisation of Intracellular Ca2+ Stores 
 
While Ca2+ influx through the NCX and VGCCs mediates a significant component of the axonal 
Ca2+ rise, several studies have reported a rise in the absence of extracellular Ca2+ (Ouardouz, 
Nikolaeva et al. 2003). This is associated with the release of Ca2+ from intracellular stores, 
such as the endoplasmic reticulum (ER). Intracellular Ca2+ storage compartments contain 
relatively high concentrations of Ca2+ (0.1-1mM). Interestingly, when myelinated ONs are 
exposed to caffeine, an agonist of ryanodine receptors, it leads to a dramatic increase in Ca2+-
sensitive OGB-2 fluorescence, suggesting that intracellular release is capable of elevating 
axoplasmic Ca2+ levels (Ren, Ridsdale et al. 2000). The major sources of intracellular Ca2+ 
release from ER is through ryanodine receptors (RyR), inositol-1,4,5-triphosphate receptors 
(IP3R), NAADP-sensitive receptors and SCaMPER (sphingolipid Ca2+ release-mediating protein 
of the ER) (Stys 2005). In contrast to previous studies, Ouardouz et al. found that the omission 
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of bath Ca2+ had no protective effect on dorsal column axons which were exposed to 60 
minutes of ischemia (Ouardouz, Nikolaeva et al. 2003). However, when intracellular stores 
were depleted with the Ca2+-ATPase inhibitor thapsigargin, there was a significant 
improvement in CAP recovery (Ouardouz, Nikolaeva et al. 2003, Ouardouz, Malek et al. 2006). 
Furthermore, the rise in [Ca2+]i in a Ca2+ free aCSF solution was abolished in the presence of  
blockers of ryanodine and IP3 receptors (Ouardouz, Malek et al. 2006).  
The L-type Ca2+ channel blockers, diltiazem and nimodipine, which block the channels voltage 
sensor, provided a significant degree of protection post-ischemia in the rat spinal cord 
(Ouardouz, Nikolaeva et al. 2003). Curiously, this effect was not observed in the presence of 
the pore-blocking agent, cadmium (Cd2+). IHC demonstrated a close link between Cav1.2/3 (L-
type channel subunits) and RyR1/2 (ryanodine receptors). This paradigm suggests that L-type 
channels sense membrane depolarisation, and signal to RyRs causing them to open and 
release Ca2+ (Ouardouz, Nikolaeva et al. 2003, Stys 2005). Ouardouz et al. proposed that the 
mechanism of intracellular release involves a “complex interplay” between AMPA-receptor 
mediated depolarisation which is detected by VGCC which subsequently promotes Ca2+ 
mobilization from intracellular stores (Ouardouz, Malek et al. 2006). Interestingly, blocking 
intracellular Ca2+ release with thapsigargin or with diltiazem, which blocks the voltage sensor 
of L-type VGCCs (which should prevent Ca2+ mediated release from ryanodine receptors), 
failed to improve functional recovery in the absence of extracellular Ca2+ in the P10 RON (Alix, 
Zammit et al. 2012). This suggests that intracellular release may be developmentally regulated.  
 
1.3.2.3: Astrocyte Injury Mechanisms 
 
Fibrous astrocytes are considered relatively resistant to ischemia when compared to axons 
and oligodendrocytes (Thomas, Salter et al. 2004). This is closely associated with their high 
energy reserves in the form of glycogen deposits, fatty acids and lactate (Rossi, Brady et al. 
2007, Doyle, Simon et al. 2008). However, astrocytes undergo a programme of reactive 
astrocytosis during ischemia, which may have obscured previous in vivo studies. In fact, 
histological studies have shown evidence that astrocytes may be much sensitive to energy 
deprivation than originally thought (Fern 2015). Interestingly, fibrous WM astrocytes are 
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considered more sensitive to acute ischemic injury than protoplasmic GM astrocytes 
(Shannon, Salter et al. 2007).  
 
Similar to axons, increases in [Ca2+]i mediates the death of neonatal in situ astrocytes (Fern 
1998). Prior to the migration of oligodendrocytes into the ON (P0-2), fura-2 loaded astrocytes 
show an dramatic increase in [Ca2+]i after 5-10 minutes of ischemia, with cell death evident 
after only 15-20 minutes (Fern 1998). Astrocyte death at this age is Ca2+-dependant process, 
mediated via Ca2+ influx is through the activation of both T- (early influx) and L- (late influx) 
type VGCC. It was also noted that neonatal astrocytes have a low Na+ conductance, and 
therefore, the Na+/Ca2+ acted to remove intracellular Ca2+ during ischemia (Fern 1998). 
 
However, the Ca2+-dependant mechanism of astrocyte injury is a maturation-dependant 
process. By P10, an age which coincides the high-risk period for PWMI, the removal of [Ca2+]e 
exacerbated astrocyte cell death (Thomas, Salter et al. 2004). Although a rise in [Ca2+]i is 
observed during ischemia, it does not mediate cell death at this age. Interestingly, the change 
in injury mechanism coincides with the down-regulation of VGCCs and an upregulation of the 
Na-K-Cl- co-transporter (NKCC) from the age of P5. Inhibition of the NKCC (with bumetanide) 
or the removal of Na+ or Cl-, prevents a large degree of astrocyte injury. This suggests the 
cellular swelling becomes a major mechanism of astrocyte injury. Astrocyte injury is initially 
prevented by blocking NKCC, which was protective for a period of up to 40 minutes of OGD. 
Complete protection was found at all time periods (up to 60 minutes) by removing 
extracellular Na+ and K+, and was found to be mediated by DIDS-sensitive HCO3- transport at 
later stages (Salter and Fern 2008). Consistent with these findings, the inhibition of VGCCs 









1.3.3: Concluding Remarks: Excitotoxic WM injury 
 
The process of ischemic WM injury involves a complex combination of distinct injury 
pathways. However, excitotoxic WM damage is now considered a central mechanism 
involved in the death of oligodendrocytes and irreversible functional injury. The involvement 




















1.4: Overall Research Aims 
 
As outlined, ischemic WM pathology is an area of high clinical relevance. Despite recent 
advances, there is still a surprising lack of effective interventions. Ischemic WM injury features 
rapid myelin disruption which ultimately leads to the failure of action potential conduction. 
However, the fundamental mechanism(s) of ischemic myelin damage is controversial. Recent 
studies have also revealed the extensive nature of glutamatergic signalling in WM, including 
between the axon and myelin sheath (the axo-myelinic synapse). The overall aims of this 
project are to determine the mechanisms of glutamate release in WM and to test the 
hypothesis that myelinic NMDA receptor activation mediates ischemic myelin damage.  
Chapter 3: Experiments in chapter 3 investigate the significance of vesicular glutamate release 
in WM, specifically in axons and fibrous astrocytes. The overall aim is to test whether 
myelinated central axons are capable of vesicular glutamate release.  
Chapter 4: Chapter 4 examines the potential mechanisms underlying a key event in the 
pathophysiology of WM stroke; ischemic glutamate release. The aim is to determine the 
pathway of glutamate release under acute ischemic conditions.  
Chapter 5: Chapter 5 examines the mechanism of ischemia-induced myelin damage in central 
WM. The specific aim is to test the hypothesis that the over-activation of myelinic NMDA 
receptors mediates myelin damage and irreversible injury during ischemia. Furthermore, I 
test a novel sub-unit specific NMDA receptor antagonist, QNZ-46.   
The work in this thesis will hopefully contribute to a better understanding of the injury 
mechanisms involved in ischemic WM. It is hoped that these findings will also contribute to 













Chapter 2:  














2.1: Animals  
 
All animal procedures conformed to local ethical guidelines. UK home office regulations were 
followed and all experiments were conducted in accordance with the UK Animals (Scientific 
Procedures) ACT 1986. All animals were sacrificed via schedule 1. Wistar rats, PLP-GFP and 
C57Bl/6 wild-type mice and were sacrificed via cervical dislocation (rats aged <P10) or 
exposed to a rising concentration of CO2, prior to cervical dislocation or exsanguination. All 
THY1/YFP (line H) and GFAP-GFP transgenic mice were sacrificed at the University of Malta, 
where animals were anesthetised using isoflurane (Vetflurane 100mg/g, Virbac.) prior to 
decapitation.  
 
For experiments requiring the use of optic nerve (ON), nerves were dissected from either 
neonatal Wistar rats (P8-12), adult Wistar rats (P90-120), adult PLP-GFP or C57Bl/6 wild-type 
mice (P80-110). For corpus callosum (CC) experiments, coronal slices were obtained from 
adult Wistar rats (P90-120), adult THY-1/YFP (Line H), GFAP-GFP or C57Bl/6 wild-type mice 
(P80–110). 
 
2.2: Optic Nerve and Corpus Callosum Isolation 
 
 
Following decapitation, the scalp was removed and the ON was severed at the optic disc by 
cutting behind the eyeballs. The skullcap was removed and the brain was quickly dissected 
into a petri dish containing oxygenated artificial cerebrospinal fluid (aCSF; see table 2.1 for 
composition). Both ONs were dissected free at the optic chiasm and placed in an oxygenated 
interface perfusion chamber (Harvard Apparatus Inc.). Following decapitation, the entire 
procedure typically took less than 2 minutes.  
 
For experiments requiring the use of brain slices, the brain was initially dissected into a petri 
dish containing oxygenated aCSF. The cerebellum and brain stem were removed, and the 
entire brain was subsequently embedded in 0.5% agrose (made-up in aCSF) and put on ice for 
5-7 minutes. The embedded brain was mounted on the platform of a vibratome (Leica 
VT1200g) using superglue and immediately immersed in an oxygenated, ice-cold HEPES 
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cutting solution (see Table 2.1 for composition. Note; brain slices carried out in the University 
of Malta were immersed in ice-cold aCSF supplemented with 75mM sucrose). The embedded 
brain was stabilised against a 4% agrose block (made up in H20), which was also superglued 
to the stage. The brain was oriented to cut coronal slices from the genu of the corpus callosum 
through the caudal extent of the hippocampus. Coronal slices (400µm thick), including the 
corpus callosum, were cut and transferred to a Haas-type interface brain slice chamber 
(Harvard Apparatus Inc.) containing oxygenated HEPES cutting solution at room temperature. 
Only slices in which the anatomical structure of the CC was clearly visible, and had a continued 
appearance across the midline were included in experiments.  
 
For the majority of experiments carried out on the CC, whole brain slices were transferred to 
an interface perfusion chamber. However, for electrophysiological CAP experiments, the CC 
was dissected out from the brain slice under a stereomicroscope. Slices were kept in ice-cold 
HEPES cutting solution and the surrounding tissue was carefully removed from the CC using a 
microscissors and forceps (Fig. 2.1). The isolated CC was immediately transferred to the 
interface perfusion chamber. The procedure typically took less than 5 minutes. Li et al. have 
since published a paper (including a supplementary video) outlining the steps involved (Li, 
Velumian et al. 2016). In order to include a sufficient number of axons running within the 
plane of a slice, CC slices between the bregma (identified by the anterior commissure at the 











Fig. 2.1: Corpus callosum isolation from coronal brain slices.  
a1) 400µm thick coronal brain slices were kept in ice-cold cutting solution. a2) Using a micro-scissors 
and forceps, the surrounding tissue was carefully separated from the CC. Once the surrounding tissue 
was removed and discarded; the isolated CC was transferred to the recording chamber. Taken from 
(Li, Velumian et al. 2016). 
 
 
2.3: Solutions and Drugs 
 
Solutions were made up using Millipore deionised water and kept in the fridge for no longer 
than one night before use. The osmolarity was tested using a vaporpressure osmometer 
(Wescor, Vapro), and corrected to 300mOsm (±10mOsm), if required. All control aCSF/HEPES 
solutions were bubbled with a 95% O2/5% CO2 gas mixture for at least 60 minutes before use, 
and continued throughout the day. Alternatively, oxygen-glucose deprivation (OGD) solutions 
were bubbled with 95% N2/5% CO2.  



























NaCl 126 126 _ 126 79 100 1.37M 92 
KCl 3 3 3 3 50 _ 27 2.5 
NaH2PO4 2 2 _ 2 2 1.9 100 1.2 
MgCl2 2 2 2 2 2 1 _ _ 
NaHCO3 26 26 _ 26 26 _ _ 30 
Glucose 10 _ 10 10 10 _ _ 25 
Sucrose _ 7 _ _ _ _ _ _ 
CaCl2 2 2 2 _ 2 _ _ 2 
NMDG/Cl _ _ 124 _ _ _ _ _ 
Choline-HCO3 _ _ 26 _ _ _ _ _ 
EGTA _ _ _ 50µM _ _ _ _ 
Glycerol _ _ _ _ _ 2 _ _ 
HEPES _ _ _ _ _ _ _ 20 
C6H7NaO6 _ _ _ _ _ _ _ 5 
Thiourea _ _ _ _ _ _ _ 2 
C3H3NaO3 _ _ _ _ _ _ _ 3 
MgSO4.7H2O _ _ _ _ _ _ _ 2 
KH2PO4 _ _ 2 _ _ _ 20 _ 
Na2HPO4 _ _ _ _ _ 8.1 _ _ 
 
Table 2.1: Composition of solutions used.  
All concentrations are in mM, unless otherwise stated. pH was adjusted to 7.4 if necessary. 
aCSF=artificial cerebrospinal fluid, OGD=oxygen-glucose deprivation, PBS=phosphate buffered saline 
and Hyd. buffer= hydration buffer used for biosensors. *When preparing zero-Na+ aCSF, 124mM 
NMDG was initially made up in 500ml water and pH was adjusted to 7.4 using concentrated 
hydrochloric acid (HCl) before the remaining ingredients were added. All the above reagents were 
purchased from Sigma-Aldrich. 
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To prepare 500ml 4% paraformaldehyde (PFA), 20g PFA powder was added to a beaker with 
450ml warm, distilled H2O with stirring. The beaker was covered with parafilm and gradually 
heated to 60°C. Note; the solution should not exceed 70°C, as this will break down PFA. 5 
drops of 2N NaOH (~1 drop per 100ml) were added to aid dissolution. Once dissolved, the 
beaker was removed from the hot plate, 50ml of 10X PBS was added and it was left cool to 
room temperature. pH was adjusted to 7.4 with HCl, the solution was filtered and aliquots 
were stored at -20°C. 
 





(+)-MK 801 maleate Tocris (Bio-techne) DMSO -20 (alloq.) 10/50 µM 
A-967079¥ Abcam DMSO -20 (alloq.) 10 µM 
Antimycin-a Sigma-Aldrich DMSO -20 (alloq.) 25 µM 
Bafilomycin a1 Viva Bioscience DMSO -20 (alloq.) 50nM 
BAPTA-AM Sigma-Aldrich DMSO -20 (alloq.) 50 µM 
Carbenoxolone (CBX) Sigma-Aldrich Water 2-8 100 µM 
CIQ Tocris (Bio-techne) DMSO -20 (alloq.) 20 µM 
Diltiazem Hydrochloride¥ Tocris (Bio-techne) H20 Room temp. 100 µM 
EGTA Sigma-Aldrich Water Room temp. 50 µM 
FM4-64 Life Technologies H20 2-8 10 µM 
Furosemide¥ Sigma-Aldrich DMSO Room temp. 5mM 
Goat Serum Sigma-Aldrich - -20 10%-PBGST 
L-aspartic acid (aspartate) Sigma-Aldrich Water Room temp. 10 µM 
L-glutamaine Sigma-Aldrich Water Room temp. 10 µM 
L-glutamic acid (glutamate) Sigma-Aldrich Water Room temp. 10-100 µM 
NBQX disodium Salt¥ Tocris (Bio-techne) H20 -20 (alloq.) 20 µM 
NBQX¥ Tocris (Bio-techne) DMSO -20 (alloq.) 20 µM 
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NPPB Sigma-Aldrich DMSO -20 (alloq.) 100 µM 
Paraformaldehyde (PFA) Sigma-Aldrich 0.1M PBS -20 4% (w/v) 
PPDA Tocris (Bio-techne) DMSO -20 (alloq.) 1-50 µM 
Pregnanolone hemisuccinate¥ Steraloids Inc. DMSO -20 (alloq.) 100 µM 
Prostaglandin E2 (PGE2) TRC DMSO -20 (alloq.) 100 µM 
QNZ-46¥ Tocris (Bio-techne) DMSO -20 (alloq.) 1-50 µM 
Rose Bengal (RB) ¥ Sigma-Aldrich H20 Room temp. 0.5 µM 
Rotenone Sigma-Aldrich DMSO Room temp. 1nM-5µM 
Sulfasalazine (SAS) Sigma-Aldrich DMSO Room temp. 250 µM 
 TBOA Sigma-Aldrich DMSO -20 (alloq.) 200 µM 
Triton X-100 Sigma-Aldrich - RT 0.5%-PBGST 
Veratridine Tocris (Bio-techne) DMSO -20 (alloq.) 10 µM 
𝜷 Cyclodextrin Sigma-Aldrich PBS RT 1mM 
 
Table 2.2: List of pharmacological reagents used.  
TRC= Toronto Research Chemicals, DMSO= Dimethyl sulfoxide, alloq.= aliquoted, PBS= phosphate 
buffered saline, PBGST= PBS/goat serum/triton mixture. ¥= experiments preformed in a darkened 
room. 
 
All reagents were added to the appropriate aCSF solutions on the day of experiment. Some 
reagents were dissolved, aliquoted and frozen down as stock solutions. In experiments using 
furosemide, the aCSF solution was adjusted accordingly to accommodate 5mM furosemide 
(i.e. NaCl concentration was reduced to 123.5mM from 126mM). When reagents were 
dissolved in DMSO, the final concentration was kept below 0.5% volume per unit volume (v/v). 
For experiments using BAPTA-AM, RONs were incubated into a petri-dish containing zero-Ca2+ 
aCSF and 50µM BAPTA-AM for 90 minutes (30 minutes at room temperature, 60 minutes at 
2-8°C). Afterwards, RONs were placed in the perfusion chamber and perfused with solutions 
without the drug. BAPTA-AM is an acetoxymethyl ester derivative of the calcium chelator 
BAPTA, and once the compound enters the cell, intracellular esterases cleave the 
acetoxymethyl group, leaving the compound permanently internalised. 
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2.4: Experimental Protocol: In vitro ischemia 
 
Following ON/CC isolation, the tissue was placed in an interface perfusion chamber (Harvard 
Apparatus Inc.) and continuously perfused with oxygenated aCSF at a rate of 0.6-1.5ml/min. 
The chamber was humidified via continuously bubbling with 95% O2/5% CO2 (gas flow: 1LPM) 
and the temperature was gradually warmed to 37±0.5°C over 60 minutes (101C Temp 
Controller, Warner Instruments). In order to regain homeostatic control following the 
dissection, nerves/slices were allowed to equilibrate for a minimum of 60 minutes before 
initial control recordings (Fig. 2.5c). At the beginning of every experiment, baseline recordings 
were made for a minimum of 10 minutes under normoxic conditions. As previously reported, 
both ON and CC slices can be maintained under control conditions for several hours with 
minimal functional or structural loss (Alix and Fern 2009, Li, Velumian et al. 2016). 
As previously discussed, ischemia is defined as an inadequate supply of essential substrates 
required for cellular metabolism. In living tissue, this is a consequence of an insufficient blood 
supply. To simulate ischemic conditions, the isolated tissue was perfused with a zero-glucose 
(substituted with 7mM sucrose), deoxygenated (pre-bubbled for 60 minutes with 95% N2/5% 
CO2) aCSF solution (Fig. 2.2). The chamber bath was simultaneously bubbled with the 95% 
N2/5% CO2 gas mixture to remove atmospheric O2. In addition, the recording chamber was 
partially covered to prevent the diffusion of atmospheric O2 to the tissue. Previous studies 
report that the concentration of O2 in the recording chamber reaches zero after 
approximately 2 minutes (Stys, Waxman et al. 1992). This is referred to as ‘oxygen-glucose 
deprivation’ or ‘OGD’ throughout. Nerves were typically exposed to OGD for 60 minutes, 
following which, normoxic conditions were re-introduced (reperfusion) for 60-90 minutes to 
ensure maximum functional recovery. Temperature, gas and aCSF flow-rates were 
maintained constant throughout. 
It must be noted that this is a global model of ischemia, where the entire tissue is subject to 
an equal degree of insult. Therefore, this does not allow for any interactions which may occur 
between a focal ischemia core, a surround penumbra and/or normoxic tissue, which may 





Fig. 2.2: Schematic representation of RON in perfusion chamber.  
Nerves were perfused with an oxygenated aCSF solution containing 10mM glucose under control 
conditions (right). To mimic ischemia, nerves were exposed to a deoxygenated aCSF solution with 
zero-glucose (left). RON= rat optic nerve, aCSF= artificial cerebrospinal fluid.  
 
For experiments using enzymatic biosensors, stable recording could not be obtained under 
anoxic conditions (see section 2.6.3 for details). Therefore, chemical ischemia was employed 
as our model; combining metabolic inhibition with glucose deprivation. To inhibit oxidative 
phosphorylation, either rotenone (1nM, neonates) or antimycin-a (25µM, adults) was added 
to an oxygenated/zero-glucose aCSF solution. Rotenone is commonly used as a broad-
spectrum insecticide and pesticide due to its potent ability to selectively inhibit complex-I of 
the mitochondrial electron transport chain (ETC). More specifically, rotenone reversibly 
inhibits NADH dehydrogenase, preventing the transfer of electrons to ubiquinone. It has 
previously shown to mimic the effects of hypoxia (Wyatt and Buckler 2004) and therefore, 
has been used by many authors as a model of chemical ischemia (Litsky, Hohl et al. 1999, 
Allen, Káradóttir et al. 2005). Antimycin-a is a potent inhibitor of electron transport at 
complex III of the ETC, and has also previously been employed as a model of ischemia (Allen, 
51 
 
Káradóttir et al. 2005, Fern 2015). All other components remained the same throughout 
recordings.  
Following every experiment, the chamber was rinsed with 1l of distilled H20. Once a week, 
the chamber was sequentially rinsed with H20, sodium phosphate tribasic, H20, a dilute 
hydrochloric acid solution and finally with H20 again. Any water in the chamber bath was 
removed at the end of every experiment. 
 




Electrophysiology is essentially the study of electrically excitable cells. As mentioned, WM 
tracts are primarily responsible for relaying electrical signals between different regions of the 
CNS. This form of communication is executed through the propagation of action potentials 
(AP) which involves the rapid change in membrane potential along an axon. The compound 
action potential (CAP) is defined as the sum of all action potentials fired from individual axons 
within a nerve bundle, when the nerve is electrically stimulated (Stys, Ransom et al. 1991). 
Electrophysiological CAP recordings from the isolated ON are widely used as a measure of 
electrical conductance, providing a quantitative measure of axonal function and conductance 
velocity. Continuous recordings act as a reliable measure of functional recovery following 
periods of energy deprivation, such as OGD. To access functional recovery from isolated WM 
tracts, CAPs were recorded from the rat/mouse ON and CC using the glass electrode 
preparation (Stys, Ransom et al. 1991). This technique was established in the 1930’s by 
Ergland and Gasser (Erlanger and Gasser 1937) and involves the electrical stimulation of one 
end of a nerve and the subsequent recording of the propagated CAP at the opposite end. 
An electrical model was developed in 1991 by Stys et al. which greatly contributed to the 
development of stable and reliable recordings which could be applied over long periods (Stys, 
Ransom et al. 1991). Treating the nerve as a single isolated fibre, the ‘intracellular potential’ 
of the nerve which is inside the recording electrode, is referred to as Ve. The intracellular 
potential of the nerve which is outside the electrode is assigned Vm (see Fig. 2.3). Without 
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stimulation, the resting potential is equal in both parts of the nerve (e.g. -70mV), with respect 
to ground. Thus, the recorded difference between Vm and Ve (Vo) is zero. A signal is only 
recorded when Vo ≠ 0. When the fibre is electrically stimulated, Vm will depolarise (become 
less negative) resulting in a transient difference between Ve and Vm. The resulting output 
voltage drop (Vo) will be recorded by the recording electrode. Initially Vo will become positive 
as Vm depolarises. However, as the action potential propagates along the fibre, Vm will 
repolarise, while Ve depolarises, resulting in Vo becoming more negative. Thus, the recorded 
CAP is the transient difference between Vm and Ve and is typically biphasic. When both Vm and 
Ve have returned to their resting potential, no signal will be recorded (Stys, Ransom et al. 
1991). However, resistive elements will strongly affect the flow of current between Vm and Ve. 
AP conduction will be met by both internal resistance (Ri) and external resistance (Ro) (see Fig. 
2.3). Ri includes the series membrane resistance, while Ro accounts for the combined 
resistance of the extracellular space, glial cells, connective tissue and the fluid layer between 
the nerve and electrode. Vo can therefore be described by the following equation;        
 
Ro (Vm – Ve) 
Ri 
 
Vo is directly proportional to Ro. Thus, increasing the external resistance will directly increase 
the size of the recorded signal, Vo, which can be achieved by inserting the nerve into a tight 








Fig. 2.3: Schematic representation of the theoretical electrical model of CAP recording from the ON.  
Shown is an optic nerve inserted into the end barrel of a recording electrode. The recorded signal, Vo, 
is a result of a voltage drop across Ro following the flow of current, i, between Vm and Ve. Vm represents 
the transmembrane potential outside the electrode, while Ve represents the transmembrane potential 




Both stimulating and recording glass electrodes (1-1.2mm diameter, Harvard Apparatus) were 
shaped via gentle heating over the flame of a Bunsen burner until the barrel bends under its 
own weight, forming a periscope shape. Sliver wire was coated with a thin chloride layer by 
immersing it in a solution containing chloride ions overnight (chlorine tablets dissolved in 
distilled water). The chlorided silver wire (Ag/AgCl) was then inserted into the lumen of each 
glass capillary. The stimulating electrode also had an Ag/AgCl wire wrapped around the 
outside of the glass capillary barrel near the opening in order for the wire to make contact 
with the perfusing aCSF solution. The electrodes were mounted in a manipulator and 
positioned at either end of the nerve. To minimise electrical interference (noise) and stimulus 
artefact field potentials, a third, identical electrode was placed parallel to the recording 
electrode, providing a differential recording. 
The stimulating electrode is connected to an isolated stimulator (Iso Stim A320; World 
Precision Instruments) via both Ag/AgCl wires, forming a returning current. The Ag/AgCl wire 
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from both the recording and subtracting electrode are connected to an amplifier (Cyber Amp 
320, Axon Instruments) via an electrode adaptor (AI405, Axon Instruments). 
All electrodes are back-filled with oxygenated aCSF. Following the equilibration period after 
dissection, the ON/CC was gently nudged into the lumen of the stimulating electrode at one 
end, and the lumen of the recording electrode at the opposite end (Fig. 2.4b). A tight fit 
around the RON was necessary to ensure the nerve did not move during the course of an 
experiment. If needed, the mouth of the glass electrode was heated over a flame to alter the 
glass diameter. Once secure, recording started.  
With younger, unmyelinated nerves, CAPs were evoked via square-wave constant current 
pulses (Iso stim A320, WPI) with a typical duration of 150-600µs. 50µs or lower pulses were 
used for the older myelinated nerves. Increasing the stimulus intensity (0-1.1mA) dramatically 
increases the size of the recorded CAP, until a plateau is reached. CAPs were elicited via 125% 
supra-maximal pulses to ensure all functional axons within the RON are recruited. Differential 
signals were amplified (Cyber Amp 320, Axon Instruments), filtered (low pass: 800-20,000 Hz), 
digitized (1401 micro3, Cambridge Electrical Design Ltd.) and displayed on a PC running Signal 
software (version 6, Cambridge Electrical Design Ltd.) (Fig. 2.4). CAPs were evoked and 










Fig. 2.4: CAP recording set-up.  
a) Photo of CAP set-up in lab. The ON is maintained on a nylon mesh on the surface of an interface 
perfusion chamber. Stimulating and recordings electrodes are connected to each end of the nerve. b) 
Schematic illustration of CAP set-up. 
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2.5.2: CAP Analysis 
 
As mentioned, the electrical model proposes a biphasic CAP (Stys, Ransom et al. 1991). This 
is the case with young unmyelinated ONs (<P12) as nearly all axons within the fibre conduct 
at similar velocity due to their uniform diameter and lack of myelin (Fig. 2.5a). However, unlike 
the homogenous population of axons in the pre-myelinated ON, the adult ON contains a 
population of axons with various diameters and thus, a variety of conductance velocities 
(Hildebrand and Waxman 1984). The resulting adult CAP consists of 3 positive peaks i.e. 
triphasic (Fig. 2.5b). 
To quantitatively access functional integrity, the peak-to-peak amplitude of biphasic CAPs was 
measured every 30 seconds of recording (neonates, Fig. 2.5a). For triphasic CAPs, the rectified 
area under the curve was calculated up to where the waveform returned to baseline (adult, 
Fig. 2.5b). Both measurements were made using Signal software by placing a cursor before 
the first peak (but after the stimulus artefact) and a second cursor where the CAP returns to 
zero. The stimulus artefact was subtracted at the end of every experiment. To accurately 
access functional recovery after reperfusion, all CAPs were normalised to the initial 10 
minutes of recordings under control conditions. Non-recoverable CAP loss indicates 













Fig. 2.5: Sample CAP trace recorded from a pre-myelinated optic nerve (P10) and a fully myelinated 
adult optic nerve.  
a) P10 CAPs are typically biphasic in shape, with a positive and negative component. CAP amplitude is 
measured from peak-to-peak (red). b) Adult CAPs typically have 3 positive peaks (i-iii) followed by a 
delayed negative component. CAP area is measured as the rectified area under the curve (red). *= 
stimulus artefact. c) Following dissection, CAP amplitude recovers to a stable plateau over 60 minutes. 
(1=CAP recording was initiated 5 minutes after dissection). All remaining CAP experiments were 
initiated after 60 minutes recovery in control aCSF (3). 
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One of the primary objectives of this project is to examine the mechanism(s) of glutamate 
release in WM. A practicable way of achieving this involved the direct measurement of 
extracellular glutamate concentration ([Glut]e) within the nerve. Sarissa Biomedical Ltd. 
(Warwick University, Coventry, UK) specialise in the development and production of 
microelectrode amperometric biosensors (sarissaprobes®) used for the detection of 
neuroactive chemicals, including l-glutamate (GLU-sensors) (Tian, Gourine et al. 2009). The 
electrochemical sensors allow for real-time detection of relatively low concentrations of l-
glutamate (limit of detection; 100nM) with a broad linear range (from 0.1μM to 100μM). The 
sensors are specifically designed for in vitro and in vivo research, but also have clinical 
diagnostic applications, capable of measuring analytes in a droplet of blood (15µl). The 
sensors have previously been used for the detection of neurochemicals in cell culture 
(Trotman, Vermehren et al. 2015) and with in situ preparations, such as the isolated rodent 
optic nerve (Yang, Hamner et al. 2014). 
Sarissaprobes® are enzymatic biosensors, which convert a substrate or analyte of interest (i.e. 
glutamate) into an active product, providing an amperometric signal which is directly 
proportional to the concentration of the substrate. The sensors are made of a hollow glass 
body containing a platinum (Pt) wire, connected to a pin at one end (see Fig. 2.6). At the 
opposite end, the exposed Pt wire (sensing area) is coated with an immobilised layer of 
glutamate oxidase, which when exposed to l-glutamate, generates hydrogen peroxide (H2O2) 
in the following oxidation reaction (Tian, Gourine et al. 2009); 
 
l-glutamate + O2 + H2O ⇌ 2-oxoglutarate + NH3 + H202 
 
The detection principle of the GLU-sensor is based on the production of H2O2, which can be 




H202           Pt wire (+500mV)         O2 + H+ + 2e 
 
The resulting current is amplified via a potentiostat (Duo-Stat ME200+, Sycopel International), 
which is connected to the sensor. Currents are recorded and displayed on a PC using Signal 
software.  
There are several features which ensure a highly selective (‘true’) glutamate signal. The 
microelectrode tip is coated with a very thin perm-selective polymer, which allows H2O2 to 
freely diffuse through to the electrode surface where it is subsequently detected by the Pt 
wire. However, it rejects any possible compounds which may interfere with readings (see 
‘inner permeable selective layer’, Fig. 2.6). The layer of glutamate oxidase is covalently linked 
to the polymer which securely immobilises the enzyme to the sensor surface and prevents 
leaching. In addition, the sensing tip is also coated with an outer perm-selective layer which 
excludes electroactive interferents, such as l-ascorbic acid, uric acid, dopamine and 5-HT, 
which may be oxidised themselves at the Pt wire (Dale, Hatz et al. 2005). However, l-
glutamate can freely diffuse through the outer perm-selective layer to the inner enzymatic 
layer. Finally, null sensors are used in every experiment. Null sensors are identical to GLU-
sensors, but lack the layer of glutamate oxidase. During recordings, both biosensor and null 
signals are recorded, but the null signal is subsequently subtracted from the biosensor signal 
to eliminate current generated from nonspecific interferants. Thus, any increase in current 
will reflect a direct increase in extracellular glutamate concentrations ([Glut]e). The GLU-
sensors are 50μM in diameter and 0.5mm in length (product number; SBS-GLU-05-50) and 






Fig. 2.6: Physical structure and principle underlying glutamate microelectrode biosensors.  




Before first use, the sensor tips were carefully bent so that the sensing tip ran parallel to the 
nerves longitudinal axis (Fig. 2.7b). To do this, the rubber sealant was grasped close to the 
sensing tip with a fine forceps and bent to the desired angle. In addition, the sensors are 
immersed in a hydration buffer (see Table 2.1) for a minimum of 10 minutes before use. 
Microlectrodes are then mounted on a manipulator and carefully lowered into the chamber. 
Sensor-selectivity was tested against compounds which have a similar structure to glutamate. 
The sensors were highly responsive when exposed to 10µM l-glutamic acid (glutamate), yet 
there was no response to either glutamine or aspartic acid (both 10µM) (Fig. 2.8a). 
For ON experiments, the tough outer membrane prevented the simple insertion of the sensor 
tip without stripping the perm-selective layers. Therefore, a small incision was made on the 
upper surface of the nerve (approximately 10-20% of the nerve diameter) using a micro-
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scissors. The CC did not require such a procedure. Sensor tips were fully inserted and moved 
laterally towards the centre of the nerve, away from the incision site (Fig. 2.7b). This was 
carried out for both GLU-sensor and null sensor. Following sensor insertion, nerves/slices 
were allowed to equilibrate for long periods before an experiment. The initial recorded 
current ([Glut]e) was high following electrode insertion, presumably due to localised tissue 
damage. [Glut]e gradually declined to a low stable baseline over a long stabilization period of 
120-180 mins (neonatal ON), 300-420 mins (adult ON) or 180-240 mins (adult CC slice) (Fig. 
2.8b). A stable baseline was recorded for a minimum of 10 minutes at the start of every 
experiment. An Ag/AgCl reference electrode was present in the chamber for all experiments.  
In order to convert sensor current into glutamate concentration, a calibration was necessary 
at the end of each experiment. To do this, electrodes were withdrawn from the nerve, as the 
tissue would impede free access of exogenous glutamate. The sensor tips were then lowered 
into the chamber and exposed to a known concentration of l-glutamic acid. It was important 
to ensure that the entire surface area of the sensor is immersed in solution. All calibrations 
were carried out in the same physiological solutions which were used that day i.e. aCSF at 
37°C. Calibrations were initially repeated with multiple concentrations of l-glutamic acid, but 
due to the reliable linear response, single point calibrations were sufficient (Fig. 2.9a-b). 
Repeated use of the sensors led to a gradual decrease in biosensor sensitivity. According to 
Sarissa Biomedical, this is a likely a consequence of enzyme degradation from proteases 
within the tissue and physical removal of enzyme at the sensor surface (sarissa-
biomedical.com) (Fig. 2.9a-b). Stock l-glutamic acid solutions were kept for no longer than 3 
months (at 4°C, Fig. 2.9c). Following calibration, the sensors were removed, stored in small 
pots containing the hydration buffer and kept at 4-8°C. Once rehydrated, they have a wet 
shelf-life of between 3 to 5 days. Exposure to air was kept to a minimum as this is known to 








Fig. 2.7: Glutamate biosensor set-up.  
a) Photo of glutamate biosensor set-up in lab. The ON/CC is maintained in an interface perfusion 
chamber. Both GLU and null biosensors are inserted inside the tissue. b) Schematic representation of 












Fig. 2.8: Selectivity of GLU-biosensors and long stabilization period.  
a) Selectivity of GLU- biosensors against equivalent concentrations of l-glutamic acid, l-glutamine and 
l-aspartic acid (10µM). Note the large current response to l-glutamic acid, which was absent during 
exposure to the other compounds. b) Sample trace of elevated [Glut]e in adult (black) and neonatal 
(grey) ON (recordings initiated 20 minutes after electrode insertion). Note how the adult ON required 












Fig. 2.9: GLU-biosensor calibration.  
a,b) GLU-biosensor i-t response curve  to various concentrations of l-glutamic acid. Note the linear 
response to concentrations up to 100µM. GLU-biosensor sensitivity decreased with time (Day 1 v Day 








As mentioned, the oxidation reaction responsible for H2O2 production requires the substrates 
l-glutamate, oxygen and water (l-glutamate+O2+H2O⇌2-oxoglutarate+NH3+H202). Despite 
previous papers reporting reliable recordings under hypoxic conditions (Dale, Hatz et al. 2005, 
Tian, Gourine et al. 2009); we could not get stable recordings following O2 withdrawal.  GLU-
biosensor sensitivity was dramatically reduced following the removal of O2 from the chamber 
(Fig 2.10a-b). In addition, this would occasionally increase the signal-to-noise ratio. This 
discrepancy may be related to the severity of oxygen withdrawal. Whereas previous papers 
using sarissaprobes® perfused samples with a deoxygenated solution (pre-bubbled with 
95%N2/5%CO2) (Dale, Pearson et al. 2000, Frenguelli, Llaudet et al. 2003, Tian, Gourine et al. 
2009), our preparation was perfused with a deoxygenated aCSF and had atmospheric O2 
removed from the chamber via bubbling the chamber bath with 95% N2/5% CO2. This protocol 
may be closer to anoxic conditions, which may account for the decrease in GLU-sensor 
sensitivity during OGD. For this reason, chemical ischemia was employed as our model of 

















Fig. 2.10: GLU-biosensors are O2 dependent.  
a) Sample i-t response curve during exposure to OGD. Not the drop in current during O2 withdrawal. 
Yet, GLU-biosensors were still responsive to l-glutamaic acid (10µM) under normoxic conditions. b) An 
alternative sample i-t response curve, showing a clear loss in sensitivity when O2 was removed from 










Immunohistochemistry (ICH) is a technique used to visualise the distribution and localisation 
of specific target antigens within tissue. The first ICH study was performed by Albert H. Coons 
et al. in 1941 (Coons, Creech et al. 1941). The technique is based on antigen-antibody 
interactions within biological tissue, which can subsequently be visualised with fluorescent 
markers (fluorophores). An antibody, or immunoglobulin (Ig), is a ‘Y’ shaped protein 
consisting of a constant Fc region and two variable fab fragments. The antigen-binding site 
(paratope) is located on the fab fragment of the antibody. The antigen-binding site selectively 
binds to the epitope of the target antigen. There are two methods of detecting bound 
antigens; the direct and indirect method. The direct method uses an antibody which is directly 
conjugated to a flurorophore or fluorochrome, which allows visualisation under a fluorescent 
microscope. The indirect method uses a second, fluorescent antibody; the unlabelled ‘primary’ 
antibody which binds directly to the antigen, and a second fluorophore-conjugated 
‘secondary’ antibody which subsequently binds to the primary antibody. 
Primary antibodies are produced by inoculating a host animal (e.g. rabbit, mouse, goat) with 
the antigen of interest. The host’s immune system will produce specific antibodies against the 
foreign antigen, which can later be withdrawn and purified. These antibodies can be either 
polyclonal or monoclonal. Polyclonal antibodies recognise many epitopes on a single antigen, 
whereas monoclonal antibodies only recognise one. The secondary antibody is generated by 
inoculating another host species with antibodies from the host species in which the primary 




ONs were immersed in a petri-dish containing 4% paraformaldehyde (PFA) for 20-30 minutes 
at room temperature. PFA forms covalent cross-links between proteins which prevents 
decomposition and stabilises cell morphology. Nerves were then transferred to a 20% (w/v) 
sucrose solution (in 1X PBS) for a further 20 minutes (cryoprotection). The tissue is 
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subsequently embedded in OCT medium (Tissue-Tek, Sakura) and frozen at -20°C. 20µm thick 
cryostat-cut (Leica) sections were mounted on SuperFrost Plus slides (ThermoFisher Scientific) 
and left to dry at room temperature. If slides were not immediately used for staining, they 
were stored at -20°C for a maximum of 1 month. 
Each slice was encircled with a hydrophobic, PAP pen and washed in 1X PBS for 5 minutes. To 
facilitate antibody access and prevent non-specific binding of secondary antibodies, sections 
were permeabilised and blocked in a 1X PBS solution containing 10% goat serum and 0.5% 
triton X (referred to as PBGST) for 2 hours at room temperature. All primary and secondary 
antibodies are diluted in PBGST. Sections were then incubated with primary antibodies 
overnight at 4°C. The sections were then washed three times in PBGST for 5 minutes, and 
incubated in the secondary antibody for 1 hour at room temperature. This was followed by a 
series of washes; 3 X 5 minute washes in PBGST, followed by 3 X 5 minute washes in 1XPBS. 
Slides were mounted with Citifluor (glycerol/PBS solution), cover-slipped and allowed to dry. 
Negative controls were carried out to ensure there was no non-specific binding of the 
secondary antibody. For this, primary antibodies were excluded. 
 
Antibody Dilution Species Clonality Company 
Neurofilament heavy (200kDa) 1:500 Mouse Monoclonal Sigma 
Neurofilament-light (70kDa) 1:500 Mouse Monoclonal Sigma 
L-glutamate Various Rabbit Polyclonal Abcam 
 
Table 2.3: List of primary antibodies used in ICH studies 
 
 
Antibody Dilution Species Company 
Alexa Fluor 488, Anti-mouse 1:1000 Goat Sigma-Aldrich 
Alexa Fluor 568, Anti-rabbit 1:200 Goat Sigma-Aldrich 
 





Attempts were made to examine glutamate distribution in the RON using an anti-l glutamate 
antibody (ab9440). The immunogen for this antibody is l-glutamate conjugated to 
glutaraldehyde. However, due to excessive auto-fluorescence from glutaraldehyde-fixed 
nerves (0.1-2.5%), reliable images were not obtained. A variety of antibody concentrations, 
fixes (glutaraldehyde, PFA, methanol-acetone, and methanol) and fix-durations were tested, 
but to no avail. In addition, sudan black was used to quench auto-fluorescence. However, this 
was unsuccessful and glutamate-staining was no longer pursued.  
 
2.7.3: Confocal Imaging and Analysis 
 
RON slices were imaged via single-photon, laser scanning confocal microscopy (Leica TCS SP8 
inverted microscope) using a x40/x63 oil objective lens. For each set of experiments, all slices 
were treated in the same way with respect to laser intensity, gain and format. Neurofilament 
staining was analysed using Image J (National Institutes of Health) and mean pixel intensity 
levels were measured from at least 3 random regions of interest (ROI) from every slice.  
 
 




Fluromyelin Red (Life Technologies) is an established red-fluorescent myelin stain. As with the 
IHC protocol, RON fixed-sections were initially blocked and permeabilised (2hrs in PBGST). 
Slices were then incubated with fluromyelin (1:300) for 20 minutes at room temperature. 
Following this, sections were washed 3 times in PBGST (5 minutes each) and 3 times in 1X PBS 
(5 minutes each), before being cover-slipped. Images were acquired using an inverted Nikon 





2.8.2: Live-tissue: Bath-loading 
 
For dual live-imaging of fluromyelin and QNZ-46, adult rat ON or brain slices (400µM thick) 
were incubated with fluromyelin (1:20) and QNZ-46 (50µM) in cutting solution for 120 
minutes at 4°C. Following which, slices were transferred to fresh cutting solution 
(fluromylein/QNZ-46 free) and images were collected via laser scanning confocal microscopy. 
Wide-field QNZ-46 imaging was performed using a Zeiss epifluorescence microscope.  
Fluorescent emission scans during excitation at 405 nm were conducted using 10nm bin width 
and the lambda-scan function; with 10mM QNZ-46 in DMSO diluted 50:50 in immersion oil. 
QNZ-46 has a peak emission at 450nm in a lipid environment (Fig. 2.11b*). *Lambda scan was 
performed by Prof. Robert Fern and Prof. Mario Valentino. For remaining experiments, QNZ-
46 was imaged following excitation at 405nm using filter settings standard for DAPI emission. 
 
2.8.3: In vivo 
 
Adult C57Bl/6 mice were injected IP. with a 200μl of 50% DMSO solution containing 1mM β-
cyclodextrin + 20mg/Kg QNZ-46 (50:50), or a vehicle control without the QNZ-46. Injections 
were performed blind by animal house staff and mice were left for 240 minutes on a warming 
pad. Other than mild sedation in both groups, attributed to the DMSO, the animals showed 
no signs of distress or aberrant behaviour. ON or brain slices were collected as above, in 













Fig. 2.11: QNZ-46 fluorescence.  
a) Molecular structure of QNZ-46 indicating the fluorescent quinazolinone backbone (blue) and the 
myelin targeting trans-stilbene region (red). b) Lambda scan of QNZ-46 fluorescence following 
excitation at 405nm in a lipid environment (10mM QNZ-46 in immersion oil). QNZ-46 fluorescence 












FM dyes are non-toxic, lipophilic styryl-compounds which have been extensively used to study 
the kinetics of vesicular fusion and recycling. The use of FM dyes as a vesicular marker relies 
on their ability to reversibly partition into lipid membranes without penetrating (Hoopmann, 
Rizzoli et al. 2012). All FM dyes have the same general structure. The dye is composed of a 
lipophilic tail, which causes the dye to partition into lipids environments, such as plasma or 
vesicular membranes (Gaffield and Betz 2006). The length of the tail region determines the 
dyes affinity for lipid membranes, with long-tailed variants, such as FM 4-64 (dyeN- (3-
triethylammoniumpropyl)- 4 -(6-(4-(diethylamino)phenyl)hexatrienyl) pyridinium dibromide), 
binding more tightly (Verstreken, Ohyama et al. 2008).  The tail-end is connected to a water-
soluble (lipophobic) head group which prevents the dye from crossing the plasma membrane. 
The head and tail groups are connected via two aromatic rings linked by a variable double 
bond region, which together create the fluorophore (Gaffield and Betz 2006, Hoopmann, 
Rizzoli et al. 2012). The number of double bonds connecting the two rings determines the 
dye’s fluorescence spectrum. Dyes with a high number of double bonds, such as FM 4-64, 




Fig. 2.12: Chemical structure of FM4-64.  
Structure of FM4-64 showing the lipophilic tail end, and the positively-charged lipophobic head group. 
Both components are connected to aromatic rings which are linked via a variable double bond bridge. 
(Hoopmann, Rizzoli et al. 2012).   
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FM-dyes are particularly useful in the study of vesicular recycling. The dyes excited state relies 
on the transfer of charge across the double-bond bridge and is highly dependent on solvent 
polarity (Gaffield and Betz 2006). The dye is practically non-fluorescent in polar, aqueous 
solution, such as water. However, once its hydrophobic tail is inserted into the outer leaflet 
of a lipid membrane (non-polar), lipophilic interactions cause the probe to become intensely 
fluorescent (Newton and Murthy 2006). In preparations capable of vesicular neurotransmitter 
release and reuptake, the dye becomes internalised within recycled vesicles, allowing for 
optical imaging of vesicular uptake/release. Measurement of vesicular exocytosis can be 
accomplished by quantifying FM-fluorescence during stimulation, where a decrease in 
fluorescence reflects the release of the vesicular-bound probe into the bath (see Fig. 2.13). 
As mentioned, FM4-64 has a pronounced red-shifted emission spectrum, well separated from 
the green/yellow emission spectra of green-fluorescent protein (GFP) and yellow fluorescent 
protein (YFP). This is highly advantageous, allowing for dual-excitation imaging of both FM-
fluorescence and endogenous fluorophores. Experiments using FM 4-64 were carried out on 
transgenic mice with either neuronal-specific expression of YFP, controlled by the THY1-
promoter (THY1-YFP (line H)), or astrocyte-specific expression of GFAP, controlled by the GFP 
promoter (GFP-GFAP (line M)).  
FM-dye imaging in intact brain slices can be difficult due to excessive background 
fluorescence (Winterer, Stanton et al. 2006). The high density of surface membrane lipid 
makes it difficult to eliminate residual membrane-bound dye, even after extensive washing 
(Pyle, Kavalali et al. 1999). It is particularly difficult to wash out the dye from damaged 
membranes in acute slices. Non-specific fluorescence may be significantly strong enough to 
dampen any vesicular-bound fluorescence. To help overcome these issues, a long recovery 
period is allowed following brain slicing. Moreover, imaging was acquired via two-photon 
microscopy (TPM), capable of providing an unrivalled signal over background fluorescence by 
suppressing out-of-focus, background fluorescence (Winterer, Stanton et al. 2006, Valentino, 






Fig. 2.13: Theory behind FM-dye vesicular imaging.  
1. FM-dye is applied to a cell or tissue, causing it to reversibly insert into the outer leaflet of the plasma 
membrane. This dramatically increases fluorescence intensity, labelling the extracellular membrane. 
2. To induce exocytosis/endocytosis, the preparation is stimulated in the presence of the dye. This 
causes vesicles to fuse with the membrane, coming into contact with the dye. 3. Subsequently, 
endocytosis will trap some of the dye molecules in retrieved vesicles. 4. The remaining extracellular 
dye is washed away, leaving only the entrapped dye in internalised vesicles. 5. The preparation is 
stimulated again in the absence of the dye, causing the fusion of vesicles with the outer-membrane, 
releasing vesicular dye into the ECS (destaining). 6. The released dye is washed away. Adapted from 





Stock FM4-64 (Life Technologies) solutions (1mM) were dissolved in deionised water and 
stored for several months at 2-8°C when protected from light (Gaffield and Betz 2006). 
Coronal brain slices (400µm thick) from transgenic animals were placed in an oxygenated 
HAAS-type interface holding chamber (Scientific Systems Design Inc.) for a minimum of 90 
minutes (at room temperature). A brain slice was then transferred to a mini submerged 
chamber (0.5ml) with a coverglass bottom (Warner Instrument Corporation, Hamden, CT) 
mounted on the stage of a custom modified, upright BX50W1 Olympus Multiphoton 
microscope (Olympus, Tokyo, Japan). Slices were held in place by means of a slice anchor 
(‘harp’) with nylon thread and perfused with room temperature oxygenated (95% O2/5% CO2) 
aCSF at a flow rate of approximately 3.5 ml/minute. Final temperature control (37 ±1°C) was 
maintained using an in-line heater (Warner Instrument Corporation, Hamden, CT) equipped 
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with a feedback thermistor placed in the chamber and the temperature raised gradually over 
1 hour. Slices were initially examined to identify a suitable region of the CC. The multiphoton 
system housed Keplerian beam expanders with IR introduction light paths to achieve perfect 
excitation efficiency and highly resolved images. A mode-locked MaiTai HP DeepSee laser 
system (Spectra- Physics) with a tuneable Ti: sapphire oscillator (690-1040nm) was used as 
the excitation light source (pulse width < 100fs; pulse repetition rate 80Mhz) and controlled 
through an acousto-optical-modulator to allow for precise changes in laser intensity. The 
Group Velocity Dispersion was electronically compensated by a prism coupled pre-chirper 
and the beam diameter adjusted by a Keplar telescope.  
Slices were perfused with 10µM FM4-64 (in aCSF) for 10 minutes. To stimulate vesicular 
exocytosis, slices were subjected to a 50mM K+ aCSF solution (depolarising solution) + 10µM 
FM4-64 for 5 minutes (Kukley, Capetillo-Zarate et al. 2007). After which, slices were returned 
to aCSF + 10µM FM4-64 for a further 20 minutes to ensure complete endocytosis. Next, slices 
were washed in aCSF (without FM4-64) for a minimum of 15-20 minutes and a suitable region 
of the CC was identified. Finally, slices were exposed to 50mM K+ aCSF for 10 minutes (or 
ischemia for 30 minutes) to promote vesicular fusion/FM4-64 unloading. Control images were 
acquired for at least 60 seconds before FM4-64 unloading. Images were acquired every 10 
seconds following laser excitation at 890nm and collected using standard red and green filter 
settings. 
 
2.9.1: FM-dye Analysis 
 
Image acquisition was performed using the Olympus FluoView software. To compare any 
changes in FM-fluorescence, pixel intensity was calculated in defined regions of interest, i.e. 
YFP+ axon cylinders or GFP+ astrocytes. Data is expressed as the percentage change in 
fluorescence intensity relative to resting fluorescence intensity before stimulation (%∆F/F) 
over time (minutes). Control experiments were repeated in control aCSF to account for 
possible photo-bleaching and/or spontaneous vesicular release. Any significant decrease in 







[Glut]e and CAP experiments were plotted as a 120-second rolling average over time and 
random spikes were removed. All data is presented as mean ± SEM. Significance was 
determined by unpaired t-test or one-way ANOVA with Holm-Šídák post hoc-test, as 
appropriate (GraphPad Prism 6). Ischemia and control experiments were interdigitated. For 
experiments requiring long periods of drug pre-treatment, appropriate control experiments 
were performed to allow direct comparison. ns P ≥ 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, 

































Chapter 3:  











3.1.1: Synaptic White Matter 
 
Synaptic transmission is a highly specialised, unidirectional mechanism of intercellular 
signalling within the CNS. It is achieved via the release of vesicular neurotransmitters, 
followed by the subsequent interaction with receptors located on a dedicated post-synaptic 
membrane. In conventional GM synapses, the arrival of an action potential leads to a 
depolarising shift in membrane potential, which opens voltage-gated Ca2+-channels (VGCCs) 
located on the pre-synaptic bouton. The subsequent rise in [Ca2+]i, is detected by 
synaptotagmin-1, which induces a conformational change in SNARE protein associations and 
leads to the fusion of neurotransmitter-laden vesicles with the pre-synaptic membrane. Once 
released, the neurotransmitter freely diffuses across the synaptic cleft and binds to 
specialised target receptors embedded in the post-synaptic membrane. 
The absence of conventional neuronal synapses in WM led to the common belief that 
vesicular exocytosis was confined to GM regions, as an exclusive mechanism of inter-neuronal 
signalling. However, there is now compelling evidence which demonstrates that vesicular 
neurotransmission is prominent in deep WM regions, distant from classical GM synapses. 
Many key features of conventional neurotransmission are evident in WM, including the 
expression of SNARE proteins and a range of neurotransmitter receptors. Axons are 
considered the pre-synaptic element in WM and are known to express the necessary 
machinery required for vesicular exocytosis, including a high density of neurotransmitter-
laden vesicles. Furthermore, axonal glutamate release is capable of evoking receptor-
mediated responses in neighbouring glial cells and myelin, acknowledged as the post-synaptic 
component of the WM synapse (Kukley, Capetillo-Zarate et al. 2007, Ziskin, Nishiyama et al. 
2007, Alix, Dolphin et al. 2008, Hamilton, Vayro et al. 2010, Alix and Domingues 2011, Gautier, 
Evans et al. 2015, Micu, Plemel et al. 2016).  
The majority of axonal projections in the CNS are glutamatergic (Spitzer, Volbracht et al. 2016). 
Consequently, glutamatergic neurotransmission appears to be the dominant form of synaptic 
signalling within WM, facilitating direct communication between axons and their 
neighbouring glial partners. However, the functional significance of glutamate signalling at 
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the WM synapse is not fully understood. While there are many similarities between GM and 
WM synapses, the structural and functional differences are indisputable (Matute, Domercq 




Fig. 3.1: The synapse.  
Simplified representation of a) the conventional GM synapse, and b) the WM synapse (in an 
unmyelinated tract). In both cases, the arrival of an action potential (AP) opens voltage-gated Ca2+ 
channels (VGCCs), which leads to the fusion of glutamate-laden vesicles with pre-synaptic membrane 
(/axolemma). Released glutamate binds to receptors located on the post-synaptic membrane, either 




3.1.2: The Pre-synaptic Partner in WM 
 
3.1.2.1: The Axon 
 
Axons are responsible for the rapid transmission of electrical signals within the nervous 
system. The first direct evidence of synaptic neurotransmission in WM came in 2007, when 
two independent groups demonstrated AMPA receptor-mediated synaptic currents in 
oligodendrocyte precursor cells (OPCs) following the electrical stimulation of unmyelinated 
axons in the corpus callosum and optic nerve (Kukley, Capetillo-Zarate et al. 2007, Ziskin, 
Nishiyama et al. 2007). Similar to neuronal synapses, spontaneous excitatory post-synaptic 
currents (EPSCs) were also recorded in OPCs at rest (Ziskin, Nishiyama et al. 2007).  
Interestingly, unmyelinated axons and OPCs form anatomically defined contacts, appropriate 
for synaptic transmission. Electron microscopy has revealed the accumulation of vesicles 
distributed along the axon-side of the axolemma, with a similar size and configuration as 
those observed in cortical GM synapses (Kukley, Capetillo-Zarate et al. 2007, Ziskin, Nishiyama 
et al. 2007, Micu, Plemel et al. 2016). Similarly, axonal varicosities containing intracellular 
vesicles are observed along unmyelinated axons following electrical stimulation, particularly 
at specialised junctions with OPC processes (Shepherd and Raastad 2003, Wake, Ortiz et al. 
2015). ‘Omega-like’ profiles of vesicular fusion with the axolemma have been documented 
along the internode of myelinated axons which were rapidly fixed following electrical 
stimulation (Micu, Plemel et al. 2016). Consistent with axons being the primary pre-synaptic 
element in WM, vesicular endocytosis (recycling) is observed in both myelinated and 
unmyelinated axons using FM-dyes (Kukley, Capetillo-Zarate et al. 2007, Wake, Lee et al. 2011, 
Wake, Ortiz et al. 2015, Micu, Plemel et al. 2016). 
Vesicular fusion requires the expression and cooperation of a number of highly specialised 
proteins embedded in the pre-synaptic and vesicular membranes. Numerous studies have 
identified the expression of axolemma-bound SNARE proteins (e.g. SNAP-25) and vesicular 
glutamate transports (VGLUTs) in both unmyelinated and myelinated axons (Alix, Dolphin et 
al. 2008, Micu, Plemel et al. 2016). Axonal punctae which co-labelled for 
synaptophysin/SNAP-25 (Kukley, Capetillo-Zarate et al. 2007) and synaptophysin/VGLUT1 
(Ziskin, Nishiyama et al. 2007) indicate that SNARE protein expression in axons is not simply a 
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consequence of anterograde transport towards the nerve terminal. In addition, pre-
myelinated axons are known to express functional VGCCs which open during action potential 
conduction (Alix, Dolphin et al. 2008). Clustered VGCC are closely associated with the 
molecular components of vesicular docking, including V-ATPase and SNAP-25 (Alix, Dolphin 
et al. 2008). As expected for vesicular exocytosis, localised rises in intra-axonal Ca2+ are also 
observed during AP conduction (Verbny, Zhang et al. 2002, Zhang, Wilson et al. 2006, Kukley, 




To date, there is no evidence to suggest that fibrous astrocytes contribute to vesicular 
neurotransmitter release in WM. However, this does not exclude them as a potential pre-
synaptic element. Cultured GM astrocytes are capable of exocytotic neurotransmitter release, 
also referred to as ‘gliotransmitter’ release (Bezzi, Gundersen et al. 2004, Montana, Malarkey 
et al. 2006). Protoplasmic astrocytes express the secretory machinery required for vesicular 
fusion, including a range of SNARE proteins (Bezzi, Gundersen et al. 2004, Volterra and 
Meldolesi 2005). In addition, electron microscopy has revealed that astrocytes contain dense 
core vesicles, which are released in a botulinum toxin B (BoNT/B) sensitive fashion  (Prada, 
Marchaland et al. 2011). Although astrocytes are generally regarded as electrically silent, they 
express a number of VGCCs, capable of elevating [Ca2+]i (Bezzi, Carmignoto et al. 1998). The 
rise in [Ca2+]i is both necessary and sufficient to induce vesicular glutamate release from 
cultured astrocytes (Parpura, Basarsky et al. 1994, Montana, Malarkey et al. 2006). 
Conversely, the stimulation of a range of receptors which elevate [Ca2+]i (e.g. metabotropic 
glutamate, prostaglandin and purinergic receptors) also evoke glutamate release (Bezzi, 
Carmignoto et al. 1998, Hamilton, Vayro et al. 2010). Intracellular Ca2+ modulates a range of 
trafficking events which may promote the insertion of proteins which promote non-vesicular 
neurotransmitter release. However, the kinetics of such events are likely to be too slow to 
explain the rapid release of neurotransmitter observed in several cultured or slice 
preparations (Hamilton and Attwell 2010).  
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While still somewhat controversial, the exocytotic release of gliotransmitters from astrocytes 
is proposed to modulate neuronal excitability and/or neuronal transmitter release (Montana, 
Malarkey et al. 2006, Hamilton and Attwell 2010). Interestingly, the co-activation of 
AMPA/kainate and metabotropic glutamate receptors on astrocytes stimulates the release of 
glutamate in a Ca2+-dependant manner, which could represent a mechanism of back-
signalling to neurons (Bezzi, Carmignoto et al. 1998). In addition, high levels of [K+]e trigger 
the release of vesicular glutamate by activating VGCCs and elevating astrocytic Ca2+ levels 
(Yaguchi and Nishizaki 2010). Considering action potential conduction elevates [K+]e, it is 
plausible that vesicular glutamate release from fibrous WM astrocytes may modulate actively 
firing axons. In support of such a theory, Sasaki et al. reported that the local application of 
glutamate along the axon of hippocampal neurons increases the width of the action potential 
waveform (Sasaki, Matsuki et al. 2011). Additionally, elevating [Ca2+]i in periaxonal astrocytes 
also leads to the broadening of action potentials, through the activation of axonal glutamate 
receptors (Sasaki, Matsuki et al. 2011).  
The expression of the synaptic protein, synaptophysin, on NG2+ glia (oligodendrocyte 
precursor cells), also raises the question of whether OPCs are also capable of vesicular fusion 
(Bakiri, Burzomato et al. 2009). Thus, it remains to be determined whether axons are the sole 
mediator of vesicular fusion in WM, or if WM glial cells are also capable of this specialised 
mechanism of communication.  
 
3.1.3: The Post-synaptic Partner in WM 
 
3.1.3.1: Oligodendrocyte Precursor Cells 
 
As mentioned, OPCs come into close contact with axons, and thus are ideally positioned to 
monitor action potential firing (Hamilton, Vayro et al. 2010). Prior to the initiation of 
myelination, developing oligodendrocytes navigate along pre-myelinated axons, forming 
synaptic-like contacts with the bare axolemma (Káradóttir, Cavelier et al. 2005, Salter and 
Fern 2005, Alix and Fern 2009). Likewise, NG2+ cells in the mature CNS are known to send out 
processes which make precise contacts with the node of Ranvier in myelinated tracts (Butt, 
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Duncan et al. 1999, Ziskin, Nishiyama et al. 2007, Hamilton, Vayro et al. 2010). Similar to 
conventional neuronal synapses, developing (and mature) oligodendrocytes display a high 
post-synaptic density at sites of contact with unmyelinated axons  (Kukley, Capetillo-Zarate 
et al. 2007, Ziskin, Nishiyama et al. 2007) and are endowed with functional AMPA/kainate 
receptors (Patneau, Wright et al. 1994, Tekkok and Goldberg 2001, Deng, Rosenberg et al. 
2003), NMDA receptors (Káradóttir, Cavelier et al. 2005, Salter and Fern 2005, Micu, Jiang et 
al. 2006, Micu, Plemel et al. 2016) and all three groups of metabotropic glutamate receptors 
(Deng, Wang et al. 2004). The amplitude and kinetics of EPSCs recorded from corpus callosum 
OPCs during exposure to hyperosmotic solution (500mM sucrose supplemented) is not 
significantly different to the response recorded in from OPCs in alternative regions of the 
brain, suggesting that the receptor density and subunit expression is similar to those found in 
GM (De Biase, Nishiyama et al. 2010). Together, these characteristics leave oligodendroglia 
as ideal biological detectors of axonal neurotransmitter release.  
Several studies have recorded EPSCs in OPCs following the electrical stimulation of axons. The 
rapid kinetics of OPC-recorded signals are characteristic of synaptic neurotransmission. 
Consistent with spontaneous vesicular fusion from axons, spontaneous EPSCs (independent 
of action potentials) were recorded in the absence of electrical stimulation, a feature which 
was abolished in the presence of AMPA receptor antagonists or tetrodotoxin (TTX) (Kukley, 
Capetillo-Zarate et al. 2007, Ziskin, Nishiyama et al. 2007). Ziskin et al. showed that EPSCs 
could still be elicited in the presence of dl-TBOA, a glutamate transporter antagonist, and 
were increased following the application of α-latrotoxin, which enhances vesicular fusion 
(Ziskin, Nishiyama et al. 2007). In contrast, bafilomycin-a1, an inhibitor of V-type H+ ATPase, 
significantly decreased the amplitude of evoked EPSCs (Ziskin, Nishiyama et al. 2007). 
Glutamate receptor-mediated signalling in WM evokes transient intracellular Ca2+ rises in 
NG2+ glia in situ (Hamilton, Vayro et al. 2010). More recent studies have also noted Ca2+ 
transients in the fine processes of OPCs, following the electrical stimulation of DRG neurons, 
a feature which was prevented following glutamate receptor blockade or BoNT/A application 





3.1.3.2: Myelin Sheath 
 
In the mature CNS, a large population of axons are myelinated; meaning only about 1% of the 
axolemma is directly exposed to the extracellular milieu. This raises the question of whether 
myelin is capable of responding to vesicular glutamate release along the internodal axolemma. 
Until recently, myelin was considered a passive insulator which solely facilitated saltatory 
action potential conduction across the nervous system. However, recent findings suggest that 
myelin may be much more reactive and dynamic than once thought. For example, myelin 
expresses isoforms of two essential Ca2+ buffering systems, Na+-Ca2+ exchanger (NCX) and 
Ca2+-ATPase, suggesting that it may play a role in ionic regulation and/or signal transduction 
(Ishii, Dutta et al. 2009, Jahn, Tenzer et al. 2009).  
Studies on early myelinating WM show a high degree of NMDA receptor subunit (NR1) 
expression on the axolemma-side of navigating oligodendrocyte processes (Alix and Fern 
2009). As these synapses are lost during development, NR1 is reportedly translocated from 
the oligodendrocyte processes into myelin, with distinct evidence of NR1 expression within 
compact myelin itself (Alix and Fern 2009). Interestingly, immunoreactivity for NMDA 
receptor subunits demonstrate that NMDA receptor expression is predominantly found along 
the outer and inner periaxonal membranes, at levels which are comparable to neuronal 
synapses (Micu, Jiang et al. 2006, Micu, Plemel et al. 2016). Thus, myelinic NMDA receptors 
are ideally position to detect internodal vesicular glutamate release. Micu et al. were the first 
to demonstrate that directly exposing myelin to iGluR agonists (NMDA + glycine or AMPA + 
cyclothiazide) led to an increase in myelin Ca2+, as did the removal of Mg2+ under resting 
conditions (Micu, Jiang et al. 2006). More recently, the same group demonstrated that 
electrically active axons elicit Ca2+ rises in the cytoplasmic compartment of myelin, a feature 
which is abolished in the presence of NMDA or AMPA/kainate receptor antagonists, TTX or 
bafilomycin-a1 (Micu, Plemel et al. 2016). These findings suggest that not only is myelin 
capable of detecting glutamate release, but also that internodal axon segments may be 
capable of releasing vesicular glutamate into the confined periaxonal space (equivalent to the 




3.1.3.3: Alternative Targets: Astrocytes and Axons? 
 
Vesicular neurotransmitter release at conventional synapses is known to mediate Ca2+ 
signalling in protoplasmic astrocytes (Bazargani and Attwell 2016). Fibrous astrocytes form 
close associations with axons and are known to respond to axonal neurotransmitter release 
(particularly ATP) (Hamilton, Vayro et al. 2008). Action potential evoked ATP release from 
axons evokes a transient rise in intracellular Ca2+ (Hamilton, Vayro et al. 2008). While 
AMPA/kainate and NMDA receptor expression has been described in protoplasmic astrocytes 
(Verkhratsky and Steinhauser 2000, Lalo, Pankratov et al. 2006), the expression of functional 
glutamate receptors on WM astrocytes has not (Huria, Beeraka et al. 2015). Therefore, based 
on our current knowledge, it seems unlikely that astrocytes are a target of synaptic 
transmission in WM.  
While developing oligodendrocytes and myelin appear to be a major target of vesicular 
release in WM, reports of glutamate receptor expression on axons, raise the question of 
whether autologous glutamate signalling occurs in WM. Myelinated spinal cord axons are 
reported to express functional AMPA and kainate receptors, capable of eliciting intra-axonal 
Ca2+ rises (Ouardouz, Malek et al. 2006, Ouardouz, Coderre et al. 2009, Ouardouz, Coderre et 
al. 2009). In addition, pre-myelinated optic nerve axons express functional NMDA receptors 
which contribute to functional injury under ischemic conditions (Huria, Beeraka et al. 2015). 
However, the significance of such glutamate receptors under physiological conditions remains 
to be determined.  
 
3.1.4: Physiological Function of Vesicular Glutamate Release in WM 
 
Glutamatergic signalling within WM provides a sophisticated method of communication 
between axons and their partner glial cells. However, the physiological significance of such 
signalling is still somewhat controversial. Although much more experimental work is required, 




3.1.4.1:  Guide OPC Migration 
 
Founder OPCs  arise in distinct regions of the ventricular zone and are known to migrate 
considerable distances towards target axons (Binamé, Sakry et al. 2013). A combination of 
chemo-repellent and chemo-tactic signals guide OPC migration along axons/nerves towards 
their final destinations. Glutamatergic input can be detected in OPCs as early as P5 in neonatal 
mice (Ziskin, Nishiyama et al. 2007). Therefore, it is possible that vesicular glutamate release 
from actively firing axons may serve as an extrinsic regulator of OPC migration (Bakiri, 
Burzomato et al. 2009).  
OPCs express NG2, an integral membrane chondroitin sulphate (Butt, Duncan et al. 1999), 
and studies have shown that NG2 interactions with intracellular and extracellular ligands 
regulate cell migration (Stallcup 2002). Interestingly, NG2 is directly coupled to AMPA 
receptors in OPCs (Stegmüller, Werner et al. 2003, Ziskin, Nishiyama et al. 2007). Quantal 
glutamate release from axons is known to occur even in the absence of defined post-synaptic 
targets (De Biase, Nishiyama et al. 2010, Alix and Domingues 2011). The absence of defined 
synaptic junctions implies that vesicular glutamate release is directly into the extracellular 
space (ECS). Consistent with the high expression of glutamate receptors on OPCs, the 
establishment of an axon-derived glutamate concentration gradient in the ECS may play a 
vital role in regulating OPC migration towards the target axon. Inhibiting NMDA receptors 
dramatically attenuates OPC migration in an in vitro migration assay using neurohypophysial 
explants (Wang, Pralong et al. 1996). Alternatively, AMPA receptor-mediated signals promote 
OPC migration in a concentration dependent manner, starting with AMPA concentrations as 
low as 50nM (Gudz, Komuro et al. 2006). Together, this suggests that glutamate-mediated 
signals act as a chemoattractant signal, which may provide positional cues, stimulating OPC 
migration towards its destination. In support of such roles, OPC processes are less closely 
associated with electrically active axons in which vesicular fusion is blocked (with BnTX or 





3.1.4.2: Promote Oligodendrocyte Maturation 
 
OPC maturation is essential for myelination. Given the importance of myelination, it comes 
as no surprise that the development of oligodendrocytes is a highly regulated process (Emery 
2010). While intrinsic cues such as a ‘developmental clock’ that counts the number of cell 
divisions (Temple and Raff 1986) play an important role in OPC development, a variety of 
extrinsic cues, such as secreted molecules and axonal surface ligands, are essential in the 
control of OPC maturation into mature myelinating oligodendrocytes. Soluble axon-derived 
signals and the formation of synapses with axons influence the differentiation of immature 
oligodendrocytes (Miller 2002, Lundgaard, Luzhynskaya et al. 2013). Several studies have 
reported that glutamate receptor activation modulates oligodendrocyte differentiation by 
inhibiting OPC proliferation while simultaneously promoting differentiation into their mature 
counterparts. The activation of NMDA receptors in subventricular zone-derived OPCs 
increases their rate of differentiation and maturation in vitro (Cavaliere, Urra et al. 2012). On 
the other hand, the application of NMDA receptor antagonists or knockdown of the obligatory 
NMDA receptor subunit, NR1, significantly attenuates NMDA-induced differentiation (Li, Xiao 
et al. 2013). More recently, Fannon et al. demonstrated that blocking neuronal activity or 
AMPA receptors impaired the morphological development of OPCs and decreased the 
expression of myelin basic protein (MBP) (Fannon, Tarmier et al. 2015). Therefore, 
glutamatergic signalling may play a part in the complex array of axon-derived signals which 
control and guide glial cell development (Yuan, Eisen et al. 1998, Kukley, Capetillo-Zarate et 
al. 2007). 
 
3.1.4.3: Activity-dependent Myelination  
 
Up until recently, the significance of activity-dependant myelination in WM tracts was a 
rather controversial topic, as myelination is known to occur in the absence of electrical activity 
(action potentials) (Shrager and Novakovic 1995). For example, OPCs differentiate and form 
compact myelin on paraformaldehyde-fixed axons (i.e. inactive/dead) (Rosenberg, Kelland et 
al. 2008). However, it is now widely accepted that neuronal activity has a significant effect on 
both the rate and degree of myelination (Demerens, Stankoff et al. 1996, Wake, Lee et al. 
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2011, Lundgaard, Luzhynskaya et al. 2013, Gautier, Evans et al. 2015). Early studies observed 
a decrease in myelination in the ON of mice which were reared in the dark, which was 
interpreted as a result of decreased ‘functional stimulation’ (Gyllensten and Malmfors 1963). 
In contrast, electrically active axons which are capable of releasing vesicular 
neurotransmitters are preferentially myelinated in a co-culture of DRG neurons and OPCs 
(Wake, Ortiz et al. 2015). Similarly, blocking synaptic vesicular release reduces the number of 
myelin sheaths in zebra fish axons, while stimulating neuronal activity increased the number 
of myelin layers produced by a single oligodendrocyte (Mensch, Baraban et al. 2015). 
Vesicular glutamate release along axons stimulates the formation of cholesterol-rich 
microdomains on post-synaptic OPCs and also promotes the local synthesis of myelin basic 
protein (MBP), a major protein constituent of myelin sheath (Wake, Lee et al. 2011).  
Using a myelinating co-culture system, Lundgaard et al. reported that myelination can occur 
via two distinct modes, resolving the prior controversy over the significance of activity-
dependant myelination (Lundgaard, Luzhynskaya et al. 2013). The first intrinsic mode of 
myelination can occur in the absence of action potential conduction and glutamate release. 
However, the second mode requires the activity-dependent release of glutamate from axons 
and the subsequent activation of NMDA receptors on oligodendroglia. The switch to this 
‘activity-dependant mode’ requires the release of either neuregulin (NRG) or brain-derived 
neurotrophic factor (BDNF) which enhances OPC sensitivity to axonal activity by increasing 
NMDA receptor mediated currents in OPCs (Lundgaard, Luzhynskaya et al. 2013). As a result, 
glutamatergic signalling enhances both the rate and degree of myelination in actively firing 
axons. Although glutamate release is not essential for myelination, it plays a central role in 
the preferential myelination of electrically active axons. Consistent with such data, there is a 
high expression of NMDA receptors on the myelinating processes of immature 
oligodendrocytes (Káradóttir, Cavelier et al. 2005, Salter and Fern 2005). Vesicular signalling 
in WM may also constitute a signal for myelin length regulation, as attenuating synaptic 
glutamate release from retinal ganglion cells increases the number of nodes and reduces the 







During development, a population of NG2+ OPCs fail to differentiate, but instead form a 
distinct population of cells in the mature CNS (Nishiyama, Chang et al. 1999, Dawson, Polito 
et al. 2003). Following demyelination in multiple sclerosis (MS), OPCs undergo a process of 
rapid proliferation and subsequent differentiation in myelinating cells which replace myelin 
sheath (Reynolds, Dawson et al. 2002, Zawadzka, Rivers et al. 2010). Recruited OPCs form de 
novo contacts with demyelinated axons suggesting that WM synapses may play an import 
role in restarting myelination (Alix and Domingues 2011, Gautier, Evans et al. 2015). Blocking 
vesicular fusion from active axons or applying glutamate receptor antagonists significantly 
attenuates re-myelination in a toxin-induced focal demyelination model (Gautier, Evans et al. 
2015). Similar to activity-dependent myelination, glutamatergic synaptic transmission 
between demyelinated axons and OPCs may regulate re-myelination in an activity-dependant 
fashion. 
 
3.1.4.5: Maintain Axon Integrity 
 
The precise role(s) of the proposed axo-myelin synapse remains elusive. In addition to axon 
ensheathment, oligodendrocytes maintain long-term axon integrity by providing metabolic 
support (Nave 2010, Lee, Morrison et al. 2012). For example, lactate derived from 
oligodendrocytes is metabolised in WM tracts during periods of energy deprivation 
(Funfschilling, Supplie et al. 2012). Oligodendroglial NMDA receptor activation promotes the 
release of lactate and the redistribution of glucose transporter, GLUT1, into the myelin 
compartment (Saab, Tzvetavona et al. 2016). Alternatively, the chronic ablation of the 
obligatory NMDA receptor subunit, NR1, in oligodendrocytes leads to GLUT1 depletion in 
myelin, and gradual WM degeneration (Saab, Tzvetavona et al. 2016). Furthermore, the 
activity-dependant release of vesicular glutamate from axons triggers the secretion of 
oligodendroglial exosomes which are subsequently internalised by the axon (Fruhbeis, 
Frohlich et al. 2013). Exosomes contain a multiple protein and RNA cargo which support 
axonal metabolism under oxidative stress (Fruhbeis, Frohlich et al. 2013). It is therefore 
possible that glutamatergic synapses between the axon and myelin may act as a signal for 
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axonal energy requirements. Such signalling may promote the transfer of energy substrates 
to fuel axons during electrical activity.  
 
3.1.4.6: WM plasticity 
 
Recent evidence suggests that axo-myelin signalling may also play a role in the long-term 
maintenance and re-modelling of myelin sheath (Wang and Young 2014). Long-term changes 
in myelinic nanostructure are closely associated with memory and learning (Lundgaard, 
Luzhynskaya et al. 2013, McKenzie, Ohayon et al. 2014). For example, training-related 
increases in myelination are regularly observed in WM (Scholz, Klein et al. 2009, Zatorre, 
Fields et al. 2012). The axo-myelinic synapse may provide a mechanism by which architectural 
changes in the structure of myelin occur based on axonal firing patterns. Double transgenic 
mice lacking both NR-2D and -3A display an increased myelin thickness resulting from an 
increased spacing between the myelin lamella (decompaction), rather than changes in the 
number of myelin layers (Micu, Plemel et al. 2016). This suggests that NMDA receptor-
mediated currents in myelin may regulate the expression of structural myelin proteins, which 
in turn may alter axonal conduction properties. Although it is unlikely to work in isolation, 
glutamatergic signalling between the axon and myelin may prove to play a vital role in 













The overall objective of this chapter is to investigate depolarisation-evoked vesicular fusion 
in WM. Previous studies have focused on post-synaptic signals as a way of detecting vesicular 
glutamate release. I aim to determine whether depolarisation-evoked vesicular release is 
capable of elevating extracellular glutamate concentrations.  
Furthermore, recent studies have reported the possible existence of a novel type of chemical 
synapse between the axon and myelin sheath i.e. the axo-myelinic synapse. I will examine the 
pattern of vesicular exocytosis in myelinated axons in order to determine whether vesicular 
fusion occurs along the internodal segment of myelinated axons. 
Finally, vesicular fusion in fibrous WM astrocytes has never been examined. I aim to compare 
depolarisation-induced vesicular release in axons and astrocytes, to determine whether 














 3.2 Results 
 
3.2.1 High-K+ induced depolarisation promotes vesicular glutamate 
release in adult white matter 
 
Elevated concentrations of extracellular K+ ([K+]e) is regularly used as a depolarising agent in 
vitro (Eng and Kocsis 1987, Takahashi, Shibata et al. 1997, Yaguchi and Nishizaki 2010). High 
[K+]e (45mM) has previously been used to evoke vesicular fusion in the developing corpus 
callosum (Kukley, Capetillo-Zarate et al. 2007). In addition, [K+]e is known to increase by 
57.5mM under pathological conditions, such as ischemia (Szatkowski and Attwell 1994, Gido, 
Kristian et al. 1997). I initially examined the effect of 50mM [K+]e (referred to as ‘high-K+’) on 
WM conductivity using the isolated adult rat CC. A brief 5-minute exposure to high-K+, 
reversibly attenuated CAP area to 3.62±3.62% (n=3), whereas, a 10-minute exposure 
completely abolished CAP conduction (0.03±0.05%, n=3) (Fig. 3.2a). Perfusion with high-K+ did 
not lead to any irreversible functional injury, with CAP recovery reaching 123.3±7.18% (n=3, 
p=0.03) of its original area following wash-out (Fig. 3.2a(i)). A similar effect was observed in 
the adult RON (Fig. 3.2b, n=1).  
Using enzymatic glutamate biosensors, extracellular glutamate concentrations ([Glut]e) were 
recorded inside the adult CC during sequential exposures to high-K+ (5 min and 10 min, 
respectively). Exposure to high-K+ evoked a rapid rise in [Glut]e, increasing by 12.95±3.57µM 
during a 5-minute stimulation (Fig. 3.3, n=10). Interestingly, [Glut]e peaked after 3.84±0.47 
minutes of high-K+, before returning towards baseline. Following a 60 minute rest period, 
slices were re-exposed to high-K+ in the presence of EAAT inhibitor, TBOA (200µM) (Baltan, 
Besancon et al. 2008). The rise in [Glut]e was unaffected by EAAT inhibition, with maximum 
peak concentrations reaching 12.60±3.03µM (n=10). This was not significantly different from 
the initial first peak in the absence of TBOA (Fig. 3.3, p=0.94, note; both peak concentrations 
were measured within the initial 5 minutes of high-K+). 
To investigate whether the rise in [Glut]e is a result of vesicular docking, CC slices were treated 
with  bafilomycin-a1 (50nM), a specific inhibitor of vesicular type H+-ATPase (V-ATPase) 
(Cavelier and Attwell 2007, Hansen, Garrido-Comas et al. 2015, Micu, Plemel et al. 2016). In 
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order to ensure sufficient depletion of glutamatergic vesicles, slices were perfused with 
bafilomycin-a1 for a minimum of 120 minutes before exposure to high-K+. Inhibition of 
vesicular loading with bafilomycin-a1 reduced the first high-K+ evoked rise in [Glut]e to 
3.89±1.94µM (n=5, Fig. 3.4a, p=0.11). Similarly, the second high-K+ evoked rise (in TBOA) was 
significantly reduced to 4.06±0.74 µM (n=5, p=0.04, Fig. 3.4b). Together, this indicates that a 




























Fig. 3.2: High-extracellular K+ reversibly blocks CAP conduction in adult WM tracts. 
 
Time-course of CAP area recorded from the adult rat corpus callosum (a) and optic nerve (b), including 
two brief exposures to high-K+ (50mM KCl). Representative CAP traces (above) are shown at different 
time points, labelled 1-3. Perfusion with high-K+ results in a rapid decline in CAP area, followed by a full 
recovery following wash-out (see inset a(i): Histogram comparing mean CAP area before and after 















Fig. 3.3: High-K+ evokes a TBOA-insensitive rise in extracellular glutamate.  
 
a) Representative [Glut]e recording from inside the adult CC during exposure to high-K+. Exposure to 
high-K+ leads to a robust increase in [Glut]e. Perfusion with the EAAT inhibitor, TBOA, led to a slight rise 
in resting [Glut]e (see arrow). Depolarisation-evoked release was unaffected in the presence of TBOA. 
b) Histogram comparing the maximum peak concentration reached in the absence and presence of 

















Fig. 3.4: High-K+ evoked glutamate release is significantly attenuated following vesicular glutamate 
depletion with bafilomycin-a1. 
 
[Glut]e time-course during a 5-minute (a) and 10-minute (b) exposure to high-K+. Note; the maximum 





3.2.2 High-K+ evoked vesicular docking in adult white matter  
 
The CC sits adjacent to GM structures with extensive glutamatergic input (Fig. 3.5a1). 
Considering there are no physical barriers separating the two regions, it is possible that the 
rise in [Glut]e recorded in the CC may be a result of synaptic glutamate release in neighbouring 
GM regions. To address this issue, I directly examined vesicular docking in the adult CC using 
the vesicular dye, FM4-64. Coronal brain slices, including the CC, were obtained from adult 
Thy-1/YFP+ mice and imaged using two-photon confocal microscopy. The mean diameter of 
all YFP+ axons is 0.86±0.02µm (Fig. 3.5a,b, n=167 axons), which is considerably higher than the 
mean diameter of unmyelinated axons in the adult mouse CC (0.25±0.01µm, (Sturrock 1980)). 
Therefore, it is highly likely that all YFP+ axons in the CC are myelinated. 
Using an established high-K+ loading protocol (see section 2.9.2, (Kukley, Capetillo-Zarate et 
al. 2007)), low magnification images revealed extensive FM4-64 (vesicular) loading 
throughout the CC, indicative of vesicular recycling (Fig. 3.6a). Furthermore, FM-loaded YFP+ 
axons were clearly identified at higher magnification (Fig. 3.6b,c). It is worth noting that 
fluorescent longitudinal cylinders, which were not YFP+ axons, were also evident (Fig. 3.6c see 
arrows), which may represent FM-loading in unmyelinated axons. Contrary to Micu et al. 
(Micu, Plemel et al. 2016), punctate fluorescence was not observed along the axon cylinder. 
Considering the average vesicle size is ~50nm in diameter, it was not possible to identify 
individual vesicles using red light microscopy which has a limit of resolution of approximately 
200-350nm (Schermelleh, Heintzmann et al. 2010). 
To monitor FM4-64 stability, FM-fluorescence in the whole CC was initially monitored under 
control conditions (note; fluorescence was measured in random circular regions of interest 
(ROI) within the CC which will include all cell types, not just YFP+ axons). FM-fluorescence 
decreased by 4.50±0.97% (n=15 random ROI/5 slices) after 10 minutes (Fig.3.8). Similar to 
[Glut]e experiments, FM4-64 fluorescence was also monitored during perfusion with high-K+. 
Following 60 seconds of baseline recording in control aCSF, exposure to high-K+ evoked a 
pronounced drop in FM-fluorescence which became significant after 60 seconds (p=0.02) (Fig. 
3.7 and 3.8). Over a 10-minute period, FM-fluorescence was reduced by 16.34±0.96% (n=24 













Fig. 3.5: Thy-1/YFP+ axons in the adult mouse CC are large diameter, myelinated axons. 
 
a1) YFP expression (green) in a coronal brain slice of an adult mouse (scale bar=2mm). Insert (a2) 
shows YFP+ axons in the CC (scale bar=40µm). b) Frequency distribution curve of YFP+ axons according 

















Fig. 3.6: Extensive FM4-64 loading is evident in myelinated axons throughout the adult corpus 
callosum. 
 
a) Low magnification image of the YFP+ CC, demonstrating widespread loading of the vesicular dye, 
FM4-64 (red), in adult WM. Individual axons (green) are reliably imaged at higher magnification 
(sample b,c) showing a clear overlay of YFP+ with FM4-64. Note: sample (c) shows FM4-64 
fluorescent longitudinal cylinders which are not YFP+ axons (C3; arrows), which may represent 













Fig. 3.7: High-K+ evoked de-staining of FM4-64 from a sample region of the corpus callosum. 
 
a) Widespread FM4-64 loading in a region of the YFP+ CC. b) Representative images of FM4-64 
emission captured at different time-points during perfusion with high K+. Note the drop in FM4-64 
fluorescence intensity (right). c) Time-course of FM4-64 fluorescence recorded from a sample region 







               
 
 
Fig. 3.8: High-K+ evoked vesicular docking in the adult corpus callosum. 
 
a, b) Time-course/histogram of the mean (±SEM) fluorescence intensity of FM4-64 in the adult mouse CC. 
Under control conditions, fluorescence intensity remains relatively stable for 10 minutes (black). Exposure 
to high-K+ leads a significant drop in relative FM4-64 fluorescence (red). c) Overlay of FM4-64 fluorescence 
(red) and extracellular glutamate concentration (black). Note how the drop in FM4-64 fluorescence 
coincides with the early rise in glutamate concentration. ns>0.5, *p<0.05, **p<0.01, ****p<0.0001. 
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3.2.4 Vesicular glutamate release in white matter originates from 
axons  
 
As previously demonstrated high-K+ produced widespread axonal depolarisation, sufficient in 
blocking AP conduction (Fig. 3.2). However, high-K+ will also depolarise all cells within WM, 
including astrocytes (Meeks and Mennerick 2007, Yaguchi and Nishizaki 2010). In an attempt 
to determine the source of K+-evoked vesicular release, FM-fluorescence was monitored in 
axons and fibrous astrocytes.  
Using Thy-1/YFP+ mice, FM-fluorescence was initially examined in individual myelinated axon 
segments. FM-loaded YFP+ axons were reliably imaged and displayed a relatively high level of 
FM-fluorescence (see Fig. 3.9a). Fluorescence intensity in axons remained stable under 
control conditions, exhibiting a 3.43±1.64% decrease after 10 minutes (Fig. 3.9/3.11, n=17 
axons/5 slices). On the other hand, high-K+ evoked a significant drop in FM-fluorescence, 
decreasing by 14.00±1.29% after 10 minutes (Fig. 3.10/3.11, n=22 axons/8 slices p=0.01). 
Similar to the whole CC, significance was reached within the initial 60 seconds of high-K+ 
(p≤0.05, Fig. 3.11). The overt drop in axonal FM-fluorescence closely resembles the decrease 
recorded from the whole CC. Furthermore, there was no evidence of localised de-staining 
along the axon cylinder.  
To access vesicular docking in WM astrocytes, experiments were repeated using GFAP-GFP+ 
mice. In contrast to axons, GFP+ astrocytes displayed a much lower level of FM4-64 staining 
(Fig. 3.12a-f). Interestingly, numerous FM-loaded axon cylinders were clearly detected in 
close proximity to astrocytes, which expressed a significantly higher level of FM-fluorescence 
(Fig. 3.12f, n= 19, p<0.0001). Furthermore, there was no significant drop in astrocyte FM-
fluorescence during exposure to high-K+ (-6.40±0.80%, n=22 astrocytes/9 slices) when 









                                   
 
 
Fig. 3.9: Axonal FM4-64 fluorescence remains stable under control conditions. 
 
a) Sample image of FM4-64 loading in an individual axon segment in the CC. b) Representative images 
captured at different time-points under control conditions. c) Time-course of axonal FM4-64 














Fig. 3.10: High-K+ evoked de-staining of FM4-64 in a sample axon segment. 
 
a) Sample image of a FM4-64 loading in an individual axon segment in the CC. b) Representative images 
captured at different time-points during perfusion with high-K+. c) Time-course of axonal FM4-64 




           
 









Fig. 3.11: High-K+ evoked vesicular docking in individual axons. 
 
Time-course/histogram of the mean (±SEM) fluorescence intensity of FM4-64 in individual axon 
segments. Under control conditions, fluorescence intensity remains relatively stable for 10 minutes 
(black). Exposure to high K+ leads a significant drop in axonal FM4-64 fluorescence (red). ns>0.5, 























Fig. 3.12: GFP+ astrocytes display almost no FM4-64 staining. 
 
a-e: Sample images of individual GFP+ astrocytes in the adult mouse CC. Note the low levels of astrocytic 
FM4-64 staining (astrocyte outline= dotted white line). Also, note the high levels of FM4-64 staining in 
several cylinder compartments nearby the astrocytes (arrow). This likely represents FM4-64 loaded 
axons. Scale bar=10µm. f: Raw FM4-64 fluorescence measured from astrocytes and from neighbouring 










 Fig. 3.13: FM4-64 fluorescence from a sample astrocyte remains stable during exposure to high-K
+.  
 
a) Sample image of FM4-64 loading in two neighbouring astrocytes (1 and 2). b) Representative images 
captured from astrocyte (1) at different time-points during perfusion with high K+. c) Time-course of 
astrocytic FM4-64 fluorescence during high K+. Numbers (1-4) correspond to representative images above 













Fig. 3.14: High-K+ does not evoke vesicular docking in white matter astrocytes.  
 
Time-course/histogram of the mean (±SEM) fluorescence intensity of FM4-64 in individual WM 
astrocytes. Under control conditions, fluorescence intensity remains relatively stable for 10 




3.2.5: Attempts to evoke vesicular glutamate release in the juvenile 
RON 
 
Considering high-K+ evoked vesicular fusion originates from axons in the adult CC, I next 
attempted to evoke vesicular glutamate release from axons in an alternative WM tract, the 
juvenile rat optic nerve (RON). While the adult mouse CC contains a large population of 
unmyelinated axons, the adult RON is fully myelinated. As we have shown, vesicular fusion in 
myelinated axons will presumably release glutamate directly into the peri-axonal space 
between the axon and overlaying myelin sheath. This will limit, or completely prevent, any 
change in [Glut]e. However, there are no such barriers in unmyelinated axons, where vesicular 
glutamate will empty directly into the extracellular space. For this reason, [Glut]e was 
recorded from the juvenile RON (P7-P17), which is predominantly unmyelinated at this age. 
Similar to the adult CC, high-K+ evoked a significant rise in [Glut]e in the developing RON. 
However, the maximum peak concentration was much lower in the RON, increasing by 
0.51±0.24µM (Fig. 3.15a,b, n=3, p<0.05). After a rest period of 30 minutes, a subsequent 
second stimulation with high-K+, evoked a smaller rise in [Glut]e (see Fig. 3.15c). Experiments 
were performed in the presence of TBOA to prevent re-uptake and/or reverse transport. 
To investigate whether action potential conduction evokes vesicular glutamate release, 
[Glut]e was recorded from inside the RON following electrical stimulation. To do this, each 
end of the nerve was inserted into the barrel of a stimulating and recording glass electrode. 
Following which, a single slit was made on the upper surface of the nerve. Both GLU and null 
sensing tips were inserted and directed towards the stimulating electrode (see Fig. 3.16a). 
However, this procedure was technically challenging and required delicate handling. CAPs 
were successfully recorded following sensor insertion, confirming that axons were still 
functional following the physical trauma of sensor insertion. Nerves were subject to a train of 
action potentials (50Hz x 1-60 seconds) and CAP amplitude was recorded every second. High-
frequency electrical stimulation resulted in a reversible drop in CAP amplitude to 52.15% after 
60 seconds, reflecting a partial failure in action potential conduction. Following which, CAP 
amplitude quickly recovered within 2 minutes (Fig. 3.16b). For this reason, all electrical 
stimulations (tests) were kept well under 60 seconds. Electrical stimulation evoked a change 
in the differential biosensor current recorded inside the nerve, indicating a rise in extracellular 
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glutamate. However, identical recordings were observed when the sensors were placed in the 
bath perfusate at a similar distance from the stimulating electrode (i.e. the RON was absent) 
(Fig. 3.16c). Attempts were made to re-position the sensors to eliminate this recorded 
artefact, but to no avail. Unfortunately, there was no additive current recorded from inside 
the ON. 
To investigate whether increasing axonal [Na+]i is capable of eliciting a rise in [Glut]e, juvenile 
RONs were exposed to veratridine (10µM), an alkaloid neurotoxin which prevents voltage-
gated Na+ channel inactivation. Exposure to veratridine, gradually blocked nerve excitability 
after 21.83±2.49 mins (Fig. 3.17a, n=3). CAP amplitude failed to recover following wash-out. 
In order to prevent reverse glutamate transport following Na+ influx, [Glut]e recordings were 
performed in the presence of TBOA (200µM). Perfusion with veratridine evoked a small rise 
in [Glut]e (Fig. 3.16b,c,  +0.26±0.17µM, n=5). However, this was not significantly different to 
time-matched controls which decreased by 0.17±0.10µM (Fig. 3.17b,c, n=4, p=0.08). 
Finally, in an attempt to evoke vesicular glutamate release from astrocytes, nerves were 
perfused with prostaglandin E2 (PGE2, 100µM), which is known to evoke Ca2+-dependant 
glutamate release in cultured astrocytes (Bezzi, Carmignoto et al. 1998). Again, experiments 
were performed in the presence of TBOA. However, perfusion with PGE2 led to no significant 
change in [Glut]e, with concentrations decreasing by 0.0004±0.06µM after 20-30 minutes (Fig. 















Fig. 3.15: High-K+ evokes a small rise in extracellular glutamate in the developing RON. 
 
a) Time-course of [Glut]e recorded in the pre-myelinated RON during exposure to high-K+ (red) and under 
control conditions (black). b) Histogram comparing the maximum glutamate concentration reached 
during high-K+ and under control conditions. Perfusion with high-K+ significantly increased [Glut]e. 
p<0.05. c) Sample time-course of [Glut]e recorded including two sequential exposures to high-K+. Note 








Fig. 3.16: A stimulus artefact prevented reliable recordings of activity-dependent glutamate release in 
the RON.  
 
a) Positioning of bio-sensors in the RON during electrical stimulation. Note the direction of the sensor 
tips moving away from the site of insertion, towards to stimulating electrode. b) Time-course of CAP 
amplitude recorded from a P16 RON, including a 60second 50Hz electrical stimulation. Shown above are 
representative CAP traces recorded before (1), immediately after (2) and several minutes after (3) 
stimulation. c) Biosensor current recordings from inside the RON and in the bath perfusate (outside RON) 
during a brief 50Hz stimulation. Note the rise in biosensor current recorded when sensors are outside 











Fig. 3.17: Sodium-channel inactivation blocker, veratridine, blocks CAP conduction but does not 
significantly elevate [Glut]e in the neonatal RON.  
 
a) Time-course of CAP amplitude during exposure to 10µM veratridine. Insert: Representative CAP image 
before (10mins) and after (50mins) veratridine. b) [Glut]e recordings during exposure to veratridine (red) 
and in control aCSF (black). c) Histogram comparing the mean glutamate concentration during the last 


















Fig. 3.18: Prostaglandin E2 does not evoke glutamate release in the neonatal RON. 
  
a) [Glut]e recordings during exposure to PGE2 and in control aCSF. b) Histogram comparing mean 
glutamate concentration during the last 10 minutes of PGE2 (from 25-35 mins) against the same period 







Neurotransmitter signalling is a highly-specialised method of intercellular communication 
within the CNS. For years, it was considered a neuronal-specific phenomenon, exclusive to 
conventional synapses in GM. However, recent reports have revealed that glutamatergic 
signalling is also an essential feature of axo-glial communication in WM. In this chapter, I have 
examined vesicular glutamate release in the adult mouse corpus callosum. The data 
demonstrates that axonal depolarisation (with high-K+) evokes a substantial rise in 
extracellular glutamate concentrations. Furthermore, glutamate release was not via the 
reversal of glutamate transporters, but rather via vesicular exocytosis. Vesicular imaging 
revealed that axons are the primary source of vesicular docking in white matter. Interestingly, 
vesicular fusion occurs along the internodal axolemma of myelinated axons. In contrast, I 
found no evidence to suggest that astrocytes contribute to vesicular glutamate release during 
elevated levels of K+. Together, this data provides the first direct comparison of vesicular 
fusion in different cellular elements in white matter and supports the existence of functional 
axo-myelinic synapses. 
 
3.3.2: Depolarisation-evoked vesicular release in WM elevates 
extracellular glutamate concentrations  
 
In recent years, several studies have demonstrated the existence of functional WM synapses. 
Many of these studies recorded post-synaptic responses, such as EPSCs in OPCs or changes in 
myelinic [Ca2+] (Kukley, Capetillo-Zarate et al. 2007, Ziskin, Nishiyama et al. 2007, Micu, Plemel 
et al. 2016). However, the change in extracellular glutamate concentrations following 
vesicular fusion has never been directly measured. The absence of confined synaptic boutons 
in WM suggests that vesicular glutamate release along the axon cylinder may lead to diffuse 
rises in [Glut]e. 
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As reviewed in Chapter 1, the efflux of K+ ions hyperpolarises the axonal membrane potential 
during AP conduction. Thus, the accumulation of [K+]e is closely associated with axonal activity 
(Connors, Ransom et al. 1982, Ransom, Ransom et al. 2000). Furthermore, anoxia/ischemia 
causes a rapid rise in [K+]e levels, capable of reaching 50-60mM in the ischemic core (Hansen 
1985, Ransom, Walz et al. 1992, Belhage, Hansen et al. 1993, Gido, Kristian et al. 1997). 
Exposure to high extracellular K+ is an established technique used to depolarise membrane 
potentials and promote vesicular fusion (Gaffield and Betz 2006, Kukley, Capetillo-Zarate et 
al. 2007, Yaguchi and Nishizaki 2010). The data presented demonstrates that exposing adult 
WM tracts to high-K+ leads to rapid axonal depolarisation, capable of blocking nerve 
excitability. Furthermore, elevating [K+]e for up to 10 minutes does not produce any 
irreversible functional injury. Using real-time glutamate biosensors, a sharp rise in corpus 
callosum [Glut]e was observed during high-K+. Interestingly, the rapid rise in glutamate was 
followed by an immediate drop, with glutamate levels quickly returning towards resting 
concentrations. This demonstrates that axonal depolarisation is capable of evoking 
endogenous glutamate release from WM cells. In addition, the characteristic profile of K+-
evoked glutamate release suggests that axonal depolarisation evokes a burst of 
neurotransmitter release followed by the depletion of glutamate stores and/or the 
upregulation of glutamate uptake. However, a similar release profile was observed in the 
presence of TBOA, a glutamate transport inhibitor, which argues against the latter. Thus, the 
data suggests that WM glutamate stores are quickly depleted following strong axonal 
depolarisation.    
During ischemia, the run-down of Na+ and K+ gradients, combined with a depolarising shift in 
membrane potential, favours the reverse operation of glutamate transporters (Rossi, Oshima 
et al. 2000, Grewer, Gameiro et al. 2008). Therefore, reverse EAATs pose as a potential 
mechanism of glutamate release during exposure to high-K+. In fact, the application of high-
K+ was traditionally used in the study of reverse EAATs (Szatkowski, Barbour et al. 1990, 
Zerangue and Kavanaugh 1996). However, the depolarisation-evoked rise in [Glut]e was 
insensitive to EAAT inhibition, demonstrating that that the counter transport of glutamate 
does not contribute to release. In contrast, release was strongly reduced via the inhibition of 
vesicular loading with V-ATPase inhibitor, bafilomycin-a1. This indicates that high [K+]e 
triggers extensive vesicular fusion in WM, leading to a diffuse rise in extracellular glutamate 
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concentrations. In agreement with previous findings, it also demonstrates that glutamate-rich 
vesicles are present in mature WM and supports the existence of WM synapses in the mature 
brain (Ziskin, Nishiyama et al. 2007, Micu, Plemel et al. 2016). The residual rise in [Glut]e in 
the presence of bafilomycin-a1 may reflect an incomplete depletion of vesicular glutamate 
stores with bafilomycin-a1. Alternatively, swelling-mediated release may contribute under 
such conditions (Su, Kintner et al. 2002).  
High-K+ evoked a significant rise in [Glut]e in the early myelinating RON, indicating that 
developing pre-myelinated WM also contains glutamatergic vesicles. Curiously, the rise in 
[Glut]e was much lower in immature WM, when compared to adult WM (0.51 v 12.95µM, 
respectively). This may reflect an expanded extracellular space in the developing RON (Huria, 
Beeraka et al. 2015). In addition, it is also possible that developing WM contains a smaller 
pool of ready-releasable glutamatergic vesicles. This may also explain the lack of significant 
glutamate release during Na+-channel inactivation (veratridine). 
 
3.3.3: Axons are the principle site of vesicular fusion in WM. 
 
These findings raise further questions. (i) Does the depolarisation-evoked rise in [Glut]e 
actually originate from WM vesicles, or is it a consequence of spill-over from neighbouring 
GM synapses? The corpus callous is surrounded by neighbouring GM structures with 
extensive glutamatergic synapses. Moreover, there are no physical barriers between the GM-
WM boarder. Thus, it is possible that excessive vesicular fusion at GM synapses diffuses into 
neighbouring structures, including the corpus callosum. (ii) Does vesicular fusion occur in 
myelinated axons? And if so, does it occur in localised regions, such as the node of Ranvier, 
or can it occur along the internodal axolemma? Unlike the rodent optic nerve, the adult 
mouse corpus callosum contains a mixed population of both myelinated and unmyelinated 
axons, with a respective ratio of 1:2 (Sturrock 1980). A rise in [Glut]e may reflect vesicular 
release from exposed regions of the axolemma, be that from unmyelinated axons and/or at 
node of Ranvier. However, measuring extracellular glutamate may not detect glutamate 
release into the confined periaxonal space. (iii) Finally, which cell type is primarily responsible 
for vesicular release in WM? As outlined in section 3.1.2.1, numerous studies have shown that 
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axons are the primary source of vesicular glutamate release in WM (Kukley, Capetillo-Zarate 
et al. 2007, Ziskin, Nishiyama et al. 2007, Alix, Dolphin et al. 2008, Micu, Plemel et al. 2016). 
However, astrocytes also contain the necessary machinery required for exocytotic release 
(Bezzi, Gundersen et al. 2004, Montana, Malarkey et al. 2006). In addition, activity-dependant 
[K+]e accumulation also promotes astrocyte depolarisation (Ransom and Goldring 1973, 
Meeks and Mennerick 2007). A recent study demonstrated that high [K+]e-evoked 
depolarisation of cultured astrocytes causes a rise in astrocytic Ca2+ levels, which 
subsequently triggers vesicular glutamate release (Yaguchi and Nishizaki 2010). Therefore, it 
is possible that vesicular glutamate originates from both astrocytes and axons during 
exposure to high-K+. To date, there has been no direct comparison of vesicular fusion within 
different cellular components in WM.  
Two-photon confocal imaging of FM4-64 (vesicular dye) emission, revealed extensive FM4-64 
loading throughout the whole corpus callosum. High-K+ evoked a robust drop in FM-
fluorescence, consistent the release of the vesicular probe into the aqueous bath solution. 
This demonstrates the extent of vesicular fusion and recycling throughout the adult corpus 
callosum. With this in mind, it is likely that a significant component, if not all, of the K+-evoked 
rise in [Glut]e originates from WM cells.  
Experiments using Thy-1/YFP+ mice allowed for the examination of vesicular docking in 
myelinated axons. Consistent with previous studies (Alix, Zammit et al. 2012), YFP+ axons in 
the mouse corpus callosum have a diameter range which is considerably higher than the 
upper limit for unmyelinated axons (Sturrock 1980). Therefore, all YFP+ axons used in this 
model are myelinated. Similar to the whole CC, high magnification images of YFP+ axons 
revealed extensive FM4-64 loading along the axon cylinder, indicative of active vesicular 
recycling in axons. Furthermore, axonal depolarisation produced rapid vesicular docking in 
myelinated axons. Interestingly, the rate of vesicular fusion/FM-unloading was highest during 
the initial minutes of high-K+; FM-emission decreased at a rate of 3.4% per minute during the 
initial 3:50 minutes, whereas, it decreased at a rate of 0.55% per minute during the final 5:10 
minutes. This is remarkably consistent with the rapid peak rise in [Glut]e recorded in the adult 
rat CC (3:50±0:28 minutes). Together, it demonstrates that depolarisation evokes an early 
burst in vesicular release from axons. 
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A recent study reported the expression of punctate FM4-64 fluorescence inside YFP+ axons 
following electrical stimulation (Micu, Plemel et al. 2016). However, I found no evidence of 
localised staining or de-staining along the axon cylinder. Therefore, the majority of vesicular 
docking must occur along internodal regions of the axolemma. This would suggest that the 
majority of vesicular neurotransmitter release is emptied directly into the periaxonal space 
between the overlaying myelin sheath and the axolemma. While I am unable to directly 
measure glutamate concentrations in the periaxonal space, one might hypothesise that due 
to its confined area, glutamate concentrations may reach levels much higher than those 
recorded in the extracellular space. Previous calculations estimate that if the average 
glutamatergic vesicle is 50nm in diameter, and contains approximately 100mM glutamate, 
the release of a single vesicle into the periaxonal space (approximate volume of 3.7µm3) 
between the axolemma and ensheathing myelin (<20nm), it would yield an average 
concentration of approximately 2µM (Burger, Mehl et al. 1989, Ziskin, Nishiyama et al. 2007, 
Micu, Plemel et al. 2016). Internodal vesicular glutamate release strongly supports the 
proposed existence of an axo-myelinic synapse in WM (Micu, Plemel et al. 2016). As discussed 
in section 3.1.4, the physiological function of such synapses may represent an essential 
mechanism by which axons can signal to overlaying myelin, the importance of which remains 
to be seen. Proposed functions include signalling for metabolic support and regulation of 
myelin nanostructure. However, this also suggests that the periaxonal space may be a 
significant site of excitotoxic injury under certain pathological conditions. 
Using a similar approach with GFAP-GFP+ mice, I examined potential vesicular fusion in 
fibrous astrocytes.  In contrast to axons, FM4-64 loading was much lower in astrocytes. In 
addition, exposure to high-K+ did not induce vesicular docking in WM astrocytes, which 
indicates that WM astrocytes are either incapable of vesicular release or that release is 
voltage-insensitive. Consistent with my findings, a previous study observed that eliciting 
transient Ca2+ rises in fibrous astrocytes (via the activation of  metabotropic, purinergic and 
prostaglandin receptors) did not evoke vesicular release in the developing corpus callosum 
(Ziskin, Nishiyama et al. 2007). Based on these findings, corpus callosum astrocytes do not 
contribute to vesicular glutamate release. Astrocytic vesicular release is a controversial topic. 
As outlined in the introduction, numerous studies have demonstrated the expression of 
SNARE proteins and vesicles in astrocytes. Vesicular glutamate (and ATP) release from 
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astrocytes is observed at conventional neuronal synapses (forming the ‘tripartite synapse’) in 
response to neuronal activity (Volterra and Meldolesi 2005). It is plausible that regional 
differences may regulate gliotransmitter release. For instance, unlike protoplasmic astrocytes 
at the ‘tripartite synapse’, fibrous astrocytes may lack the ability to exocytose.  
 
3.3.3: Source of Ca2+ during depolarisation? 
 
An important feature of vesicular fusion is its Ca2+ dependency. Thus, a rise in axonal Ca2+ 
must precede vesicular glutamate release in the corpus callosum. Previous studies have 
demonstrated that axonal neurotransmitter release is strongly Ca2+ cooperative and involves 
highly localised Ca2+ micro-domain signalling (Kukley, Capetillo-Zarate et al. 2007). In addition, 
Ca2+ transients are observed in corpus callosum and optic nerve axons following electrical 
stimulation (Verbny, Zhang et al. 2002, Kukley, Capetillo-Zarate et al. 2007). However, the 
exact mechanism by which intra-axonal Ca2+ levels increase is controversial. Although my data 
provides no information on this, one can hypothesise on the source of Ca2+ based on the 
literature. Interestingly, Ca2+ transients in pre-myelinated axons are reduced in low 
extracellular Ca2+. Similarly, excitatory post-synaptic currents (EPSC) are dramatically 
attenuated in OPCs under low extracellular Ca2+ conditions, which would support the direct 
influx of extracellular Ca2+ (Kukley, Capetillo-Zarate et al. 2007). Functional voltage-gated Ca2+ 
channels (VGCC) are expressed in the axolemma of pre-myelinated WM axons and are closely 
associated with vesicular apparatus such as SNAP-25 and V-ATPase (Alix, Dolphin et al. 2008). 
Similarly, K+-mediated de-staining of FM1-43 is significantly prevented in the presence of 
calcium channel blocker, Cd2+, which together suggests that Ca2+ influx through VGCCs on 
unmyelinated axons mediates vesicular fusion (Kukley, Capetillo-Zarate et al. 2007, Ziskin, 
Nishiyama et al. 2007).  
While this strongly suggests that vesicular glutamate release is triggered by Ca2+ influx through 
VGCCs, the internodal axolemma of myelinated axons may have limited availability to [Ca2+]e 
due to the ensheathing myelin layers. The average AP-evoked Ca2+ transient recorded in the 
mouse ON axon is approximately 10-fold lower in myelinated axons when compared to pre-
myelinated axons (Verbny, Zhang et al. 2002). Previous reports have demonstrated that 
VGCCs redistribute to form clusters at the node of Ranvier during development (Alix, Dolphin 
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et al. 2008). Similarly, immunostaining for L-type Ca2+ channels (Cav1.2 subunit) in myelinated 
axons of rat molars, demonstrated that although VGCC expression was present along the axon 
membrane, staining intensity was highest at the node of Ranvier (Westenbroek, Anderson et 
al. 2004). Therefore, it is plausible that Ca2+ influx at the exposed node and the lateral 
diffusion of axonal Ca2+ may evoke internodal vesicular release. However, consistent with my 
findings that there is no evidence of localised vesicular fusion along the axon, there are no 
spatial variations in either the amplitude or shape of AP-induced Ca2+ transients along 
myelinated axons (Zhang, Wilson et al. 2006). Furthermore, the photolysis stimulation of 
axonal Ca2+ release at a designated point along the axon (“an artificial node”) has a space 
constant of Ca2+ diffusion of between 30 and 40µm. Considering the average internodal length 
of a myelinated mouse ON axon is 138µm (Butt, Colquhoun et al. 1994), the lateral spread of 
Ca2+ from the node of Ranvier is insufficient to explain the spatially uniform rise in internodal 
Ca2+ during AP conduction (Zhang, Wilson et al. 2006).  In agreement, Ca2+ diffusion 
coefficients in Myxicola axoplasm is relatively slow and is impeded by axoplasmic organelles 
(al-Baldawi and Abercrombie 1995). This raises the question of where the depolarisartion-
induced rise in internodal Ca2+ originates. Although VGCCs reportedly redistribute to the node 
of Ranvier during development (Alix, Dolphin et al. 2008), several studies have reported that 
a low density of VGCCs are uniformly distributed along the internode of myelinated axons 
(Brown, Westenbroek et al. 2001, Ouardouz, Nikolaeva et al. 2003). Interestingly, the block 
of VGCCs abolish Ca2+ transients in myelinated axons (Jackson, Trout et al. 2001, Zhang, 
Wilson et al. 2006). However, myelinated axons also contain intracellular stores of Ca2+ 
capable of elevating axoplamic concentrations following release (Ren, Ridsdale et al. 2000). A 
recent study by Micu et al. reported that the axoplasmic rise in [Ca2+]i during the electrical 
stimulation of myelinated axons, originates from intracellular Ca2+ stores (Micu, Plemel et al. 
2016). They demonstrated that vesicular release from myelinated axons is attenuated by 
either the L-type voltage-gated Ca2+ channel inhibitor, nifedipine, or by antagonising Ca2+ 
release from ryanodine-sensitive intracellular stores. Consistent with previous studies 
(Ouardouz, Nikolaeva et al. 2003), these findings indicate that VGCCs along the internodal 
axon segment of myelinated axons sense depolarisation, which subsequently gates Ca2+ 
release from intra-axonal stores such as the axoplasmic reticulum (Micu, Plemel et al. 2016). 
It is plausible therefore, that depolarisation-evoked Ca2+ rises in axons originate from either 
extracellular influx or intracellular efflux, dependent on the presence of myelin. It would be 
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interesting to test whether the depolarisation-evoked rise in [Glut]e or vesicular docking in 
myelinated axons is affected by the removal of extracellular Ca2+. Similarly, is the release of 
Ca2+ from the axoplasmic reticulum sufficient to induce vesicular fusion in myelinated axons?  
 
In summary, this chapter demonstrates that K+-evoked depolarisation of the adult corpus 
callosum evokes extensive vesicular fusion in axons which leads to elevated extracellular 
glutamate concentrations. In contrast, astrocytes do no contribute to vesicular 
neurotransmitter release. Vesicular fusion along the axolemma of myelinated axons supports 
novel findings which suggest that axons signal to the overlaying myelin in an 
activity/depolarisation dependent manner. However, the significance of axonal vesicular 
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4.1.1: Ischemia and Excitotoxicity 
 
In the previous chapter, I reviewed the importance of glutamatergic signalling in WM and 
examined the significance of vesicular glutamate release in axons. As mentioned, resting 
extracellular glutamate concentrations ([Glut]e) are kept in the low micromolar range (~1-
2µM) under physiological conditions (Rutledge and Kimelberg 1996). This is primarily due to 
the actions of glutamate transporters (EAATs). However, under acute ischemic conditions, the 
excessive release of glutamate, combined with the failure of its re-uptake mechanisms, leads 
to a dramatic rise in [Glut]e throughout the CNS (Andiné, Sandberg et al. 1991, Pu, Li et al. 
2000). Elevated [Glut]e triggers a cascade of deleterious events, including the pathological 
influx of Ca2+ ions through ionotropic glutamate receptors, a series of events collectively 
known as excitotoxicty (see section 1.2.4).  
Glutamate was first implicated in the pathogenesis of ischemic brain injury in 1982 by 
Jørgenson and Diemer (Jorgensen and Diemer 1982). They noted that rats which were subject 
to cerebral ischemia, displayed a selective pattern of neuronal loss which closely resembled 
regions of high glutamate uptake. Shortly after, Benveniste et al. used microdialysis to 
measure an 8-fold increase in [Glut]e in the rat hippocampus during a 10 minute period of 
ischemia (Benveniste, Drejer et al. 1984). Initially, the involvement of glutamate-mediated 
damage was a controversial topic, as elevated [Glut]e was also recorded in regions which 
showed no signs of irreversible injury following cerebral ischemia (Globus, Busto et al. 1990). 
Choi and Rothman were among the first to report that blockers of iGluRs (i.e. 
AMPA/kainate/NMDA) reduced the infarct volume in animal models of focal ischemia (Choi 
and Rothman 1990). It is now well established that glutamate-mediated excitotoxicity plays a 
pivotal role in the development of irreversible ischemic brain injury. As outlined in the 
previous chapter, the unequivocal expression of iGluRs throughout WM leaves these 
structures particularly vulnerable to excitotoxic injury during energy deprivation. Similar to 
GM, excitotoxicity is now recognised as a crucial mechanism involved in the development of 
ischemic WM pathology. 
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4.1.1.1: Oligodendrocyte- AMPA/kainate receptor mediated injury  
 
Oligodendrocytes are the myelinating cells of the CNS and are essential for the transmission 
of rapid saltatory action potential conduction (Bradl and Lassmann 2010). Oligodendrocyte 
cell death can have a profound effect on WM function, as a single oligodendrocyte is typically 
responsible for the myelination of up to 50 neighbouring axons (Velumian and Samoilova 
2014). They are considered the most vulnerable cell type within the CNS and are highly 
sensitive to transient ischemia (Dewar, Underhill et al. 2003, Matute 2011). Numerous studies 
have shown that oligodendrocyte cell death during ischemia is primarily mediated via the 
sustained activation of AMPA and kainate receptors which are diffusely located on the 
oligodendrocyte cell soma. Excitotoxic injury of oligodendrocytes was first observed in 1993 
by Oka et al. who found that exposing oligodendrocyte cell culture to glutamate (for 24 hours) 
lead to high levels of cell death (Oka, Belliveau et al. 1993).  
Oligodendrocyte cell death is entirely dependent on the toxic influx of Ca2+ and its subsequent 
accumulation in the intracellular compartment. As a result, oligodendrocyte cell death during 
ischemia is prevented in the absence of extracellular Ca2+ (Matute, Sanchez-Gomez et al. 1997, 
Fern and Moller 2000). Several studies have shown that Ca2+ entry through activated 
AMPA/kainate receptors is the primary route of Ca2+ influx during acute ischemia (Matute, 
Sanchez-Gomez et al. 1997, Mcdonald, Althomsons et al. 1998, Li and Stys 2001, Micu, Jiang 
et al. 2006, Tekkok, Ye et al. 2007). Conversely, the pharmacological inhibition of 
AMPA/kainate receptors is sufficient in preventing OGD-induced cell death (Fern and Moller 
2000, Tekkok and Goldberg 2001, Tekkok, Ye et al. 2007). In vivo studies have shown that the 
AMPA/kainate receptor antagonists, NBQX and topiramate, attenuate ischemia-induced WM 
injury in both developing and mature rodents (Follett, Rosenberg et al. 2000, Tekkök and 
Goldberg 2001, Rosenberg 2014). 
Early oligodendrocyte cell death is the hallmark characteristic of periventricular white matter 
injury (PWMI) in the developing brain. The death of immature oligodendrocytes can lead to 
severe myelination disturbances, such as hypomyelination. Interestingly, the high risk period 
for PWMI (between weeks 23-32 of gestation in humans) coincides with a key point in 
oligodendrocyte development, when OPCs are progressing into immature oligodendrocytes 
and beginning to invade neighbouring axon tracts with their fine processes (Butt and Ransom 
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1993, Thomas, Salter et al. 2004, Fern 2011). At this age, developing oligodendrocytes are 
more sensitive than any other cell type, both in cell culture and in situ (Fern 2011). In addition, 
there are more sensitive than their earlier or later counterparts (Bergles, Roberts et al. 2000, 
Stys 2005). This raises the question as to why developing oligodendrocytes are so susceptible 
to injury at this age. Curiously, developing OPCs have an immature system for dealing with 
oxidative stress. For example, they have low levels of glutathione peroxidase and a poor 
ability to remove hydrogen peroxide from the cell, when compared with mature 
oligodendrocytes (Nave 2010). However, their heightened vulnerability during this period is 
predominantly associated with an elevated expression of Ca2+-permeable AMPA/kainate 
receptors (Back, Han et al. 2002, Deng, Rosenberg et al. 2003). Furthermore, immature WM 
oligodendrocytes, and their mature counterparts, have a low expression of GluR2 subunits, 
which makes them particularly susceptible to Ca2+ influx when activated (Deng, Rosenberg et 
al. 2003). 
 
4.1.1.2: Oligodendrocyte/Mylein- NMDA receptor mediated injury 
 
While blocking AMPA/kainate receptors during ischemia prevents oligodendrocyte cell death, 
it does not preserve their myelinating processes. Interestingly, NMDA receptors are 
differentially expressed on the processes of immature oligodendroglia and also mediate toxic 
[Ca2+]i rises during ischemia (Káradóttir, Cavelier et al. 2005, Salter and Fern 2005). For 
example, the application of MK-801 (NMDA receptor antagonist) prevents the detachment of 
oligodendrocyte processes during OGD (Salter and Fern 2005). In addition, oligodendrocyte 
NMDA receptors contain an unusual subunit composition. The presence of the NR3 subunit 
leaves them relatively resistant to Mg2+  blockade at a resting membrane potential, and 
therefore, susceptible to activation in the absence of strong depolarisation, typically provided 
by AMPA/kainate-receptor activation (Káradóttir, Cavelier et al. 2005). NMDA receptor 
blockade with memantine significantly attenuates the loss of developing oligodendrocytes in 
a rat model of PVL (Manning, Talos et al. 2008). Taken together, these findings demonstrate 
that the combined activation of both AMPA/kainate and NMDA-receptors, ultimately 
mediates to the demise of oligodendrocytes during acute periods of ischemia.  
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Myelin can protect underlying axons from physical mechanical damage by acting as a 
protective cushion, but it can also shield the axonal membrane from harmful substances in 
extracellular milieu under pathological conditions (Schäbitz, Li et al. 2000, Harukuni and 
Bhardwaj 2006). However, rapid myelin damage is a common feature of ischemic WM injury 
(Pantoni, Garcia et al. 1996). Interestingly, NMDA receptor subunits are shifted from 
oligodendrocyte cell processes to compact myelin sheath during myelination (Alix and Fern 
2009). Chemical ischemia leads to an accumulation of Ca2+ in both oligodendrocyte cell bodies 
and the cytosolic compartment of myelin sheath in the adult RON (Micu, Jiang et al. 2006). 
This rise in Ca2+ is abolished in both compartments in the presence of kynurenic acid, a broad 
spectrum iGluR blocker. Consistent with previous findings, Micu et al. reported that the 
AMPA/kainate receptor antagonist, NBQX, prevented the Ca2+ rise in oligodendrocyte cell 
bodies. Interestingly, NBQX only had a modest effect on the myelinic Ca2+ rise indicating that 
the elevated Ca2+ levels in myelin must operate through a distinct mechanism and is not just 
a passive feature of Ca2+ diffusion from the cell soma. It was found that the rise in myelinic 
Ca2+ is a result of Ca2+ influx through activated NMDA receptors, as it was abolished following 
the application of NMDAR antagonists (MK-801, 7-CKA and D-AP5). Furthermore, NMDA 
receptor blockade (with 7-CKA) ameliorated the pathological loosening and fragmentation of 
myelin sheath during ischemia (Micu, Jiang et al. 2006). On the other hand, they found little 
evidence of axonal protection following NMDA receptor inhibition. Myelin is known to 
contain Ca2+-dependant enzymes which may be activated following Ca2+ influx, promoting the 
breakdown of lipids and proteins (Fu, Wang et al. 2007). Similar to NMDA receptor expression 
on the myelinating processes of immature oligodendrocytes, NR3 subunits are also found in 
myelinic NMDA receptors. As a result, they are also relatively resistant to Mg2+ blockade, 
leaving them more susceptible to activation (Stys and Lipton 2007). Excitotoxic myelin injury 
will be examined in more detail in chapter 5. 
 
 
4.1.1.3: Excitotoxic WM damage contributes to irreversible functional injury  
 
While the above findings suggest that excitotoxic damage primarily effects oligodendrocytes 
and the myelin they manufacture, recent evidence demonstrates that the over-activation of 
glutamate receptors also contributes to the irreversible functional injury observed after 
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ischemia (Micu, Jiang et al. 2006, Ouardouz, Coderre et al. 2009, Ouardouz, Coderre et al. 
2009). Importantly, it is the loss of action potential conduction which underlies a variety of 
clinical disabilities observed in patients who suffer either periventricular WM injury or stoke 
(Baltan, Carmichael et al. 2014).  
Li and Stys (2000) were among the first to demonstrate that excitotoxic WM injury promotes 
the irreversible functional injury of myelinated WM tracts. They found that the sustained 
activation of iGluRs with either glutamate (1mM), AMPA (100µM) or kainate (500µM) lead to 
an irreversible decrease in CAP amplitude recorded from isolated spinal dorsal columns. 
Interestingly, they also noted that while axon cylinders were unaffected by glutamate, glial 
cell and myelin damage was clearly evident. In contrast, Tekkok at al. found that extended 
periods of perfusion with glutamate, AMPA or kainate had no effect on WM integrity in the 
mouse ON (MON), even when AMPA receptor desensitisation was blocked with cyclothiazide 
(Tekkok, Ye et al. 2007). However, they did find that exposure to a relatively short period of 
OGD (15 minutes) in the presence of glutamate, exacerbated functional recovery. In contrast, 
blockade of AMPA/kainate receptors during OGD dramatically reduced the degree of WM 
injury, increasing post-OGD CAP area from 21% to 72% (Tekkok, Ye et al. 2007). This has also 
been documented in alternative WM tracts; a selective AMPA/kainate receptor antagonist, 
NBQX, prevents the irreversible loss in CAP area and axonal structure (SMI-31 
immunofluorescence) following 20 minutes of OGD in the adult corpus callosum (Tekkok and 
Goldberg 2001). Similarly, using an in vivo model of spinal cord ischemia, Kanellopoulos et al. 
demonstrated that the administration of NBQX reduced ischemia-induced WM damage 
(based on axonal counts) following aortic occlusion, and improved locomotor function 6 
weeks after the insult (Kanellopoulos, Xu et al. 2000). While the over-activation of 
AMPA/kainate receptors play a crucial role in ischemia-induced WM injury, its effects seem 
to be magnified in older WM tracts (Baltan, Besancon et al. 2008). Baltan et al. discovered 
that the protective effect of NBQX was actually enhanced in MONs from animals aged 
between 12 and 24 months, a phenomenon which was attributed to an earlier and greater 
degree of glutamate release (Baltan, Besancon et al. 2008). In addition to AMPA/kainate 
receptor mediated injury, NMDA receptor blockade preserves post-OGD CAP amplitude in 
pre-myelinated and early myelinating WM tracts (Bakiri, Hamilton et al. 2008, Alix and Fern 
2009, Huria, Beeraka et al. 2015). 
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This raises the question as to how glutamate receptors mediate functional injury. It is possible 
that the activation of glutamate receptors located on the axonal membrane may directly lead 
to irreversible axon damage. In the pre-myelinated RON, NR1 receptor subunits co-localised 
with small pre-myelinated axons and expression strongly correlated with areas of focal axonal 
injury (Huria, Beeraka et al. 2015). In addition, the activation of NMDA receptors on the 
axolemma of pre-myelinated axons mediates a significant degree of functional loss in the  P2 
RON (Huria, Beeraka et al. 2014). Similarly, the expression of Ca2+-permeable AMPA and 
kainate receptors on dorsal column myelinated axons suggest that the direct activation of 
axonal glutamate receptors may mediate toxic Ca2+ influx during ischemia (Ouardouz, Coderre 
et al. 2009, Ouardouz, Coderre et al. 2009, Huria, Beeraka et al. 2014). However, axonal AMPA 
receptors are only weakly permeable to Ca2+ (Ouardouz, Coderre et al. 2009) and the 
application of iGluR agonists has little effect on CAP conduction (Tekkok, Ye et al. 2007). To 
date, there have been no reports of functional NMDA receptor expression on the axolemma 
of mature axons.  
Alternatively, it is plausible that axonal injury may be secondary to oligodendrocyte damage 
and myelin breakdown. Interestingly, the focal breakdown of small pre-myelinated axons is 
observed at sites of contact with navigating oligodendrocyte processes (Alix and Fern 2009). 
The same study also reported that while NR1 (a NMDA receptor subunit) reactivity was high 
in navigating oligodendrocyte processes, the was no evidence of NR1 expression in the axonal 
membrane (Alix and Fern 2009). Consistent with the hypothesis that oligodendrocyte injury 
leads to axonal damage, the application of NMDA receptor antagonists during OGD leads to 
the complete protection of small diameter, unmyelinated axons, which significantly preserves 
CAP conduction (Alix and Fern 2009). iGluR-mediated injury of oligodendrocytes may enhance 
axonal injury through the release of toxic cellular components and/or the loss of trophic 
support (Tekkok and Goldberg 2001). For example, NMDA receptor-mediated injury of the 
navigating oligodendrocyte processes can lead to a local release of K+ ions, which can in turn 
cause axonal depolarisation and lead to cytotoxic swelling (Alix and Fern 2009). Furthermore, 
saltatory action potential conduction is not supported following myelin degeneration (Smith 
1994). Therefore, it is likely that the demise of oligodendrocyte/myelin plays an important 




4.1.1.4: Sensitivity of Axo-glial Synapses 
 
Immature oligodendrocytes and myelin sheaths express a variety of functional iGluRs, with 
levels comparable to those at conventional synapses (Kukley, Capetillo-Zarate et al. 2007, 
Micu, Plemel et al. 2016). As mentioned in the previous chapter, they are considered the post-
synaptic element in the WM synapse. Interestingly, WM synapses are particularly vulnerable 
under pathological conditions such as hypoxia-ischemia. A consistent feature of ischemia-
induced injury in WM is the high degree of damage to OPC processes, which form synaptic-
like junctions with unmyelinated axons (Káradóttir, Cavelier et al. 2005, Salter and Fern 2005, 
Shen, Liu et al. 2012). In addition, the focal splitting and separation of myelin lamella is an 
early event during energy deprivation (Micu, Jiang et al. 2006, Fern, Matute et al. 2014). This 
heightened sensitivity has shown to be at least partly related to the high expression of 
glutamate receptors (particularly NMDARs) (Káradóttir, Cavelier et al. 2005, Salter and Fern 
2005, Micu, Jiang et al. 2006).  
When Shen et al. examined the fine structural changes in WM following hypoxia-ischemia 
(unilateral carotoid ligation), they noted that while the nucleus of oligodendroglia generally 
appeared normal, their processes were heavily vacuolated (Shen, Liu et al. 2012). In addition, 
while post-synaptic densities were abundant in control regions, there was a profound 
decrease in their number following ischemia, consistent with the selective 
degradation/retraction of oligodendrocyte processes. Similarly, during exposure to OGD, 
oligodendrocyte processes detachment and disintegration is apparent within 20 minutes, an 
event which precedes injury to the cell soma (Salter and Fern 2005). As mentioned, this 
process is prevented in the absence of [Ca2+]e or by  blocking NMDA receptors (Káradóttir, 
Cavelier et al. 2005, Salter and Fern 2005).  
While glutamatergic signalling is considered a physiological process in WM, such findings 
indicate that axo-glial and axo-myelinic synapses are significant sites of excitotoxic damage 
under ischemic conditions. This heightened sensitivity is likely due to the close spatial 
relationship between axons and oligodendroglia/myelin, and the high expression of iGluRs on 
the post-synaptic membrane of WM synapses. In addition, it is possible that the confined 
dimensions of oligodendrocyte processes mean that even small rises in [Ca2+]i can be toxic in 
such a restricted intracellular space.  
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4.1.2: Potential sources of endogenous glutamate:  
 
Elevated [Glut]e clearly plays a central role in ischemic WM pathology. Glutamate release is 
therefore a crucial step in initiating the excitotoxic cascade. Excitotoxic injury is observed in 
isolated WM tracts, which indicates that the ischemic rise in [Glut]e must originate from WM 
cells. The three main cellular elements in WM; axons, astrocytes and oligodendrocytes all 
pose as potential sources of ischemic glutamate release. Several studies have analysed 
physiological glutamate levels in cells using immuno-electron microscopy. Interestingly, both 
axons and oligodendrocytes contain the highest levels of glutamate-like reactivity in 
developing periventricular WM and mature dorsal columns (Li and Stys 2001, Back, Craig et 
al. 2007). Wilke et al. also reported high glutamate levels in oligodendrocytes and ‘non soma’ 
regions of the developing ON (Wilke, Thomas et al. 2004). In contrast, astrocyte levels are 
relatively low in both developing and mature WM tracts (Li and Stys 2001, Wilke, Thomas et 
al. 2004, Back, Craig et al. 2007), which may relate to their high levels of glutamate synthase, 
which converts glutamate into glutamine, as part of the glutamate-glutamine cycle. 
Alternative sources of glutamate in vivo may originate from neighbouring GM regions, choroid 
epithelia and ependymal cells (Wilke, Thomas et al. 2004). 
Axons are the primary functional element in WM and contain high concentrations of cytosolic 
glutamate (~4mM (Volpe 2008)) under control conditions. Therefore, they represent a major 
repository of glutamate in WM. Using semiquantitative glutamate immunohistochemistry, 
several studies have reported axons as a major source of ischemic glutamate release in WM. 
When the Na+ and K+ gradients are disrupted in the adult spinal cord, there is a significant 
release of endogenous glutamate from axon cylinders (Li and Stys 2001). Similarly, axonal 
glutamate levels in the adult spinal cord are significantly reduced following 60 minutes of 
anoxia (Li, Mealing et al. 1999). Axonal glutamate levels in periventricular WM are also 
reduced after hypoxia (by ~60%) (Back, Craig et al. 2007). As demonstrated in the previous 
chapter, axons are a significant source of glutamate-laden vesicles, which contain glutamate 
concentrations exceeding 50mM. Thus, axonal vesicular glutamate may also contribute to 
axonal glutamate release during ischemia (Kukley, Capetillo-Zarate et al. 2007, Alix, Dolphin 
et al. 2008, Micu, Plemel et al. 2016).  
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Oligodendrocyte glutamate levels are also attenuated during hypoxia (Li, Mealing et al. 1999, 
Back, Craig et al. 2007). Earlier studies have shown that oligodendrocytes are capable of 
releasing toxic levels of glutamate, which subsequently activates iGluRs located on the 
oligodendrocytes themselves (Fern and Moller 2000). However, Wilke et al. reported the net 
accumulation of oligodendrocyte glutamate levels following ischemia, rather than the 
depleted levels that would be observed with an overall net release (Wilke, Thomas et al. 2004). 
This suggests that oligodendrocytes ability to release glutamate may be dependent on their 
developmental stage and/or location (Fern, Matute et al. 2014). Although physiological 
astrocytic glutamate levels are low, their glutamate stores are slightly depleted following 
ischemia in developing WM (Wilke, Thomas et al. 2004, Back, Craig et al. 2007). However, in 
mature WM, astrocyte glutamate levels are unaltered by 60 minutes of anoxia (Li, Mealing et 
al. 1999). Thus, the source of ischemic WM glutamate release is still somewhat unresolved, 
as all three of the main cellular elements are capable of release. 
 
4.1.3: Potential mechanisms of glutamate release during ischemia 
 
Alongside the possible sources of endogenous glutamate, there are a variety of potential 
release mechanisms which can operate under acute ischemic conditions. The precise 
pathway(s) of glutamate release during ischemia is currently unknown.  
 
4.1.3.1: Reverse Excitatory Amino Acid Transporters (EAATs) 
 
EAATs are electrogenic, Na+-dependant transporters which utilise the Na+ gradient across the 
plasma membrane as a driving force for glutamate reuptake (Danbolt 2001). As discussed in 
chapter 1, EAATs are primarily responsible for maintaining low extracellular glutamate 
concentrations under physiological conditions. Intriguingly, the inhibition of EAATs (with 
TBOA) in oligodendrocyte cell cultures and in the ON leads to a significant rise in extracellular 
glutamate levels, which consequently leads to excitotoxic cell death, demyelination and 
axonal damage (Domercq, Etxebarria et al. 2005). Under acute ischemic conditions, 
inadequate levels of cellular ATP leads to the rapid failure of the Na+/K+-ATPase pump and 
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subsequently, the failure of EAAT uptake. However, the inevitable run-down of the Na+  and 
K+ gradients favour the reversal of EAATs, where glutamate is pumped into the extracellular 
space (Danbolt 2001). Due to the electrogenicity of EAATs, the associated depolarising shift 
in membrane potential also promotes their reversal. The reversal of EAATs was first 
demonstrated by Szatkowski et al. when they reported that elevating [K+]e around glial cells 
evoked an outward membrane current reflecting glutamate release in whole-cell clamped 
Muller cells (Szatkowski, Barbour et al. 1990). The reverse operation of EAATs is now 
recognised as the major glutamate release pathway in ischemic GM (Rossi, Oshima et al. 2000, 
Grewer, Gameiro et al. 2008).  
While the pathway of ischemic glutamate release in WM is still a topic of debate, several 
studies have reported that like GM, the reversal of EAATs contribute to ischemic glutamate 
release in WM (Li, Mealing et al. 1999, Li and Stys 2001, Tekkok, Ye et al. 2007, Hamilton, 
Kolodziejczyk et al. 2016). Both the developing and mature RON express the 3 main 
transporter sub-types; EAAC-1, GLT-1 and GLAST (Domercq, Sánchez-Gómez et al. 1999, 
Arranz, Hussein et al. 2008).  In cultured oligodendrocytes, rapid ischemic cell death is 
mediated via the gating of AMPA/kainate receptors (Fern and Moller 2000). Interestingly, this 
study demonstrated that glutamate originated from the oligodendrocytes themselves via the 
reversal of EAATs. Early studies by Li and Stys found that the inhibition of EAAT with l-trans-
PDC, led to a significant improvement in CAP recovery in the adult rat spinal dorsal column 
following Na+/K+-ATPase inhibition and anoxia, conferring a similar degree of protection to 
that observed in the presence of AMPA-receptor antagonist, GYKI52466 (Li, Mealing et al. 
1999, Li and Stys 2001). Furthermore, they found that the anoxia-induced depletion of axonal 
and oligodendrocyte glutamate stores was prevented by l-trans-PDC (Li, Mealing et al. 1999). 
Similar results were observed in the adult ON where the application of TBOA, a non-
transportable EAAT blocker, led to improved functional recovery in the MON, by completing 
preventing the pathological release of glutamate from the nerve (measured by HPLC) (Tekkok, 
Ye et al. 2007). As mentioned, older WM is more susceptible to irreversible ischemic injury 
due to an earlier and larger rise in glutamate levels (Baltan, Besancon et al. 2008). Baltan et 
al. found that the enhanced release of glutamate is a result of an increased expression of 
EAATs (particularly GLT-1) in older WM (Baltan, Besancon et al. 2008). Curiously, GLT-1 is most 
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heavily expressed on astrocytes in WM, which contain relatively low levels of glutamate 
(Arranz, Hussein et al. 2008, Schousboe, Scafidi et al. 2014).  
Interestingly, the inhibition of EAATs during ischemia is also reported to exacerbate neuronal 
injury in organotypic cortical slices (Soria, Pérez-Samartín et al. 2014). Moreover, TBOA 
shortened the latency to anoxic depolarisation suggesting that glutamate transporters remain 
active and continue to uptake extracellular glutamate during the beginning of ischemia. 
 
4.1.3.2: Vesicular exocytosis 
 
The data presented in the previous chapter demonstrated the significance of vesicular 
glutamate release in WM. Depolarisation-evoked vesicular exocytosis is capable of 
significantly elevating extracellular glutamate concentrations (by ~13µM, see Fig.3.3). 
However, the contribution of vesicular glutamate release during ischemia is currently 
unknown.  
Vesicular glutamate loading is an ATP-dependant process, powered by the action of V-type 
H+ ATPase (V-ATPase). The V-ATPase pumps H+ ions inside the vesicular lumen, forming a high-
proton gradient and a positive vesicular membrane potential (Cavelier and Attwell 2007). 
Vesicular glutamate transporters (VGLUTs) utilize this positive membrane potential to load 
glutamate inside the vesicles. Therefore, under ischemic conditions, inadequate ATP levels 
will lead to the run-down of the H+ gradient and membrane potential, which will eventually 
lead to a gradual loss of glutamate from its vesicular stores. However, the depletion of 
glutamate from vesicles can take several hours following V-ATPase inhibition (Cavelier and 
Attwell 2007), suggesting that Ca2+-dependant vesicular exocytosis may occur in the absence 
of ATP. Moreover, a rise in axonal Ca2+ during anoxia/ischemia (see 1.3.2.2) will likely increase 
the frequency of vesicular exocytosis. 
Several studies have reported that excessive vesicular fusion at neuronal synapses is the 
earliest mechanism of glutamate release, typically within 10 minutes following the onset of 
ischemia (Katchman and Hershkowitz 1993, Wahl, Obrenovitch et al. 1994, Dawson, Djali et 
al. 2000, Jabaudon, Scanziani et al. 2000, Fleidervish, Gebhardt et al. 2001, Kawakami, 
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Sekiguchi et al. 2001). Ischemia-induced vesicular fusion is likely a result of ischemic 
depolarisation, as an increase in [K+]e depolarises  membranes and leads to a rise in [Ca2+]i 
levels. For example, the initial 15 minutes of ischemia is characterised by an increase in the 
frequency of EPSCs recorded in the calyx of Held synapse (Lee and Kim 2015). This increase in 
EPSCs was paralleled by an gradual rise in [Ca2+]i. The inhibition of VGCCs significantly inhibits 
ischemic glutamate release from cultured hippocampal neurons and attenuates neuronal 
injury (Kimura, Sawada et al. 1998). However, the protective effect of VGCC inhibitors is 
reduced when the length of ischemia is increased. This data suggests that vesicular exocytosis 
may occur for a sufficiently long period, until vesicular stores are depleted, following which 
alternative mechanisms come into play (Nishizawa 2001). However, vesicular release is not 
always an early event. Szatkowski and Attwell described two distinct phases of glutamate 
release following a reduction of blood flow (Szatkowski and Attwell 1994). The reversal of 
EAATs activate Ca2+-permeable NMDA receptors which elevated intracellular Ca2+ levels. It is 
the rise in [Ca2+]i that reportedly mediates the excessive fusion of vesicular glutamate.  
Although vesicular glutamate release is likely to occur early on in ischemia, it can contribute 
to a significant component of total glutamate release. In cerebrocortical slice cultures, the 
OGD-induced rise in extracellular glutamate, and subsequent cell death, is significantly 
suppressed in the presence of VGCC blockers or inhibitors of vesicular exocytosis (Fujimoto, 
Katsuki et al. 2004). In addition, a significant component of glutamate (and aspartate) release 
from human cerebrocortical slices was inhibited in Ca2+-free medium, characteristic of 
vesicular exocytosis (Marcoli, Bonfanti et al. 2004). Intravenous injections of a pre-synaptic 
N-type Ca2+ channel antagonist (SNX-111), significantly reduced both the concentration of 
[Glut]e and infarct volume in rats with middle cerebral artery occlusion (Takizawa, 
Matsushima et al. 1995). 
While much of this work represents vesicular release at conventional synapses in GM, to date, 
there is little evidence of ischemia-induced vesicular release in WM. Interestingly, Káradóttir 
et al. noted a dramatic rise in the frequency of post-synaptic currents recorded in OPC upon 
exposure to ischemia, suggesting an increase in exocytotic neurotransmitter release 
(Káradóttir, Cavelier et al. 2005). Similar synaptic currents were recorded under control 
conditions and were abolished in the presence of tetrodotoxin (TTX), indicating that vesicular 
glutamate release originates from neighbouring axons (Káradóttir, Cavelier et al. 2005). 
137 
 
Therefore, the glutamate-rich vesicles present in these axons, pose as a potential source of 
glutamate efflux during OGD. In addition, the close associations and sensitivity of axo-glial 
synapses suggests that excessive vesicular fusion will dramatically elevate [Glut]e at these 
synapses, which may contribute to their sensitivity during ischemia. 
 
4.1.3.3: Swelling-mediated glutamate release/ Clasmatodendrosis 
 
Astrocyte swelling is one of the earliest responses to ischemia in the human CNS (Kimelberg 
2005). During energy deprivation, the failure of the sodium-pump leads to a dramatic increase 
in [K]e, combined with the accumulation of Na+ (and Cl-) ions within cells. [K+]e is reported to 
increase from a resting level of 2.7-3.5mM (Somjen 2002), reaching between 50-80mM 
(Somjen 1979, Gido, Kristian et al. 1997). High [K+]e can stimulate the activation of the Na+ K+ 
Cl- co-transporter 1 (NKCC-1), which is expressed on fibrous WM astrocytes (Su, Kintner et al. 
2002, Wilke, Thomas et al. 2004). The NKCC is a symporter which mediates the electroneutral 
transport of Na+, K+ and Cl- into cells (in a respective ratio of 1:1:2). The increased activity of 
NKCC-1 co-transporter contributes to the movement of excessive amounts of Na+, K+ and Cl- 
into cells. An increase in intracellular osmolytes is rapidly followed by water which can easily 
diffuse across the water permeable cell membrane. However, this process is accelerated by 
the presence of aquaporin, particularly AQP-4 in astrocytes, which are a specialized class of 
water channels (Kimelberg 2005). NKCC null mice or bumetanide (a specific NKCC blocker) 
treated astrocytes show no cell swelling in response to high [K+]e, suggesting that NKCC 
activation is required to produce astrocyte swelling (Su, Kintner et al. 2002). In addition, the 
depolarising shift in membrane potential will attract the movement of negatively charged Cl- 
ions into cells. Similarly, lactic acidosis is a well-documented feature of ischemia (Rehncrona, 
Rosén et al. 1981). Intracellular acidosis activates the Na+/H+ exchanger, which will try to 
alleviate intracellular proton build up. In exchange for proton efflux, sodium ions are 
transported into cells, contributing to a build-up of intracellular Na+ and further exacerbating 
cellular swelling (Kimelberg 2005).  
If astrocyte swelling is severe enough, it can lead to the rupture of cell membranes, and the 
enviable release of intracellular glutamate.  However, in response to an increased cellular 
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volume, astrocytes try to compensate by opening volume-regulated anion channels (VRAC) 
(Kimelberg 2005, Malarkey and Parpura 2008). VRACs are outward rectifying channels which 
allow the release of intracellular osmolytes, down their concentration, into the extracellular 
space (Kimelberg 2005). VRACs are capable of releasing excitatory amino acids, like glutamate, 
when activated. Swelling-mediated release of glutamate was first reported by Kimelberg et 
al. in 1990, who monitored radiolabelled glutamate levels in response to hypotonic media  
(Kimelberg, Goderie et al. 1990). In vivo studies of ischemic GM indicate that cell swelling-
induced increases in extracellular glutamate are mediated by anion channels (Seki, Feustel et 
al. 1999). High [K+]e-induced glutamate release is inhibited by anion channel blockers like L-
6644711 and NPPB (Rutledge and Kimelberg 1996, Malarkey and Parpura 2008). Swelling-
mediated glutamate release in WM leads to excitotoxic cell death in nearby developing 
oligodendrocytes during ischemia (Wilke, Thomas et al. 2004). Wilke et al. (2004) found that 
inhibiting the NKCC largely prevents the toxic rise in [Ca2+]i in developing oligodendrocytes 
during ischemia. 
In addition to VRACs, swelling-mediated glutamate release can also occur via a process known 
as clasmatodendrosis; the detachment and disintegration of astrocyte processes which occurs 
in parallel  to astrocytic cell body swelling (Fern 2011). Fibrous astrocytes have numerous, 
highly ramified cell processes that extend from the soma. The loss of these fine cell processes 
is regularly reported during ischemia (Davies, Loddick et al. 1998, Thomas, Salter et al. 2004). 
Clasmatodendrosis was first recorded in 1961 when a reduction in blood flow led to the loss 
of distal astrocyte processes (Friede and van Houten 1961). Detachment of astrocyte 
processes leads to a loss in membrane integrity, which may liberate high levels of intracellular 




Gap junction channels are a special class of ion channel which mediate the intercellular 
transfer of ions and molecules between neighbouring cells (Ye, Wyeth et al. 2003). They are 
typically composed of two aligned connexin hexamers on the membranes of two 
neighbouring cells. These pores can pass relatively large molecules of up to 1kDa in size (John, 
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Kondo et al. 1999). Gap junctions couple astrocytes and oligodendrocytes forming a ‘glial 
syncytium’ within the CNS (Orthmann-Murphy, Abrams et al. 2008). In addition, gap junctions 
are reported to mediate the transfer of ions and molecules across the lamella of myelin 
sheath, a process which is much faster than radial diffusion through myelin (Balice-Gordon, 
Bone et al. 1998, Nualart-Marti, Solsona et al. 2013).  
However, single unopposed connexions can still act as functional channels known as hemi-
channel. Functional hemi-channels exist in situ in WM (Ye, Wyeth et al. 2003). They are 
voltage-sensitive, where channels are typically closed at resting membrane potential, but can 
open following strong depolarisation (Trexler, Bennett et al. 1996). In addition, ambient levels 
of extracellular divalent cations (e.g. Ca2+) keep hemi-channels in a closed state. Ye et al. (2003) 
discovered that exposure to a divalent cation-free solution induced the release of glutamate 
in cultured and in situ astrocytes in the mouse ON. Glutamate release could be prevented by 
several gap junction blockers such as heptanol, octanol and carbenoxolone. This raises the 
question of whether glutamate release through hemi-channels contributes to elevated [Glut]e 
under ischemic conditions. 
Gap junction activation is reported to contribute to the development of ischemic brain injury 
(Rawanduzy, Hansen et al. 1997, Davidson, Green et al. 2012). Interestingly, metabolic 
inhibition activates a non-selective current in ventricular myocytes, a feature which is blocked 
by gap-junction blocker, La3+ (Kondo, Wang et al. 2000). Similarly, exposure to chemical 
ischemia promotes the uptake of positively and negatively charged gap junction permeant 
molecules (e.g. Lucifer yellow) into cultured astrocytes (Contreras, Sánchez et al. 2002). 
Uptake was significantly reduced in the presence of gap junction blockers indicating the 
opening of unopposed hemi-channels during ischemia. Ischemia leads to the 
dephosphorylation of Cx43, a major constituent of gap junctions (Contreras, Sánchez et al. 
2002). Cx43 dephosphorylation can lead to a loss in gap junction coupling during ischemia and 
studies have found that neuronal cell death is reduced in Cx43 deficient mice (Frantseva, 
Kokarovtseva et al. 2002). In the ischemic ON, ATP release through hemi-channels activates 
P2X7 receptors which promote irreversible excitotoxic injury (Domercq, Perez-Samartin et al. 




4.1.3.5: Glutamate-cystine antiporter 
 
The final potential pathway of glutamate release is through the glutamate/cystine antiporter 
(system Xc-). This is a Na+-independent, membrane-bound antiporter involved in the co-
transport of cystine and glutamate in and out of cells, respectively. Glutamate release via the 
glutamate-cystine antiporter is reportedly a major source of extracellular glutamate under 
physiological conditions (Baker, Xi et al. 2002). However, Cavelier et al. suggested that 
physiological levels of extracellular cystine are too low to generate tonic glutamate release 
(Cavelier and Attwell 2005). Cystine is an essential substrate in glutathione synthesis, a major 
cellular antioxidant (McBean 2002). The maintenance of intracellular glutathione, particularly 
during periods of oxidative stress, promotes the activity of the glutamate/cystine antiporter, 
which mediates the cellular uptake of extracellular cystine in exchange for intracellular 
glutamate. As a result, the rapid upregulation of the antiporter during oxidative stress will 
promote glutamate release, potentially elevating [Glut]e to toxic levels (McBean 2002, Conrad 
and Sato 2012). 
While physiological extracellular cystine levels may be too low to grant excessive glutamate 
release (Cavelier and Attwell 2005), there are several reports of increased activity under 
ischemic conditions. mRNA and protein levels of the exchanger are upregulated in cell culture 
following chemical ischemia (Reissner 2014). In addition, increased activity of the glutamate-
cystine antiporter is observed in a rat model of MCAO (Soria, Pérez-Samartín et al. 2014). 
Interestingly, the blockade of the glutamate-cystine antiporter significantly reduced 
glutamate receptor-mediated currents in cortical neurons and reduced the degree of cell 
damage during OGD (Soria, Pérez-Samartín et al. 2014). Furthermore, lipopolysaccharide (LPS) 
activated microglial cells in the isolated RON, release excessive amounts of glutamate via the 
antiporter, which lead to widespread oligodendrocyte cell death (Domercq, Sánchez-Gómez 








The over-activation of iGluRs play a central role in ischemic WM pathology. Surprisingly, the 
rise in extracellular glutamate, responsible for iGluR activation, has never been directly 
measured in WM under ischemic conditions. Furthermore, the source and mechanism(s) of 
glutamate release under acute ischemic conditions are currently unknown.  
The primary aim of this chapter is to determine whether extracellular glutamate 
concentrations increase during ischemia. Using enzymatic biosensors, I plan to establish a 
time-course of ischemic glutamate release in a model WM tract. 
In doing so, I hope to determine the mechanism(s) of glutamate release under such conditions. 
Glutamate release will therefore be examined under a variety of conditions and 
pharmacological treatments aimed at blocking the different potential release pathways 









Fig. 4.1: Potential sources and mechanisms of ischemic glutamate release in white matter. 
Schematic representation of glutamate release mechanisms from axons, astrocytes and 
oligodendrocytes. GLUT= glutamate, iGluR= ionotropic glutamate receptor, Ca2+=calcium. 
1: EAATs (excitatory amino acid transporters): Reverse glutamate transport 
2: Exocytosis: Ca2+-dependent vesicular release 
3: VRAC (volume regulated anion channels): Swelling mediated release/clasmatodendrosis 
4: Hemi-channels: Unopposed gap junctions 
5: System Xc-: Glutamate/cystine antiporter 








4.2 Results: Part (a): Developing WM 
 
4.2.1 Ischemia-induced rise in extracellular glutamate in developing 
WM 
 
Ischemia-induced glutamate release is a central event in the irreversible injury of developing 
WM (Wilke, Thomas et al. 2004, Back, Craig et al. 2007, Alix and Fern 2009, Alix, Zammit et al. 
2012). In order determine the mechanism(s) of glutamate release; a time-course of [Glut]e 
was established in the developing P10 RON and CC, predominantly pre-myelinated WM tracts. 
The change in [Glut]e was monitored during exposure to chemical ischemia.  
A stable resting [Glut]e was recorded in oxygenated aCSF for a minimum of 10 minutes before 
exposure to ischemic conditions. The mean resting [Glut]e within the extracellular space of 
the P10 RON was 1.36±0.31µM (n=70 RONs). Resting [Glut]e in the P10 corpus callosum (CC) 
was not significantly different, at 3.52±1.30µM (n=12, p=0.55, Fig 4.2). For comparison 
purposes, all release data was normalised to the initial baseline recordings under control 
conditions, and glutamate concentrations are plotted as the change in extracellular glutamate 
concentrations (∆Glut).  
 
  
Fig. 4.2: Resting [Glut]e in early myelinating WM.  
Bar chart comparing the resting [Glut]e in the P10 RON 
and the P10 CC.  Measurements were taken in control 
oxygenated aCSF (mean ± SEM).  
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Due to the oxygen-dependency of the glutamate biosensors (see section 2.6.3), chemical-
ischemia was employed as our model of energy deprivation. Electrophysiological compound 
action potential (CAP) recordings were used to access the functional injury induced by a range 
of rotenone concentrations, plus zero glucose. Under control normoxic conditions, CAP 
amplitude remained stable over the course of 105 minutes (108.50±4.53%, n=10, Fig. 4.3c,e-
f). In contrast, exposing nerves to chemical ischemia, led to a rapid drop in CAP amplitude, 
eventually leading to a complete block in nerve excitability. There was no sign of functional 
recovery following 60 minutes of reperfusion using rotenone concentrations of 5nM and 
above (Fig 4.3a-b). However, using 1nM rotenone, CAP amplitude recovered to 6.49±2.23% 
(n=10, Fig. 4.3a-f). For all remaining experiments on the P10 RON/CC, 1nM rotenone and zero-
glucose was used to mimic ischemic conditions. 
Resting [Glut]e within the P10 RON remained relatively stable for at least 75 minutes under 
control conditions, with a maximum increase of 0.15±0.08µM (n=4) during the entire 
recording period (Fig 4.4a,c). However, upon exposure to chemical-ischemia, [Glut]e began to 
increase within 4-7 minutes and continued to do so at a steady rate throughout the entire 
ischemic period (Fig 4.4b-c). The maximum concentration recorded after 30 minutes of 
ischemia was 5.64±0.84µM (n=14) higher than the starting resting [Glut]e. Upon reperfusion, 
[Glut]e quickly decreased, eventually returning to baseline levels after 30 minutes (Fig. 4.4b-
c). Interestingly, the early rise in [Glut]e  closely correlates to the early loss in CAP amplitude 
(taken as 10% of maximum glutamate rise and 10% decline in CAP amplitude, respectively, 
ns= 0.17, Fig. 4.4e-f). 
To investigate whether the ischemia-evoked rise in [Glut]e is a common feature throughout 
developing WM, [Glut]e was also monitored in the P10 CC. Resting [Glut]e within the P10 CC 
remained stable under control conditions, increasing by a maximum of 0.48±0.34µM (n=3) 
over 75 minutes (Fig 4.5a,c-d). Chemical-ischemia evoked a robust increase in [Glut]e, with 
concentrations reaching 9.27±1.41µM (n=4) after 30 minutes, not significantly different to 
the RON (p=0.11, Fig.4.5b,c-f). However, unlike the ON, [Glut]e remained significantly elevated 












Fig. 4.3: Chemical-ischemia induced injury in the developing RON.  
 
a) CAP time-course comparing the effects of zero-glucose and a variety of concentrations of rotenone (5µM 
to 1nM) on the P10 RON. b) CAP recovery following exposure to zero-glucose and a variety of concentrations 
of rotenone (5µM to 1nM). c) Representative CAP trace after 5 minutes (black) and 105 minutes (red) under 
control conditions. d) Representative CAP trace before (black) and after (red) 30 minutes of chemical ischemia 
(1nM rotenone/zero-glucose). e) CAP time-course comparing control conditions to chemical-ischemia (1nM 
rotenone/zero-glucose). f) CAP recovery under control conditions and following exposure to 30 minutes of 







Fig. 4.4: Chemical-ischemia evokes a dramatic increase in extracellular glutamate concentration in the P10 
RON.  
 
a) Individual [Glut]e recordings under control conditions. b) Individual [Glut]e recordings during exposure to 
chemical-ischemia. c) Mean change (±SEM) in [Glut]e under ischemic and control conditions. d) Data summary 
comparing the maximum concentration change in extracellular glutamate and the area under the curve (total 
glutamate release) under both conditions. e) Overlay of CAP amplitude (red) and [Glut]e (black) time course 
showing the early rise in [Glut]e as CAP begins to decline. f) Histogram comparing the time taken for [Glut]e to 











Fig. 4.5: Chemical-ischemia evokes a dramatic increase in extracellular glutamate concentration in the P10 rat 
CC.  
 
a) Individual [Glut]e recordings under control conditions. b) Individual [Glut]e recordings during exposure to 
chemical-ischemia. c) Mean change (±SEM) in [Glut]e under ischemic and control conditions. d) Data summary 
comparing the maximum concentration change in extracellular glutamate and the area under the curve (total 
glutamate release) under both conditions. e) Overlay of ON (black) and CC (red) extracellular glutamate changes 
during chemical ischemia. Note the heightened [Glut]e during reperfusion in the CC. f) Histogram comparing the 
maximum peak concentration change in ON and CC. g) Histogram comparing the glutamate concentrations 
following 30 minutes of reperfusion in both tracts. ns p>0.05, **p<0.01, *** p<0.001. 
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4.2.2 Reverse EAATs are not responsible for the ischemic rise in 
extracellular glutamate 
 
Reverse glutamate transport is considered the primary mechanism of ischemic glutamate 
release in GM regions of the CNS (Rossi, Oshima et al. 2000, Baltan, Besancon et al. 2008). In 
an effort to reveal the mechanism(s) of glutamate release in developing WM, the reversal of 
EAATs posed as an attractive starting point. While the expression of functional EAATs has 
previously been reported in the developing ON (Arranz, Hussein et al. 2008), their capacity to 
maintain low extracellular concentrations has not. RONs were initially perfused with the 
potent glutamate transport blocker TBOA (200µM) under control conditions. Exposure to 
TBOA induced a significant rise in [Glut]e, increasing by 0.43±0.06µM within 10 minutes (n=22, 
p<0.0001, Fig. 4.6b-c). [Glut]e remained elevated in the presence of TBOA. In contrast, there 
was no detectable rise in time-matched controls (n=4, Fig. 4.6a,c). These findings 
demonstrate the physiological regulation of extracellular glutamate by glutamate 
transporters in developing WM. 
To access the potential involvement of reverse transport during ischemia, ONs were subject 
to chemical-ischemia in the presence of TBOA. Surprisingly, perfusion with TBOA (15 minutes 
before, during and 15 minutes after the insult) had no significant effect on either the onset or 
total glutamate release during ischemia, with concentrations increasing by 4.10±0.97µM (n=6, 
p=0.99 (v control ischemia), Fig. 4.7a-b). To further probe the involvement of EAATs, we took 
advantage of their Na+-dependency and examined release under zero-Na+ conditions (DeSilva, 
Kabakov et al. 2009). Nerves were perfused with a zero-Na+ aCSF solution (NMDG substituted) 
for a minimum of 20 minutes before exposure to chemical-ischemia. Consistent with the 
TBOA findings, there was no significant reduction in overall glutamate release under these 
conditions, with concentrations increasing by 4.64±0.22µM (n=4, p=0.99, Fig. 4.8a-b).  
Excitotoxic injury mediates a significant component of ischemia-induced functional injury in 
the P10 RON (Alix and Fern 2009). To further validate my findings, electrophysiological CAP 
recordings were examined in the presence of TBOA. Exposure to TBOA did not alter baseline 
CAP amplitude under control conditions. Moreover, it had no effect on either the latency to 
CAP failure during chemical-ischemia, nor did it improve CAP recovery following reperfusion 
(1.31±1.08%, n=4 (v 6.49±2.23% (control)), p=0.18, Fig. 4.9a-c). CAP recordings were also 
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examined using oxygen-glucose deprivation (OGD) as an alternative model of ischemia. CAP 
amplitude gradually declined over the course of 60-minutes of OGD, but did not block out, 
reaching 7.47±1.28% of its initial size. Following 90 minutes of reperfusion, CAP amplitude 
recovered to 36.27±5.44% (n=8, see Fig. 4.9e). Again, experiments were repeated in the 
presence of TBOA (15 minutes before, during and 15 minutes after). TBOA did not alter the 
rate of CAP decline during OGD, reaching 8.27±2.38% after 60 minutes. Furthermore, there 
was no significant improvement in CAP amplitude following reperfusion (31.52±5.67%, n=8, 
p=0.55, Fig. 4.9d-f). Together these experiments show that while EAATs regulate extracellular 
glutamate under physiological conditions, they are not the primary source of excitotoxic 
































Fig. 4.6: Functional EAATs regulate extracellular glutamate under physiological conditions.  
 
a) The maximum glutamate concentration recorded during two sequential time periods in control aCSF 
(i.e. 0-10mins (grey) v 10-20 mins (red)). b) The maximum glutamate concentration recorded in control 
aCSF (grey) and in the presence of TBOA (red). c) Time-course of extracellular glutamate demonstrating a 

















Fig. 4.7: Inhibition of EAATs with TBOA does not prevent the rise in extracellular glutamate under 
ischemic conditions.  
 
a) Ischemia-induced glutamate release in the presence of TBOA. b) Histogram showing the effect of TBOA 























Fig. 4.8: Removal of extracellular Na+ does not prevent the rise in extracellular glutamate under ischemic 
conditions.  
 
a) Ischemia-induced glutamate release under zero-Na+ conditions. b) Histogram showing the effect of zero-
Na+ on extracellular glutamate. ns p>0.05. 
Fig. 4.9 (next page): Inhibition of EAATs with TBOA, does not improve CAP recovery following 
chemical ischemia or OGD.  
 
a) Representative CAP trace showing no improvement in functional recovery in the presence of TBOA, 
following 30 minutes of chemical-ischemia (black=before, red=after). b,c) CAP time-course and histogram 
demonstrating how TBOA does not prevent the irreversible CAP decline during chemical-ischemia. d) 
Representative CAP trace showing no improved functional recovery in the presence of TBOA following 60 
minutes of OGD (black=before, red=after). e,f) CAP time-course and histogram demonstrating how TBOA 










4.2.3 Excessive vesicular fusion significantly contributes to elevated 
glutamate concentrations during ischemia. 
 
Next, I investigated whether vesicular glutamate release contributes to the rise in [Glut]e. 
Data from the previous chapter demonstrated that vesicular fusion along WM axons is 
capable of significantly elevating [Glut]e. To examine the significance of Ca2+-dependant 
vesicular release during modelled ischemia, [Glut]e was initially monitored under zero-Ca2+ 
conditions. Extracellular Ca2+ (i.e. CaCl2) was omitted from the perfusing aCSF solution and 
EGTA (50µM) was added to chelate trace Ca2+ down to low nM concentrations (Alix and Fern 
2009). RONs were exposed to zero-Ca2+ aCSF 20 minutes before the start of chemical-
ischemia, during and for the initial 35 minutes of reperfusion, a protocol which was maximally 
protective in a previous study (Alix and Fern 2009). Under zero-Ca2+ conditions, [Glut]e 
gradually increased when nerves were rendered ischemic. Although significance was not 
reached, total glutamate release did appear reduced under these conditions (2.86±0.64μM, 
n=5, p=0.18, Fig. 4.10a-b).  
We reasoned that the rise in intracellular Ca2+, which is necessary for vesicular exocytosis, 
may also originate from intracellular stores (Ren, Ridsdale et al. 2000, Ransom and Brown 
2003, Micu, Plemel et al. 2016). To eliminate any potential rises in intracellular Ca2+, 
experiments were repeated using BAPTA-AM-treated nerves. Nerves were initially incubated 
in BAPTA-AM (50µM), a membrane permeable form of the intracellular Ca2+ chelator, BAPTA, 
for 90 minutes. Ischemia-induced glutamate release in BAPTA-AM treated nerves was 
significantly reduced under zero-Ca2+ conditions (1.88±0.38μM, n=4, p=0.03, Fig. 4.10c-d). 
However, there was no significant difference between BAPTA-AM treated and untreated 
nerves (p=0.98), and so the source of intracellular Ca2+ is inconclusive. Nonetheless, the 
extracellular rise in glutamate seemingly operates via a Ca2+-dependant mechanism, as 
predicted for vesicular fusion.  
In an effort to directly prevent vesicular glutamate release, I investigated the effect of 
bafilomycin-a1 (baf-a1, 50nM) (Hansen, Garrido-Comas et al. 2015). Baf-a1 is a selective 
inhibitor of the vacuolar-type H+ ATPase (V-ATPase), responsible for producing a positive 
membrane potential and high concentration of H+ ions within vesicles. As mentioned, VGLUTs 
utilize the high H+ gradient to package glutamatergic vesicles. The inhibition of the V-ATPase 
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will lead to an inevitable run-down of the H+ gradient, and thus, the gradual depletion of 
vesicular glutamate stores. RONs were perfused with baf-a1 for 120 minutes before exposure 
to ischemia. However, reports claim that the application of baf-a1 doesn’t completely deplete 
glutamatergic vesicular stores unless vesicular turnover is promoted in the presence of baf-
a1 (Cavelier and Attwell 2007). Considering the rationale behind vesicle-depletion with baf-
a1 and the fact that high-K+ evokes vesicular fusion in WM (see previous chapter), nerves 
were briefly perfused with a ‘high-K+’ (10mM) aCSF solution (x2) during the 120 minute baf-
a1 pre-treatment period. Exposure to high-K+ caused a considerable drop in CAP amplitude, 
decreasing by 26.86±5.01% (n=3) after 5 minutes, and by 42.68±16.95% (n=3) after 10 
minutes (Fig. 4.11a-c). However, it had no significant effect on CAP amplitude after wash-out 
(97.26±1.43% (start) v 98.13±11.46% (end), n=3, p=0.94, Fig. 4.11c).  
Following this pre-treatment protocol, and in the continued presence of baf-a1, glutamate 
release was significantly attenuated during 30 minutes of chemical-ischemia, with a maximum 
increase of 1.15±0.29μM (n=4), versus 4.55±0.82μM (n=6) in time-matched controls 
(p=0.0056, Fig. 4.12a-b). Using the same pre-treatment protocol (i.e. brief exposures to high-
K+), glutamate release was also monitored in the presence of rose bengal (RB; 50µM), a potent 
inhibitor of VGLUTs. Similarly, RB significantly reduced the rise in [Glut]e during ischemia 
(1.98±0.47μM, n=6, p=0.013, Fig. 4.12c-d), confirming the involvement of vesicular exocytosis.  
Given that vesicular glutamate release mediates a significant component of the elevated 
[Glut]e, I next attempted to determine whether depleting nerves of their vesicular stores can 
reduce irreversible injury during ischemia. The ‘high-K+’ pre-treatment protocol had no 
significant effect on CAP recovery following 60 minutes of OGD, when compared to control 
OGD experiments (control OGD:  45.98±5.69% (n=14), v high-K+ OGD: 51.55±6.54% (n=4), 
p=0.63, Fig. 4.13a-b). For this reason, the OGD data was pooled (pooled OGD: 47.04±4.58% 
(n=18)). In the presence of baf-a1, there was a significant improvement in CAP amplitude 
recovery post-OGD (68.44±8.03%, n=9, p=0.04, Fig. 4.13c-e). Together, these findings strongly 
indicate that excessive vesicular fusion mediates a significant component of the early rise in 
extracellular glutamate levels. 
While inhibiting vesicular fusion significantly reduced glutamate release, it did not completely 
abolish the rise in [Glut]e. This suggests that an alternative mechanism of release may be 
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operating alongside vesicular fusion. I therefore, re-examined the involvement of reverse 
EAATs. [Glut]e was measured from baf-a1 treated nerves, in the presence of TBOA (200µm). 
As expected, glutamate release was significantly reduced when compared to control nerves 
(1.34±0.18µM, n=5, p=0.002, Fig. 4.14a-b). However, there was no additive reduction in total 




























Fig. 4.10: Glutamate release is significantly attenuated under zero-Ca2+ conditions.  
 
a) Ischemia-induced glutamate release in a zero-Ca2+ aCSF solution containing 50µM EGTA. b) Histogram 
demonstrating the effect of zero-Ca2+ on [Glut]e. c) Ischemia-induced glutamate release from BAPTA-AM 
treated ONs in a zero-Ca2+ aCSF solution containing 50µM EGTA. d) Histogram demonstrating the effect 



















Fig. 4.11: Perfusing nerves with 10mM KCl aCSF to promote vesicular turnover, reversibly decreases 
CAP amplitude.  
 
a) Representative CAP images recorded from the P10 RON in control aCSF and following either 5 or 10 
minutes of 10mM KCl aCSF. Time points correspond to the CAP time-course below (b). b) CAP amplitude 
plotted against time showing a decrease in amplitude during perfusion with 10mM KCl. c) Histogram 















Fig. 4.12: The rise in extracellular glutamate is significantly reduced in vesicle-depleted nerves.  
 
a) Ischemia-induced glutamate release in bafilomycin-a1 treated nerves. b) Histogram demonstrating 
the effect of bafilomycin-a1 on [Glut]e. c) Ischemia-induced glutamate release in rose bengal treated 














Fig. 4.13: Depleting nerves of their vesicular stores, significantly improves functional recovery following 60 
minutes of OGD.  
 
a) CAP time-course showing no significant difference in OGD sensitivity between nerves which were pre-
exposed to 10mM KCl and those which were not (control OGD). b) Histogram showing no significant 
difference in CAP amplitude between the two groups. c) Representative CAP traces from control OGD and 
bafilomycin-a1 treated OGD (black: before, red: after) d) Bafilomycin-a1 treated nerves (vesicle depleted) 
show an improvement in CAP recovery after 60 minutes of OGD. e) Data summary of CAP recovery showing 

















Fig. 4.14: Blocking EAATs with TBOA does not abolish the remaining rise in glutamate from 
bafilomycin-a1 treated nerves.  
 
a) Ischemia-induced glutamate release from bafilomycin-a1 treated nerves in the presence of TBOA. 
b) Histogram demonstrating the effect of bafilomycin-a1 and TBOA on [Glut]e. ns p>0.05, **p<0.01. 
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4.2.4 Blocking alternative glutamate release pathways did not 
significantly reduce the ischemic rise in extracellular glutamate 
 
Considering vesicular fusion does not fully account for the rise in [Glut]e, I investigated three 
alternative glutamate release mechanisms which could potentially contribute to the high 
[Glut]e in developing WM. As previously mentioned, the activation of the NKCC co-transporter 
during ischemia promotes astrocyte cell swelling. In addition, swelling opens a range of VRACs, 
which are capable of glutamate release. To determine whether swelling-mediated 
mechanisms of glutamate release operate during acute ischemia, [Glut]e was monitored in 
the presence of furosemide (5mM), an effective NKCC inhibitor. However, the application of 
furosemide had no significant effect on glutamate release, with concentrations reaching 
6.53±1.62µM (n=6, p=0.99, Fig. 4.15a-b). In addition, glutamate release was also examined in 
the presence of NPPB (100µM), a VRAC blocker. Yet again, this had no significant effect on 
[Glut]e (3.43±0.88µM, n=5, p=0.78, Fig. 4.15c-d). Together, this indicates that swelling-
mediated glutamate release does not contribute to the excitotoxic build-up of extracellular 
glutamate. 
Next, I proceeded to test the potential for glutamate efflux via gap junction hemi-channels.  
Glutamate release was monitored in the presence of the gap-junction blocking agent, 
carbenoxolone (100µM)(Ye, Wyeth et al. 2003). However, this had no significant effect on the 
[Glut]e time-course during ischemia, with concentrations reaching 4.41±0.81µM (n=6) 
following 30 minutes of chemical ischemia (p=0.67, Fig. 4.16a-b). 
Finally, I examined potential glutamate release via the glutamate-cystine antiporter.  To do 
this, [Glut]e was monitored in the presence of sulfasalazine (250µM) (Soria, Pérez-Samartín 
et al. 2014), a non-substrate inhibitor of the glutamate-cystine antiporter. Again, sulfasalazine 
did not have a significant effect on either the latency or magnitude of glutamate release 
during ischemia, with peak concentrations reaching 6.01±1.10µM (n=5, p=0.99, Fig. 4.16c-d).  
Together it demonstrates that vesicular exocytosis is the primary mechanism of ischemic 
glutamate release in developing WM (Fig. 4.17a-b). However, it must be noted that although 
no significant contribution was found with EAATs, swelling-mediated release, hemi-channels 
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or the glutamate-cystine antiporter, the blockade of vesicular release did not completely 
























Fig. 4.15: Swelling-mediated glutamate release does not significantly contribute to the rise in 
extracellular glutamate.  
 
a) Ischemia-induced glutamate release in the presence of furosemide. b) Histogram showing the 
effect of furosemide on [Glut]e. c) Ischemia induced glutamate release in the presence of NPPB. d) 















Fig. 4.16: Blocking either hemichannels or the glutamate-cystine antiporter does not prevent the 
rise in [Glut]e.  
 
a) Ischemia-induced glutamate release in the presence of carbenoxolone (CBX). b) Histogram 
showing the effect of carbenoxolone on [Glut]e. c) Ischemia induced glutamate release in the 














Fig. 4.17: Summary of [Glut]e recordings during exposure to modelled ischemia under all 
conditions and pharmacological treatments.  
 
Techniques aimed at preventing vesicular glutamate release significantly reduce the rise in 
extracellular glutamate during 30 minutes of ischemia.  
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4.3 Results: Part (b): Adult WM 
 
4.3.1 Ischemia-induced rise in extracellular glutamate in adult WM 
 
Glutamate receptor-mediated injury is also implicated in the development of ischemic WM 
damage in mature WM (Stys 1998, Tekkok, Ye et al. 2007, Baltan, Besancon et al. 2008). Given 
that ischemia evokes a robust rise in [Glut]e in the developing RON, I sought to determine 
whether the same can be said for the adult RON. And if so, is release via the same mechanism? 
Initially, resting [Glut]e was measured within the adult RON (>P90) in oxygenated aCSF. The 
mean resting [Glut]e was 8.9±1.4µM (n=40), significantly higher than the P10 RON 
(1.36±0.31µM, n=70, p<0.01, Fig. 4.18). Resting [Glut]e in the adult RON was also significantly 
higher than the adult CC and adult mouse optic nerve (MON) which were 1.61±1.8µM (n=15) 




Unlike the P10 RON, 30-minutes perfusion with 1nM rotenone/zero-glucose did not lead to 
irreversible functional damage (data not shown). For this reason, nerves were perfused with 
a known effective concentration of antimycin-a (25µM) and zero-glucose aCSF (chemical-
ischemia) (Allen, Káradóttir et al. 2005, Bakiri, Hamilton et al. 2008). To access functional 
Fig. 4.18: Resting [Glut]
e
 in adult WM.  
Bar chart comparing the resting [Glut]
e 
in the adult 
RON, CC and MON.  Measurements were taken in 
control oxygenated aCSF (mean ± SEM). **= p<0.01. 
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recovery following exposure to chemical-ischemia, CAP area was monitored over time. CAP 
area remained relatively stable under control conditions, showing a slight increase following 
165 minutes (116.0±5.75%, n=4, Fig. 4.19a,c-d). In contrast, simulation of ischemia (with 
antimycin-a/zero-glucose) resulted in a gradual decline in CAP area over the course of 60 
minutes. CAP area did not recover following 60 minutes reperfusion (0.07±0.1%, n=3, 
p<0.0001, Fig. 4.19b-d).  
[Glut]e remained stable under control conditions, with a maximum increase of 1.62±0.5µM 
(n=4) during 105 minutes of recording in oxygenated aCSF (Fig. 4.20a,c-d). Upon exposure to 
chemical-ischemia, there was a dramatic increase in [Glut]e within 5 minutes. Similar to the 
developing RON, the onset of glutamate release closely coincides with the early decline in 
CAP area (Fig. 4.20e-f, p=0.27). [Glut]e continuously increased throughout the ischemic period, 
reaching a maximum concentration of 26.96±6.0µM (n=13, p=0.04, Fig. 4.20b-d). Upon 
reperfusion, [Glut]e quickly decreased towards baseline levels. Due to the high variability in 
the adult RON, ischemic glutamate release data was split into two interleaved groups for 
























Fig. 4.19: Chemical-ischemia induced injury in the myelinated RON.  
 
a) Representative CAP trace after 5 minutes (black) and 165 minutes (red) under control conditions. b) 
Representative CAP trace before (black; 5 mins) and after 60 minutes of chemical ischemia (red; 165 mins). 
c) CAP time-course comparing control conditions to chemical ischemia. d) CAP recovery under control 









Fig. 4.20: Exposure to chemical-ischemia dramatically elevates extracellular glutamate concentrations in 
the adult RON.  
 
a) Individual [Glut]e recordings under control conditions. b) Individual [Glut]e recordings during exposure to 
60 minutes of chemical ischemia. c) Mean change (±SEM) in [Glut]e under control and ischemic conditions. 
d) Data summary comparing the maximum concentration change in [Glut]e and the area under the curve 
under control and ischemic conditions. e) Overlay of CAP amplitude (red) and [Glut]e (black) time course 
showing the early rise in [Glut]e as CAP begins to decline. f) Histogram comparing the time taken for [Glut]e 
to increase by 10%, and for CAP to decrease by 10%. ns p>0.05, ** p<0.01.  ** p<0.01. 
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4.3.2 Reverse EAATs are not responsible for the ischemia-induced 
rise in extracellular glutamate in adult WM 
 
The previous experiments on the developing RON showed that the reversal of EAATs do not 
contribute to the ischemia-induced rise in glutamate levels. This result was somewhat 
surprising considering several papers have reported EAATs as the source of glutamate release 
in mature WM tracts (Tekkok, Ye et al. 2007, Hamilton, Kolodziejczyk et al. 2016). Therefore, 
it is plausible that developmental changes of the molecular architecture within the ON, could 
lead to changes in the mechanisms of ischemic glutamate release. Moreover, it has been 
reported that there is an up-regulation of GLT-1 expression in older WM (Baltan, Besancon et 
al. 2008).  
To investigate the significance of EAATs in adult WM, I initially examined the effect of EAAT 
inhibition under control conditions. Unlike the P10 RON, perfusing the adult RON with TBOA 
(200µM) had no significant effect on resting [Glut]e, with concentrations slightly decreasing 
by 0.14±0.2µM (n=6) during the initial 10 minutes of TBOA exposure (p=0.52, Fig.4.21a-b). In 
contrast, exposure to TBOA induced a significant increase in resting [Glut]e in the adult corpus 
callosum (0.88±0.41µM, n=9, p=0.04, Fig.4.21c-d). 
To test whether reverse EAATs contribute to the elevated [Glut]e during ischemia, [Glut]e was 
measured in the presence of TBOA (15 minutes before, during and 15 minutes after chemical 
ischemia). TBOA had no significant effect on either the early onset of release or total 
extracellular concentrations after 60 minutes of chemical-ischemia (TBOA: 22.53±3.73µM, 
n=6, versus control: 27.98±6.8µM, n=7; p=0.99, Fig. 4.22a-b). To further probe the 
involvement of EAATs, [Glut]e was also recorded under zero-Na+ conditions (NMDG-
substituted). However, this treatment resulted in a significant exacerbation of ischemia-
induced glutamate release, with concentrations reaching 53.77±13.70µM (n=5, versus control: 
27.98±6.8µM, n=7; p=0.005, Fig.4.22c-d). Consistent with my findings in the P10 RON, the 
results suggest that reverse EAATs do not contribute to glutamate release in the adult RON.  
Previous studies which have reported the involvement of reverse EAATs in ischemic WM 
pathology have used the adult MON as their model WM tract (Tekkok, Ye et al. 2007, Baltan, 
Besancon et al. 2008). I therefore decided to investigate whether the differences in our 
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findings may be due to inter-species differences between the rat and mouse. Resting [Glut]e 
within the adult MON was recorded for 15 minutes before exposure to 60 minutes of 
chemical-ischemia. Ischemia induced a dramatic rise in [Glut]e, which surprisingly peaked 
after only 26.63±1.09 minutes, reaching 35.60±9.85µM before rapidly falling back towards 
baseline levels (Fig. 4.23a-b, n=4). Unlike the adult RON, where glutamate release is 
continuous throughout the 60-minute insult, the distinctive glutamate release profile 
recorded in the adult MON suggests that glutamate stores may become depleted after 25-30 
minutes, which may be related to its smaller size. Nonetheless, glutamate release in the MON 
was examined in the presence of TBOA (200µM). Although TBOA did appear to reduce the 
overall rise in [Glut]e, statistical significance was not reached (18.07±6.98µM, n=5, p=0.22, Fig. 
4.23a-b). Not enough nerves were examined to convincingly show the involvement of EAATs 
























Fig. 4.21: Exposure to TBOA under physiological conditions does not elevate resting [Glut]e in the adult 
RON, but does in the CC. 
 
a) Exposure to TBOA under control conditions does not change basal [Glut]e levels in the RON. b) Data 
summary comparing the maximum concentration during 10 minutes of control aCSF with the first 10 minutes 
of exposure to TBOA in the ON. c) Exposure to TBOA under control conditions significantly increases basal 
[Glut]e levels in the adult CC. d) Histogram comparing the maximum concentration during 10 minutes of 










Fig. 4.22: Inhibition of EAATs with TBOA or under zero-Na+ conditions does not prevent the ischemia-
induced rise in extracellular glutamate in the adult RON.  
 
a) Ischemia-induced glutamate release in the presence of TBOA in the ON. d) Histogram showing the effect 
of TBOA on [Glut]e. c) Ischemia-induced glutamate release under zero-Na+ conditions. d) Histogram 




















Fig. 4.23: Ischemia-induced glutamate release in the adult MON peaks after 25-30 minutes, and is not 
significantly reduced by TBOA.  
 
a) [Glut]e time-course showing the rise in glutamate during ischemia and the effect of TBOA on glutamate 
release in the myelinated MON. b) Histogram showing the effect of TBOA on [Glut]e. ns p>0.05. 
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4.3.3 Vesicular glutamate contributes to the ischemia-induced rise 
in extracellular glutamate in adult WM 
 
Previous experiments on the unmyelinated P10 RON show that excessive vesicular fusion is 
capable of elevating extracellular glutamate levels, a phenomenon which occurs early in 
ischemia. In addition, experiments from chapter 3 show that myelinated axons are also 
capable vesicular docking. Therefore, I next accessed whether vesicular fusion contributes to 
the rise in [Glut]e during ischemia in the adult RON. 
To test the significance of vesicular release in the adult RON, [Glut]e was recorded under zero-
Ca2+ conditions. RONs were perfused with a zero-Ca2+ aCSF solution containing EGTA (50µM) 
for 20 minutes before, during and 35 minutes after ischemia. Similar to the P10 RON, a 
significant decrease in [Glut]e was observed in the absence of extracellular Ca2+. [Glut]e 
reached 10.48±1.4µM (n=6) following 60 minutes of chemical ischemia, significantly lower 
than the time-matched control (25.78±11.05µM, n=6, p=0.04, Fig. 4.24a-b).  
Provided the removal of extracellular Ca2+ is sufficient to reduce glutamate release, I next 
attempted to uncover the route of Ca2+ influx during ischemia. Ca2+ influx through voltage 
gated Ca2+ channels (VGCCs) is reported to mediate anoxic damage in the mature RON (Brown, 
Westenbroek et al. 2001). The application of diltiazem (100µM), an L-type Ca2+ channel 
blocker, had a similar effect on ischemic [Glut]e as zero-Ca2+, attenuating glutamate 
concentrations to 12.89±3.73µM (n=7, Fig. 4.24c-d). However, statistical significance was not 
achieved (p=0.09). Nonetheless, the data indicates that a significant component of glutamate 
release is via Ca2+ dependant vesicular exocytosis.  
Following this, an effort was made to deplete nerves of their vesicular glutamate stores using 
the same bafilomycin-a1 pre-treatment protocol as used with the neonatal RON (i.e. 120 
minutes perfusion with bafilomycin-a1, including two brief exposures to 10mM KCl). The 
maximum peak concentration reached was slightly reduced to 19.85±3.75µM in the presence 
of bafilomycin-a1, but it was not statistically significant (n=6, p=0.49, Fig. 4.25a-b). However, 
I was not convinced that 10mM KCl was sufficient to promote sufficient vesicular turnover 
during the pre-treatment period. For this reason, a known effective concentration of K+ was 
used; 50mM (see Chapter 3). However, again bafilomycin-a1 produced an insignificant 
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decrease in total glutamate release (Baf-a1: 24.85±6.94µM, n=6 versus Control: 
31.73±8.14µM, n=5, p=0.37, Fig. 4.25c-d). The lack of a significant reduction in bafilomycin-
a1 treated nerves is curious considering the removal of Ca2+ prevented a significant 
component of release.  
A more direct way of examining vesicular fusion in myelinated WM is with the use of FM4-64. 
Coronal brain slices (400µM) including the corpus callosum were obtained from adult Thy-
1/YFP+ mice. Slices were loaded with FM4-64 using an established ‘high-K+’ loading protocol 
(see ‘Materials and Methods’). As previously demonstrated, widespread FM4-64 loading was 
observed in YFP+ axons. Using two-photon confocal microscopy, FM-fluorescence was 
monitored for 30 minutes under control conditions (i.e. oxygenated aCSF). Over the course of 
30 minutes, axonal FM-fluorescence decreased by 16.21±2.69% (n=23, Fig. 4.26), which may 
reflect a combination of spontaneous vesicular release and/or photo-bleaching due to 
relatively long periods of recording. However, the pronounced drop in FM-fluorescence was 
exacerbated following exposure to chemical ischemia (Fig. 4.27). Axonal FM-fluorescence 
became significantly reduced after 15 minutes of ischemia (p=0.02), decreasing by 27.33±2.0% 
after 25-30 minutes (n=35, p=0.0013, Fig. 4.28a-b). FM4-64 de-staining is indicative of 
vesicular docking occurring along the axon cylinder. As previously demonstrated in chapter 3, 
all YFP+ axons in the mouse CC are myelinated, with a mean diameter of 0.86±0.02µM (n=167), 
which is considerably higher than the largest diameter unmyelinated axon. As with K+-evoked 
vesicular release, there was no evidence of localised de-staining along the axon cylinder, and 
therefore, the vast majority of vesicular fusion must occur underneath the myelin sheath, 












Fig. 4.24: Glutamate release is reduced under conditions aimed at preventing vesicular release.  
 
a) Ischemia-induced glutamate release from adult RONs in a zero-Ca2+ aCSF solution. b) Histogram 
demonstrating the effect of zero-Ca2+ conditions on [Glut]e c) Ischemia-induced glutamate release in the 












Fig. 4.25: Depleting nerves of their vesicular stores with bafilomycin-a1, does not significantly reduce 
glutamate release. 
a) Ischemia-induced glutamate release in bafilomycin-a1 treated nerves (10mM KCl pre-treatment protocol). 
b) Histogram demonstrating the effect of bafilomycin-a1 on [Glut]e. c) Ischemia-induced glutamate release in 
bafilomycin-a1 treated nerves (50mM KCl pre-treatment protocol). d) Histogram demonstrating the effect of 










Fig. 4.26: FM4-64-loaded axons show a slight decrease in FM-fluorescence over 30 minutes in control 
aCSF.  
 
a)  Image of YFP+ axons in the mouse CC. An individual axon segment (indicated by a dotted boarder and 
arrow) was selected for analysis. b) Selected YFP+ axon segment is highly fluorescent with FM4-46 after 
loading protocol. c) Representative time-course of axonal FM fluorescence remains relatively stable under 
control conditions. Representative images at different time points are numbered 1-4 (1=1 minute, 2=10 















Fig. 4.27: FM4-64-loaded axons display a large drop in FM-fluorescence during 30 minutes of chemical 
ischemia.  
 
a)  Image of YFP+ axons in the mouse CC. An individual axon segment (indicated by a dotted boarder and 
arrow) was selected for analysis. b) Selected YFP+ axon segment is highly fluorescent with FM4-46 after 
loading protocol. c) Representative time-course of axonal FM fluorescence showing a decrease during 
chemical ischemia. Representative images at different time points are numbered 1-4 (1=1 minute, 2=10 











Fig. 4.28: FM4-64-loaded axons show a significant decrease in fluorescence during chemical ischemia. 
 
a) Time-course of FM fluorescence from all individual axons under control conditions. b) Time-course of FM 
fluorescence from all individual axons during chemical ischemia. c) FM fluorescence time-course comparing 
chemical ischemia to control. d) Data summary under both conditions showing a significant drop in 
fluorescence after 15 minutes. * p<0.05, ** p<0.001. 
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4.3.4 Alternative release mechanisms do not contribute to elevated 
extracellular glutamate levels.  
 
Next, I investigated alternative release mechanisms which could contribute to the rise in 
[Glut]e. To exclude the possibility of the increased function of the glutamate-cystine 
antiporter, glutamate release was monitored in the presence of a known effective 
concentration of sulfasalazine (SAS, 250µM) (Soria, Pérez-Samartín et al. 2014), a non-
substrate inhibitor of the glutamate-cystine antiporter. However, the application of SAS had 
no significant effect on total glutamate release during ischemia. The maximum peak 
concentration reached was not significantly different to control nerves, with concentrations 
reaching 18.14±2.32µM (n=6, p=0.98 versus control; 27.98±6.8µM (n=7); Fig. 4.29a-b). It must 
be noted that [Glut]e appeared to plateau during the final 20 minutes of ischemia, indicative 
of a reduction in the rate of release during the later phase of ischemia. 
I also tested the possibility of swelling-mediated release using furosemide (5mM), a NKCC 
inhibitor. However, ischemia-induced [Glut]e was not significantly different in the presence of 
furosemide, with concentrations reaching 31.18±3.80µM (n=4, p=0.93 versus control; 
27.98±6.8µM (n=7), Fig. 4.30c-d). 
Together, this data indicates that like the P10 RON, excessive vesicular fusion contributes to 
the elevated extracellular glutamate levels recorded in the adult RON. However, the failure 
to completely abolish glutamate release under conditions aimed at preventing vesicular 
fusion (see Fig. 4.31) leave open the possibility that multiple mechanisms may collectively add 
to the rise in [Glut]e. This would require further investigation which was beyond the scope of 

































Fig. 4.30: Swelling-mediated glutamate release does not significantly contribute to the rise in 
extracellular glutamate.  
 
a) Ischemia-induced glutamate release in the presence of furosemide (5mM). b) Histogram showing the 
effect of furosemide on [Glut]e. ns p>0.05. 
Fig. 4.29: Inhibition of the glutamate-cysteine antiporter with sulfasazine (SAS) does not significantly 
reduce the rise in extracellular glutamate.  
 
a) Ischemia-induced glutamate release in the presence of sulfasazine (250µM). b) Histogram showing the 


















Fig. 4.31: Summary of ischemic glutamate release in the adult RON under a variety of conditions and 
pharmacological conditions 
 
a) Glutamate release under conditions aimed at preventing EAAT reversal, swelling-mediated release 
and the glutamate/cysteine antiporter. b) Glutamate release under conditions aimed at preventing 







The human brain is highly susceptible to prolonged periods of ischemia. Considering WM 
constitues approximately 50% of the adult human brain, it comes as no surprise that WM 
pathology is regularly observed following a variety of ischemic insults. Moreover, WM injury 
is of particular importance as the loss in axon function is fundamental to to the severe clinical 
impairments suffered by patients. Recent studies have demonstrated that excitotoxicty is a 
central injury mechansim underlying irreversible WM damage. As a result, glutamate release 
is a critical event in the pathophysiology of ischemic WM injury. In this chapter, I have 
established a glutamate release time-course in several WM tracts, and  examined the the 
potential mechanims of ischemic glutamate release in developing and mature WM. I found 
that exposure to conditions which mimic ischemia led to a robust rise in [Glut]e. Suprisingly, 
glutamate release was not via the reversal of glutamate transports. Similarly, release through 
hemichannels, the glutamate/cystine antiporter or volume regulated anion channels did not 
contribute to the rise in [Glut]e. However, [Glut]e was significantly attenuated under 
conditions aimed at preventing vesicular fusion. Furthermore, depleting nerves of their 
vesicular glutamate stores improved functional recovery following oxygen-glucose 
deprivation. Together the data presented in this chapter demonstrates that excessive 
vesicular glutamate release during ischemia contributes to excitotoxic WM injury. 
 
 
4.3.2: Ischemia evokes a rapid increase in extracellular glutamate in 
WM 
 
Excitotoxicity is associated with a range of neurological disorders including Alzehimers’, 
vascular dimentia, diabetic cognitive dysfunction and ischemia (Hynd, Scott et al. 2004, Baskys 
and Hou 2007, Tekkok, Ye et al. 2007, McCrimmon, Ryan et al. 2012). Techniques, such as 
microdialysis, have revealed that hypoxia/ischemia evokes a robust rise in extracellular 
glutamate in GM regions of the CNS (Benveniste, Drejer et al. 1984, Andiné, Sandberg et al. 
1991, Cui, Zhang et al. 1999). While techniques such as high preformance liquid 
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chromatography (HPLC) have been used to detect glutamate fold-changes in the perfusate of 
isolated WM preparations (Ye, Wyeth et al. 2003, Tekkok, Ye et al. 2007, Yang, Hamner et al. 
2014), the direct change in [Glut]e within WM has never been recorded. However, the recent 
development of enzymatic glutamate biosensors (sarissaprobes©), allows for real-time 
detection of glutamate concentrations within live tissue. Using glutamate biosensors, real-
time changes in [Glut]e was recored from inside model WM tracts, the RON and CC. 
 
As predicted, the resting [Glut]e in the ECS was in the low micromolar range. Considering 
experiments are conducted several hours after sensor insertion when [Glut]e has stabalised 
to a steady level, it is unlikely that these measurments reflect non-physiological elevations 
resulting from acute physical damage. With the exception of the adult RON, resting [Glut]e 
was between 1.3 and 4.5µM in all WM preparations. This is consistent with numerous studies 
which have recorded resting [Glut]e in the range of 1 and 5µM in various brain regions, in a 
variety of mammalian species (Moussawi, Riegel et al. 2011). This tonic pool of [Glut]e likely 
results from a balance of spontaneous vesicular glutamate release/release via glutamate-
cystine antiporter and glutamate uptake via Na+-dependent transporters (Baker, Xi et al. 2002, 
Moussawi, Riegel et al. 2011). As mentioned, glutamate transports (EAAT) are primarily 
responsible for the maintainence of low extracellular concentrations throughout the CNS. I 
found that inhibiting EAATs evokes a significant rise in resting [Glut]e in most WM tracts, with 
levels increasing by approximatly 25%. In support of Arranz et al. (2008) who demonstrated 
the expresssion of functional EAATs in WM, this suggests that EAATs maintain low glutamate 
concentrations in both developing and adult WM. Interestingly, the inhibition of EAATs did 
not elevate [Glut]e in the adult RON. Baltan et al. (2008) reported that there is a two-fold 
increase in GLT-1 protein expression in older WM. They also reported that this phenoenomon 
may be specific to WM as there was not detectable change in GLT-1 expression  in the 
hippocampus. While the upregulation of EAAT expression was identified as a possible 
explanation for the enhanced release of glutamate during OGD (measured by HPLC) in this 
study, it also suggests that glutamate uptake may also be enhanced under physiological 
conditions. This may be releated to the heightened resting [Glut]e recorded in the adult RON 
(8.9µM; versus 1.4µM in the P10 RON), as more EAATs are required to regulate glutamate 
homeostasis. Alternatively, the heightened resting [Glut]e may be due to impaired EAAT 
transport in the adult RON. Nonetheless, glutamate transport in the adult RON was insensitive 
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to  TBOA. However, TBOA did  increase [Glut]e in the adult CC. Therefore, further experiments 
would be required to explain the ususal result in the adult RON.  
 
Exposing nerves to ischemia evoked a striking increase in [Glut]e in both developing and 
mature WM tracts. Intriguingly, glutamate release occurred within minutes of ischemia, with 
[Glut]e typically increasing within the initial 5 minutes. The early onset of glutamate release 
was somewhat unexpected, as the aforementioned study by Baltan et al. (2008), found that 
glutamate levels began to increase after ~30 minutes in the MON (1 month old). However, it 
must be noted that HPLC measurments, as were used in this paper, are only detected once 
glutamate diffuses out from the ECS, through the outer membrane of the nerve and into the 
bath perfusate. Thus, biosensors will likely reflect a more accurate onset of glutamate release. 
In additon, it is likely that chemical ischemia depletes ATP levels much quicker than OGD. For 
example, my data demonstrates that nerve excitability is typically blocked within 30 minutes 
of chemical ischemia, whereas, 60 minutes OGD does not abolish CAP conduction (see Fig. 
4.9 for comparision). Interestingly, the early initiation of glutamate release coincides with the 
early loss in nerve excitability during chemical-ischmia. This indicates that there is a readily 
releasable pool of intracellular glutamate within WM and that release is dependent on early 
events such as the initial loss in ionic homeostasis.   
 
Following the onset of release, [Glut]e continued to increase throughout the duration of 
ischemia, demonstrating a contineous release of endogenous glutamate from WM cells, 
which subsequently accumulates in the ECS. [Glut]e increased at a steady rate throughout the 
entire 30-minute insult in the neonatal RON. Interestingly, increasing the duration of ischemia 
from 30 to 60 minutes with the adult RON, revealed a slight decrease in the rate of glutamate 
release during the later phase of ischemia in several nerves (6 out of 13). This might reflect 
the depletion of glutamate stores as energy deprivation persists or may be due to a second 
component of release mediated by an alternative release mechanism. Consistent with the 
depletion of glutamate stores, [Glut]e peaked after only 25-30 minutes in the adult MON, 
before gradually returning to baseline. 
Ischemia produced a respective 5.6µM, 9.3 µM and 27µM [Glut]e increase in the neonatal 
RON, neonatal CC and adult RON glutamate levels, suggesting that ischemic glutamate release 
is a common feature thoughout WM and at different development stages. [Glut]e is 
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contineously washed away in the perfusing aCSF  in our experimental set-up, and so it is 
reasonable to presume that [Glut]e accumulates in vivo producing much higher levels. 
Ischemia-induced changes in [Glut]e were comparible to levels recorded in several GM 
preparations (Wahl, Obrenovitch et al. 1994, Graf, Kumura et al. 2001). Upon the initiation of 
reperfusion, [Glut]e rapidly returned towards basline, which may reflect glutamate re-uptake 
as ionic gradients are re-established, or may be a result of glutamate wash-out into the bath 
perfusate. Nonetheless, exposure to ischemia evokes a early transient rise in WM [Glut]e, 
likely responsible for the over-activation of iGluRs.   
 
 
4.3.3: Reverse EAATs do not mediate ischemic glutamate release in 
WM 
 
In 2000, two independent groups demonstrated that reverse EAATs are responsible for the 
majority of ischemic glutamate release in GM regions of the CNS (Jabaudon, Scanziani et al. 
2000, Rossi, Oshima et al. 2000). Interestingly, several reports have since emerged that 
reverse transport also contributes to glutamate release in WM. As previously mentioned, the 
application of EAAT inhibitors improves functional recovery following ischemia/anoxia in 
isolated WM preparations (Li, Mealing et al. 1999, Tekkok, Ye et al. 2007). More recent work 
by Hamilton et al. reported that preloading brain slices with PDC reduced the ischemia-
evoked inward current in oligodendrocytes by 68%, similar to the reduction observed in the 
presence of glutamate receptor antagonists NBQX and D-AP5 (Hamilton, Kolodziejczyk et al. 
2016). Therefore, the established view is that glutamate release during ischemia is via the 
reversal of glutamate transporters.  
However, despite the expression of functional EAATs in WM, blockers of EAATs (TBOA and 
zero-Na+) did not prevent the ischemia-induced rise in [Glut]e in either the developing or adult 
RON. The lack of contribution from EAATs was surprising considering their reported 
involvement in alternative WM studies. One notable difference between my work and these 
previous reports is the model of ischemia used. While my study employs chemical ischemia, 
previous studies predominantly used OGD as a model of energy deprivation. Therefore, it is 
plausible that more severe ischemic insults, such as chemical-ischemia, may evoke release via 
alternative mechanisms. However, consistent with my [Glut]e experiments, I found no 
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significant improvement in post-OGD CAP recovery in the presence of TBOA. Alix and Fern 
(2009) also reported that zero-Na+ conditions do not preserve either CAP amplitude or the 
ultrastructural integrity of P10 RONs exposed to 60 minutes OGD. In addition, previous 
studies used HPLC to show transport-mediated release in the ON. Changes in glutamate levels 
in the bath perfusate may reflect glutamate release from glial limitans and the pia matter 
surrounding the nerve. In contrast, my methodological approach directly measures glutamate 
levels in the extracellular space.  
Curiously, glutamate release was exacerbated under zero-Na+ conditions in the adult RON. 
Similarly, several other studies have reported an increase in OGD-induced neuronal damage 
in the presence of EAAT inhibitors (Fujimoto, Katsuki et al. 2004, Soria, Pérez-Samartín et al. 
2014). A possible explanation for this is that EAATs contribute to the clearance of extracellular 
glutamate during ischemia (Namura, Maeno et al. 2002). However, I found that [Glut]e in the 
adult RON was unaffected in the presence of TBOA, which argues against this idea. An 
alternative explanation for this discrepancy is that the newly established transmembrane Na+-
gradient under zero-[Na+]e conditions (ECS:0mM, intracellular:~10mM), may actually 
promote the reversal of EAATs. In fact, high cytosolic concentrations of Na+ are known to 
promote reverse glutamate transport and excitotoxicity in rat hippocampal slices (Roettger 
and Lipton 1996, Raley-Susman, Kass et al. 2001). Nonetheless, together the data suggests 
that contrary to expectation, reverse glutamate transport does not mediate the ischemic rise 
in [Glut]e in WM. Accordingly, disrupted glutamate homeostasis must operate via an 
alternative mechanism(s). 
 
4.3.4: Vesicular fusion contributes to ischemic glutamate release in 
WM  
 
In the previous chapter I presented data which revealed the significance of vesicular 
glutamate release in WM. Moreover, the data demonstrates that exposing WM to 50mM K+, 
a concentration that is comparable the level recorded during cerebral ischemia (Gido, Kristian 
et al. 1997), evokes a significant increase in [Glut]e, a consequence of vesicular docking along 
WM axons. As mentioned, excessive vesicular fusion during ischemia is an early event in GM. 
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Káradóttir et al. (2005) also noted that when exposed to in vitro ischemia, the early inward 
current recorded in whole-cell clamped OPCs included an increase in the frequency of 
‘synaptic current-like’ events.  
Experiments under zero-Ca2+ conditions were carried out to determine whether the ischemic 
rise in [Glut]e was Ca2+-dependent, as expected for vesicular exocytosis. [Glut]e in the pre-
myelinated RON was dramatically attenuated when Ca2+ was omitted from perfusate. 
Interestingly, glutamate release was slightly lower when intracellular Ca2+ was also chelated 
with BAPTA-AM, yet there was no significant difference between experiments with or without 
BABPA-AM. Thus, my data does not resolve the precise source of intracellular Ca2+ required 
for vesicular fusion. [Glut]e was significantly reduced in the presence of either bafilomycin-a1 
or rose bengal, inhibitors of vesicular glutamate loading. Together this indicates that vesicular 
glutamate release contributes to the accumulation of [Glut]e during ischemia. Consistent with 
these findings, post-OGD CAP amplitude was significantly higher in nerves which were treated 
with bafilomycin-a1, further demonstrating that vesicular glutamate release promotes 
irreversible WM injury in early myelinating WM.  
The experiments carried out on the adult RON also suggest that vesicular fusion contributes 
to the rise in [Glut]e in fully myelinated WM. Similar to the P10 RON, [Glut]e was significantly 
reduced under zero-Ca2+ conditions in the adult RON, again suggesting that Ca2+ influx 
promotes vesicular fusion. Although statistical significance was not reached, blocking voltage-
gated Ca2+ channels (VGCC) did appear to reduce glutamate release. In fact, there was no 
significant difference between zero-Ca2+ and VGCC blockade experiments. Although, the 
variability of glutamate changes in the adult RON during ischemia may have concealed a 
significant effect of VGCC blockade. However, since there was no significant reduction in the 
presence of VGCC blockers, it is possible that Ca2+ influx occurs through an alternative 
pathway, such as the Na+/Ca2+ exchanger (or a combination of both). Nonetheless, a 
significant component of the high [Glut]e is released via a Ca2+-dependent mechanism, as 
predicted from vesicular exocytosis. 
Curiously, the application of bafilomyin-a1 did not significantly reduce the ischemia-evoked 
rise in glutamate in the adult RON. These findings provide an anomaly which is difficult to 
explain. There are several reasons as to why bafilomycin-a1 did not reduce [Glut]e, as it did in 
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the pre-myelinated nerve. As discussed in the section 3.1.4, vesicular glutamate release plays 
a critical role in oligodendrocyte migration and maturation. Thus, it is plausible that vesicular 
fusion may be much more evident in early myelinating WM. However, recent studies (Micu, 
Plemel et al. 2016), experiments from the previous chapter and the fact that zero-Ca2+ 
reduced [Glut]e by approximately 60% (or ~15µm) indicate that adult WM also contains 
substantial vesicular pools. Another possibility to consider is incomplete myelin penetration. 
The principle difference between the P10 and adult RON is the presence of myelin sheath. 
Myelin sheath poses as a significant diffusion barrier and thus, may limit drug accessibility, 
reducing the concentration of the baf-a1 (Mr=622.83) which reaches axonal vesicles. Similarly, 
this may also work in reverse by confining internodal vesicular glutamate to the periaxonal 
space. In contrast, the P10 RON and CC are predominantly unmyelinated structures, where 
vesicular glutamate release along axons will diffuse directly into the ECS. However, the Ca2+-
dependent component of the elevated [Glut]e does not support this theory. Provided 
ischemia-evoked vesicular fusion is an early event (Katchman and Hershkowitz 1993, Marcoli, 
Bonfanti et al. 2004), it is probable that vesicular glutamate release accounts for a larger 
component of total [Glut]e during a shorter length of ischemia i.e. P10 nerves were exposed 
to 30 minutes of ischemia, while adult RONs were subject to 60 minutes. However, the profile 
of glutamate release in the adult RON indicates that bafilomycin-a does not delay the onset 
of glutamate release.  
While the [Glut]e data demonstrates that vesicular fusion is a major component of ischemic 
glutamate release in the developing RON, it does not convincingly show that it is 
unequivocally involved in the adult RON. For this reason, FM4-64 was used to directly visualise 
vesicular fusion in myelinated axons during ischemia. Similar to my findings in the previous 
chapter, FM4-64 loaded, myelinated (YFP+) axons were evident throughout the adult mouse 
CC. Homogenous FM-dye de-staining along the axon was triggered by chemical ischemia, 
confirming that ischemia evokes vesicular fusion along myelinated axons.  
While axonal vesicular fusion appears to be a major pathway of glutamate release in WM, it 
is highly unlikely that it operates in isolation. Experiments aimed at blocking vesicular 
exocytosis failed to completely abolish the ischemic rise in [Glut]e. The inhibition of EAATs in 
‘vesicle-depleted nerves’ (bafilomycin-a1 treated) failed to eliminate the residual rise in 
[Glut]e. In addition, the inhibition of swelling-mediated release, hemi-channels or the 
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glutamate-cystine antiporter failed to reduce [Glut]e in both developing and mature WM 
tracts. However, due to the variability of glutamate changes, it may not be possible to uncover 
small decreases without repeating experiments on a high number of nerves. While my 
findings failed to reveal a second mechanism, I cannot conclusively exclude a potential role 
for these alternative pathways. Further experiments which combine the inhibition of vesicular 
release with alternative mechanisms would be required address this issue. Furthermore, 
alternative pathways are likely to operate during longer periods of ischemia, as vesicular pools 
are depleted. The data provided in this chapter does not challenge the idea that alternative 
release mechanisms may operate under ischemic conditions, but rather indicates that 
vesicular fusion is a significant mechanism of release. 
 
In conclusion, I have demonstrated that ischemia evokes a robust rise in extracellular 
glutamate concentrations in two model WM tracts, the ON and CC. This build-up in glutamate 
is likely responsible for the glutamate receptor-mediated injury observed in a variety of WM 
studies. Surprisingly, I show for the first time that glutamate release was not via reverse EAATs, 
but rather via vesicular exocytosis in both unmyelinated and myelinated axons. This 
unexpected pathway of glutamate release contributes to irreversible injury in developing WM. 
Furthermore, the pattern of FM4-64 unloading (vesicular fusion) during ischemia indicates 
that the majority of vesicular fusion in myelinated axons occurs under the myelin sheath. 
Intriguingly, the internal surface of myelin expresses high levels of NMDA receptors (Micu, 
Jiang et al. 2006). Therefore, vesicular glutamate release into the periaxonal space may play 






































5.1.1: Current treatments and therapeutic strategies for dealing 
with ischemic stroke 
 
Despite our current knowledge on the mechanisms which underlie irreversible neurological 
injury during ischemia, there is a distinct lack of effective therapeutic interventions. Ischemic 
stroke involves a variety of injury pathways including ionic imbalance, excitotoxicity, 
acidification, oxidative stress, apoptosis and inflammation. Furthermore, these events occur 
at different stages following the onset of ischemia. Due to the complex nature of ischemic cell 
death, single mechanistic treatments are often incapable of preventing widespread injury. In 
addition, the window of opportunity following the onset of ischemia is relatively short and as 
a result, many patients miss out on potential interventions. As mentioned in section 1.3.2, the 
incidence of stroke is continuously increasing due to an ageing population. In addition, 
recurrent strokes represent nearly a third of all stroke cases. Therefore, prophylactic 
treatments which elevate injury tolerance may prove to be invaluable in the treatment of 
acute ischemia. In addition, treatments which include a combination of therapeutic 
approaches, or procedures which target numerous injury pathways are more likely to improve 
clinical outcomes (George and Steinberg 2015).  
 
5.1.1.1: Thrombolysis (t-PA) and Mechanical Thrombectomy 
 
The primary objective following the onset of ischemia is the restoration of blood circulation. 
Currently, the only FDA approved pharmacological agent used in the treatment of acute 
stroke is thrombolytic tissue-plasminogen activator (t-PA). t-PA works by dissolving the clot 
(thrombolysis), which subsequently restores blood flow to the ischemic region. It is an 
endogenous serine protease found in endothelial cells which catalyses the conversion of 
plasminogen to its active form, plasmin (Nagai, Yamada et al. 2004). Plasmin’s primary 
function is the lysis of blood clots (fibrinolysis). Meta-analysis of clinical trials have shown that 
vessel recanalization via t-PA is the most successful predictor of improved neurological 
outcomes in ischemic-stroke patients (Rha and Saver 2007). t-PA is known to improve clinical 
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outcomes in patients if administered intravenously within the initial 3 hours of a stroke 
(Disorders and Group 1995, Stankowski and Gupta 2011). Although t-PA is the gold standard 
in stroke treatment, the vast majority of stroke patients do not receive this treatment due to 
the narrow window of opportunity. It is estimated that only 2% of patients receive 
thrombolysis (Stankowski and Gupta 2011). In addition, t-PA exacerbates haemorrhagic 
stroke. In fact, in approximately 6% of patients, t-PA leads to an intracranial haemorrhage 
which can cause either serious disability or death in some cases (Stankowski and Gupta 2011). 
Therefore, patients must be examined (usually via MRI or ST scan) to determine whether the 
stroke is ischemic or haemorrhagic in nature. This takes time and thus, prolongs the period 
before a suitable treatment is administered. In addition, previous findings also indicate that 
t-PA administration may also promote excitotoxic damage due to its interactions with NR1 of 
the NMDA receptor (Liberatore, Samson et al. 2003). t-PA acts to restore the blood supply 
within the brain, however, it does not prevent cellular injury pathways during ischemia, nor 
does it prevent secondary injury associated with reperfusion.  
While t-PA is effective in removing relatively small clots, it is regularly fails to degrade larger 
ones. After administrating t-PA, physicians can use neuro-imaging to determine whether t-PA 
administration was sufficient to dissolve the clot. If not, mechanical thrombectomy is typically 
the next step. Mechanical thrombectomy is an endovascular procedure in which large-vessel 
blood clots are physically removed via a stent retriever at the site of blockage within the brain.  
A stint retriever is a wire-caged device which is delivered via a catheter in the groin of the 
patient up to the blocked artery. It expands to stretch the walls of the blood vessel and 
subsequently captures the blood clot. This procedure can be done up to 8 hours following the 
onset of a stroke (Mordasini, Zubler et al. 2012). 
 
5.1.1.2: Therapeutic Hypothermia 
 
Alongside the restoration of blood flow, minimising damage to both grey and white matter 
regions is of upmost importance during ischemia. Mild brain hypothermia is currently being 
investigated as a neuroprotective strategy during acute stroke. Mild hypothermia (2-5°C 
decrease in the core body) is an established technique used to reduce metabolic activity and 
subsequently reduce the requirement for essential nutrients, such as oxygen and glucose. In 
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addition, several injury pathways involve the activation of numerous deleterious enzymes 
which are highly temperature dependant (Zhao, Steinberg et al. 2007). Similarly, therapeutic 
hypothermia decreases the production of excitatory neurotransmitters and free radical 
formation (Gibson and Andrews 2013). Current methods for the induction of hypothermia 
include the intravenous infusion of refrigerated NaCl (0.9%), vascular cooling catheters or by 
surface cooling via closed loop water-feedback systems such as cooling caps or heat exchange 
pads (Gibson and Andrews 2013). Recent studies have also investigated the effect of 
pharmacologically induced hypothermia using a neurotensin receptor 1 (NTR1) agonist, 
ABS201 (Choi, Hall et al. 2012). In a model of focal ischemia in mice, ABS201 reduced the core 
brain and body temperature by 2-5°C within 15-30 minutes, reduced the infarct volume by 
30-40% and improved sensorimotor outcomes 21 days after the insult (Choi, Hall et al. 2012). 
Mild hypothermia provides considerable protection in animal models of cerebral ischemia, 
capable of reducing the infarct volume by up to 40% (van der Worp, Sena et al. 2007). 
Lowering the temperature from 37 to 32/31°C dramatically improves post-OGD functional 
recovery in isolated WM preparations (Stys, Waxman et al. 1992, Baltan, Besancon et al. 2008). 
It is known to improve neurological outcomes in infants who suffer neonatal encephalopathy 
and in patients who suffer cardiac arrest (Bernard , Gray  et al. 2002, Shankaran , Pappas  et 
al. 2012). However, current methods of cooling are often impractical in intensive-care clinical 
situations. Furthermore, therapeutic hypothermia is closely associated with a number of 
adverse effects including hypothermia (Sydenham, Roberts et al. 2009), hypotension, 
hyperglycemia (Nielsen, Sunde et al. 2011) and shivering, which is known to increase 
metabolic oxygen demand (Gibson and Andrews 2013).  
 
5.1.1.3: Cortical Stimulation 
 
Cortical stimulation is a promising new technique aimed at reorganising neuronal circuits 
within the CNS to improve functional recovery following ischemia (George and Steinberg 
2015). Functional recovery after stoke is closely associated with neuronal plasticity and 
rewiring of regions adjacent to the infarct core (Cheng, Wang et al. 2014). The remodelling of 
neuronal connections is facilitated by electrical signalling which is known to promote the 
release of a variety of trophic factors including brain-derived neurotropic factor (BDNF) and 
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neuregulin (Lundgaard, Luzhynskaya et al. 2013). As previously discussed, activity-dependent 
glutamate release promotes re-myelination and WM plasticity. Non-invasive techniques such 
as the application electrical fields via transcranial magnetic stimulation (TMS), transcranial 
direct current stimulation (tDCS) or optogenetics leads to improved functional improvements 
in animal models (Cheng, Wang et al. 2014, George and Steinberg 2015). Similarly, tDCS of 
the motor cortex significantly improves motor function (measured by Jebsen-Taylor Hand 
Function Test) in patients with chronic cerebral ischemia (Hummel, Celnik et al. 2005).  
 
5.1.1.4: Stem Cell Therapy 
 
Stem cell therapy is an exciting new frontier and has become an area of intense research for 
numerous pathological disorders. Stem cells are multipotent/pluripotent cells with the ability 
to develop into a variety of different cell types (George and Steinberg 2015). The exogenous 
application of transplanted stem cells to the damaged region following a stroke provides a 
direct method of cell replacement in the infarcted area. Stem cell therapy has shown 
promising results in animal models. For example, in a mouse model of hypoxia-ischemia, 
mesenchymal stem cells (MSCs) which were intranasally transplanted 10 days following the 
insult, dramatically decreased the degree of grey and white matter loss by 34% and 37%, 
respectively and significantly improved sensorimotor function (van Velthoven, Kavelaars et al. 
2010). The acute delivery of stem cells following the onset of ischemia (within 48 hours) is 
capable of reducing the size of the lesion and also decreases the degree of cell death in the 
surrounding penumbra (Bliss, Andres et al. 2010). Although more research is required to fully 
understand the mechanisms of repair following neuronal loss, the production of trophic 
factors are known to stimulate several endogenous repair pathways (Hicks and Jolkkonen 
2009, Bliss, Andres et al. 2010, van Velthoven, Kavelaars et al. 2010). Conversely, MSCs 







5.1.1.5: Pharmacological Neuroprotection 
 
Unfortunately, there are currently no FDA-approved pharmacological agents for minimising 
brain injury during ischemia. Numerous neuroprotective drugs have shown promise in 
experimental animal models, with many demonstrating an ability to salvage ischemic tissue. 
Despite this, such compounds have failed in human clinical trials (Dirnagl, Iadecola et al. 1999). 
There are a number of reasons behind this disappointing outcome. 
The response to pharmacological interventions is much more complex in humans. While the 
onset of ischemia/reperfusion is regularly defined in animal models, the onset of symptoms 
does not always coincide with the onset of ischemia in humans. As a result, drug 
administration can be delayed for several hours, which may lie outside the window of 
opportunity. In addition, unfavourable pharmacokinetic properties of compounds can lead to 
poor drug uptake, lack of efficacy and unacceptable side-effects (Dirnagl, Iadecola et al. 1999). 
For example, MK-801, an anti-excitotoxic agent, has proven to be highly protective in animal 
models, yet even low doses produces renal toxicity and other adverse effects in clinical trials. 
MK-801 is a broad-spectrum NMDA receptor antagonist which blocks all NMDA receptors. 
Consequently, MK-801 blocks critical physiological NMDA receptor signalling, which caused 
lapses into a coma in human trials (Lipton 2004). Considering the importance of NMDA 
receptor-mediated currents in WM alone (see section 3.1), the complete, unspecific inhibition 
of all NMDA receptors can hinder cell survival and therefore, must be avoided. In order to 
overcome this issue, compounds like memantine, which block excessive NMDA receptor 
activation without interfering with physiological functions, are currently being tested in the 
treatment of acute stroke. Memantine is clinically approved for the treatment of chronic 
neurodegenerative diseases such as Alzehimers’. Its rapid association-dissociation kinetics 
prevents the accumulation of the drug in the NMDA receptor channel, allowing for normal 
physiological transmission (Lipton 2004, Stys and Lipton 2007). Experimental work on 
cultured oligodendrocytes and the ON found that the application of clinically relevant 
concentrations of memantine significantly protects juvenile WM from irreversible ischemic 
injury (Bakiri, Hamilton et al. 2008).  
However, one of the primary reasons for the failure of many neuroprotective compounds is 
thought to be due to the anatomical difference between the CNS of experimental animal 
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models (mainly rodents) and humans. As mentioned, WM constitutes approximately 14% of 
the rodent brain by volume, whereas the adult human brain occupies approximately 50%. 
Thus, nearly all pre-clinical studies have inadvertently focussed on protecting GM regions, 
while underestimating the involvement of WM damage during ischemia (Matute, Domercq 
et al. 2013). In addition, the traditional view that WM is less vulnerable to ischemia has 
hindered our understanding of WM injury pathways. Importantly, there are distinct 
differences between the injury mechanisms involved in GM and WM ischemia.  Therefore, 
the development of effective treatments relies on the discovery of pharmacological 
compounds which can also preserve WM structures.  
 
5.1.2: White Matter NMDA Receptors 
 
NMDA receptors are ionotropic glutamate receptors. When compared to AMPA/kainate 
receptors, NMDA receptors have much slower gating kinetics and as a result, largely generate 
the latter component of EPSCs (Dingledine, Borges et al. 1999). NMDARs have received much 
attention in recent years due to their key involvement in modulating synaptic strength 
(plasticity), a feature which is closely related to their propensity to flux relatively large Ca2+ 
loads (Tong, Shepherd et al. 1995, Stys and Lipton 2007, Blanke and VanDongen 2009, Vyklicky, 
Korinek et al. 2014). NMDARs are highly permeable to Ca2+ ions showing a 10-fold selectivity 
for Ca2+ ions over Na+ (Mayer and Westbrook 1987, Stys and Lipton 2007). Consequently, cells 
which express functional NMDARs are particularly susceptible to excitotoxic damage. 
NMDARs have long been implicated in a variety of neurological disorders including ischemia 
(Ogden and Traynelis 2011). Thus, there is a high demand for effective NMDAR antagonists 





NMDA receptors are tetrameric ion channels which incorporate subunits from three distinct 
families; NR1, NR2 and NR3. The NR1 subunit has 8 different splice variants which originate 
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from a single gene (Zukin and Bennett 1995, Jin and Woodward 2006). In contrast, NR2 and 
NR3 are encoded by 4 and 2 genes, respectively (Vyklicky, Korinek et al. 2014). Functional 
receptors require the expression of two mandatory glycine-binding NR1 subunits, in 
combination with two NR2(A-D) and/or NR3(A-B) subunits (Vyklicky, Korinek et al. 2014). The 
composition of NR2(A-D) subtypes incorporated in the receptor strongly dictates its 
functional properties (Cull-Candy, Brickley et al. 2001). However, functional NR2-lacking 
NMDA receptors are also evident in WM (Piña-Crespo, Talantova et al. 2010). 
All subunits are structurally homologous, expressing an extracellular amino-terminal domain, 
an extracellular ligand binding domain, a transmembrane domain comprised of three 
transmembrane helices plus a re-entrant loop, and a cytoplasmic C-terminus (Paoletti and 
Neyton 2007, Vyklicky, Korinek et al. 2014). Activation of conventional NR1/NR2 receptors 
requires the simultaneous binding of glutamate on each NR2 subunits and glycine (co-agonist) 
on each NR1 subunit (Kleckner and Dingledine 1988, Clements and Westbrook 1991). 
Receptor activation induces a conformational change, leading to ion channel opening and a 




Fig. 5.1: Schematic representation of the NMDA receptor.  
The image shows a side-profile of a conventional NMDAR incorporating the ‘glycine-binding’ NR1 and 
‘glutamate/NMDA-binding’ NR2 subunits. The model illustrates the binding sites of several 
modulators including Mg2+, MK-801, memantine, Zn2+, sulfhydryl nitric oxide (SNO), glycine, glutamate 
and NMDA. Taken from (Stys and Lipton 2007).  
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WM NMDA receptors have a unique subunit composition. There are several reports that 
oligodendrocyte and myelinic NMDA receptors incorporate the NR1, NR2C, NR2D and/or 
NR3A subunits (Káradóttir, Cavelier et al. 2005, Salter and Fern 2005, Micu, Jiang et al. 2006, 
Micu, Plemel et al. 2016). The NMDA-mediated rise in myelinic Ca2+ during chemical ischemia 
is insensitive to specific blockers of NR2A and -2B blockers (Micu, Jiang et al. 2006). Similarly, 
NMDA-mediated currents in developing oligodendrocytes are unaffected by either ifenprodil, 
which inhibits NR2B-containing receptors, or by pregnenolone sulphate, which potentiates 
NR2A and -2B receptors (Káradóttir, Cavelier et al. 2005). On the other hand, high levels NR2C 
and NR3 subunit expression is evident on the myelinating processes of developing and mature 
oligodendrocytes (Káradóttir, Cavelier et al. 2005, Salter and Fern 2005). Genetic ablation of 
either the NR2D or NR3A subunits, dramatically reduced activity evoked increases in myelinic 
Ca2+ levels (Micu, Plemel et al. 2016). Interestingly, NR3 subunit expression can exist both 
with and without NR2 subunits (Stys and Lipton 2007, Vyklicky, Korinek et al. 2014). NR1/NR3 
form ‘glycine only’ receptors as they are gated by glycine alone and do not require glutamate 
for activation (Stys and Lipton 2007, Piña-Crespo, Talantova et al. 2010). Furthermore, 
functional ‘glycine only’ NMDA receptors are present in CNS myelin (Piña-Crespo, Talantova 
et al. 2010).  
As previously mentioned, WM NMDA receptors are approximately 10 times less sensitive to 
Mg2+ blockade, when compared to conventional neuronal NMDA receptors (Káradóttir, 
Cavelier et al. 2005). Receptors expressing NR2C/D and/or NR3 subunits are relatively 
resistant to Mg2+ block, but are less permeable to Ca2+ ions (Sasaki, Rothe et al. 2002, Stys and 
Lipton 2007). Thus, WM NMDA receptor activation may occur in the absence of strong 




Given the Ca2+ permeability of NMDARs, receptor activation is highly controlled. NMDARs 
express several modulatory sites for endogenous ligands. NMDAR activation requires the 
simultaneous binding of two molecules of a co-agonist. Glycine, an endogenous amino acid, 
is the main co-agonist at extrasynaptic NMDA receptors (Papouin, Ladepeche et al. 2012). 
However, a variety of alternative molecules (e.g. serine and alanine) can also activate 
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receptors as co-agoinsts (Vyklicky, Korinek et al. 2014). Similarly, NMDAR activation is voltage-
dependent. At resting membrane potential, ionic flux through NMDA receptors is physically 
blocked by extracellular Mg2+ ions. While physiological concentrations of extracellular Mg2+ 
are ~2mM, the intracellular concentrations of such ions is in the micro-molar range. Thus, at 
a negative resting membrane potential, an inward flux of Mg2+ ions prevails and subsequently 
binds to a Mg2+-binding site located within the receptor pore. (Note; it has been reported that 
intracellular Mg2+ ions are also capable of blocking current flow (Johnson and Ascher 1990)). 
However, this block is rapidly relieved following membrane depolarisation (Kampa, Clements 
et al. 2004). AMPA/kainate receptor-mediated depolarisation promotes the removal of the 
Mg2+ blockade by a process of electrostatic repulsion (Qian and Johnson 2002, Paoletti and 
Neyton 2007, Blanke and VanDongen 2009). Endogenous Zn2+ is another non-competitive 
antagonist of NMDA receptors. Zn2+ selectively inhibits NR2A expressing receptors and does 
not operate in a voltage dependant manner (Westbrook and Mayer 1987, Paoletti and Neyton 
2007). In addition, NMDA receptors are also strongly modulated by extracellular pH (Traynelis 
and Cull-Candy 1990). The receptors are selectively inhibited by H+ ions and thus display a 
higher degree of inhibition in acidic environments. The IC50 for H+ ions resides close to a 
physiological pH of 7.4. Therefore, under control conditions, receptors are not fully activated 
(Traynelis and Cull-Candy 1990). Furthermore, NMDA receptors desensitize in the sustained 
presence of glutamate, decreasing current flow over time (Nahum-Levy, Lipinski et al. 2001). 
This includes a Ca2+-dependant form of desensitization where increasing concentrations of 
intracellular Ca2+ decreases receptor activity via a negative feedback loop (Rosenmund, Feltz 
et al. 1995).  
Following the discovery of distinct NMDA receptor subunits, a variety of sub-unit selective 
compounds have become available. First generation NMDAR antagonists (e.g. MK801) failed 
to discriminate between different subunits. The development of tolerable sub-unit selective 
antagonists would permit the regulation of receptor inhibition in a region-specific manner 
(Ogden and Traynelis 2011). Thus, subunit-selective antagonists pose as a promising 
therapeutic agent to overcome the unselective inhibition of all NMDA receptors and thus, 
minimise the unacceptable side-effects. Unfortunately, there are no truly selective NR3 
selective antagonists available at the moment. However, a range of NR2 sub-unit selective 
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antagonists are. The regional diversity of NR2 (A-D) subunits throughout the CNS may aid in 
the development of acceptable neuroprotective agents.    
 
5.1.3: Ischemic Myelin Damage:  
 
Myelin can protect underlying axons in several ways. As discussed in chapter 3, myelin 
provides metabolic support to actively firing axons. In addition, myelin acts as a protective 
cushion which can protect axons from physical trauma (Reeves, Doperalski et al. 2014). 
Paranodal myelin loops form a tight junction with the axonal membrane, forming a insulating 
seal around the axon cylinder. Although there are narrow gaps which separate the myelin and 
the axon at the paranodal junction flanking each node (~2-4nm) (Mierzwa, Shroff et al. 2010), 
the insulating myelin sheath forms a diffusional barrier between the axon and the 
extracellular space (Velumian and Samoilova 2014). Therefore, myelin can shield the 
axolemma from potentially harmful substances in the extracellular milieu (Reeves, Doperalski 
et al. 2014). In theory, this can also exacerbate myelin injury under pathological conditions. 
The tight axo-myelinic junction leaves the periaxonal space particularly susceptible to the 
accumulation of potentially toxic substances. For example, K+ released from under-laying 
axons during electrical stimulation is known to accumulate in in the periaxonal space (David, 
Barrett et al. 1993, Brazhe, Maksimov et al. 2011). This could potentially promote the 
degradation of myelin sheath under pathological conditions such as ischemia. 
Myelin sheath is highly susceptible to ischemic injury. Myelin degradation and decompaction 
occurs rapidly following the onset of ischemia, typically within the initial 30 minutes. For 
example, adult SD rats subject to four-vessel occlusion display early demyelination and a drop 
in MBP levels (Chen, Yi et al. 2013). Similarly, Walker et al. also found a dramatic decrease in 
MBP staining following transient global ischemia (bilateral common carotid occlusion) in adult 
mice (Walker and Rosenberg 2010). Ultrastructural analysis of the adult rat cerebellum and 
ON has revealed that ischemia leads to the focal splitting, loosening and separation of myelin 
lamella (Micu, Jiang et al. 2006, Hamilton, Kolodziejczyk et al. 2016). 
Myelin damage is fundamental to the functional loss WM experiences in a number of disease 
states including multiple sclerosis (MS), traumatic brain injury (TBI), stroke and cerebral palsy 
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(Fern, Matute et al. 2014, Mierzwa, Marion et al. 2015, Macrez, Stys et al. 2016, Saab, 
Tzvetavona et al. 2016). As previously mentioned, NaV1.2 expression along unmyelinated 
axons facilitates AP conduction prior to the initiation of myelination. However, during 
myelination, NaV1.2 expression is replaced by clusters of NaV1.6 at the node of Ranvier in order 
to facilitate saltatory conduction in myelinated axons. Acutely demyelinated axons lack the 
insulating properties of myelin sheath. As a result, demyelination increases membrane 
capacitance and decreases membrane resistance. Therefore, in the absence of intact myelin, 
clustered Na+ influx at the node is typically incapable of depolarising the newly demyelinated 
axon segment. Although, NaV1.2 expression may persist in myelinated axons, they are unable 
to support AP conduction following demyelination (Smith 1994, Debanne, Campanac et al. 
2011). Therefore, axons regularly exhibit complete conduction block following myelin 
breakdown (Smith 1994).  
 
5.1.4: NMDA receptor involvement in myelin damage? 
 
While the decompaction and breakdown of internodal myelin is a major cause of WM 
dysfunction, the mechanism(s) of myelin injury during ischemia is a highly debated topic at 
the moment. The established view is that the rise in [Glut]e is responsible for the over-
activation of myelinic NMDA receptors, which facilitates the excessive influx of Ca2+ ions. 
Although myelin is electrically silent (Saab, Tzvetavona et al. 2016), several studies have 
shown that myelin disruption is a Ca2+-dependent process. The activation of Ca2+-dependent 
enzymes, such as calpain, is recognised as a trigger for myelin breakdown during ischemia 
(Lankiewicz, Marc Luetjens et al. 2000). Early studies by Li and Stys (2000) found that 
incubating dorsal column WM with glutamate (1mM for 3hours) led to severe myelin damage, 
characterised by the degeneration of MBP (Li and Stys 2000). The expression of NMDA 
receptor subunits throughout compact myelin, combined with their ability to permit Ca2+ 
influx, leaves myelin susceptible to excitotoxic injury under ischemic conditions (Káradóttir, 
Cavelier et al. 2005, Micu, Jiang et al. 2006, Micu, Plemel et al. 2016). NMDA-receptor 
activation is known to mediate a direct rise in myelinic Ca2+, which promotes the pathological 
loosening and vacuolation of myelin sheath during metabolic inhibition (Micu, Jiang et al. 
2006, Pina-Crespo, Talantova et al. 2010). 
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Despite evidence of NMDAR-mediated myelin breakdown during ischemia and the expression 
of functional NMDA receptor subunits in myelin (Karadottir, Cavelier et al. 2005, Micu, Jiang 
et al. 2006, Pina-Crespo, Talantova et al. 2010, Micu, Plemel et al. 2016), there is currently no 
evidence demonstrating functional protection of fully-myelinated WM tracts following the 
application NMDAR antagonists. As outlined in section 4.1.1.3, NMDAR blockade improves 
post-OGD functional recovery in the pre-myelinated and early-myelinating RON (P0-P28) 
(Bakiri, Hamilton et al. 2008, Alix and Fern 2009, Huria, Beeraka et al. 2015). However, this is 
closely associated with the direct protection of small diameter pre-myelinated axons. While 
non-NMDAR antagonists are known to preserve CAP conduction in fully-myelinated WM 
following ischemia (Li, Mealing et al. 1999, Kanellopoulos, Xu et al. 2000, Tekkök and Goldberg 
2001, Tekkok, Ye et al. 2007, Baltan, Besancon et al. 2008), numerous studies have found no 
significant functional protection in the presence of NMDAR antagonists (Yam, Dunn et al. 
2000, Tekkok, Ye et al. 2007, Baltan 2016). For example, treating adult MONs with the broad-
spectrum AMPA/kainate receptor antagonists, NBQX and CNQX,  dramatically improves post-
OGD CAP recovery by 45.3% and 42.8%, respectively (Tekkök, Ye et al. 2007). However, the 
same study found no significant improvement following treatment with NMDAR antagonists, 
MK-801, 7-CKA and DL-AP7. In fact, NMDAR inhibition, with 7-CKA, is reported to hinder post-
OGD functional recovery in the adult MON (Baltan 2016). 
As a result, the involvement of ischemic NMDA receptor activation in fully-myelinated WM 
tracts is controversial. Several reports have challenged the idea. Recently, Hamilton et al. 
(2016) published findings which demonstrate that current flow through NMDA receptors only 
accounts for a small component of the total inward current recorded from whole-cell clamped, 
mature cerebellar oligodendrocytes during ischemia (Hamilton, Kolodziejczyk et al. 2016). 
Interestingly, they found the application of NMDA did not lead to an elevation in [Ca2+]i levels 
in either the soma or myelinating processes of mature oligodendrocytes. Instead, 
approximately 70% of the ischemia evoked rise in [Ca2+]i was via TRP-A1 channels, which are 
activated by elevated [H+]i. While Hamilton et al. relied on live imaging from the cytoplasmic 
domain of oligodendrocytes, it must be noted that this region is distinct from the myelin 
sheath. Yang et al. (2014) proposed a plausible explanation as to why NMDA receptors are 
not involved in WM ischemia. The proton binding site on NMDA receptors leave it particularly 
sensitive to changes in extracellular pH. They suggested that the drop in pH during ischemia 
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(acidosis) blocks NMDAR-mediated ion fluxes. Interestingly, they found that NMDAR blockade 
prevents the morphological disruption to myelin and significantly preserves CAP area 
following an alternative form of energy deprivation, algycemia. They noted that unlike 
ischemia, aglycemia leads to an alkaline shift in pH and a decrease in [Glut]e, as glutamate is 
metabolised in a desperate effort to generate ATP. In contrast, elevated intracellular 
oxaloacetate levels promote an increase in extracellular levels of aspartate, an alternative 
NMDA receptor agonist (Yang, Hamner et al. 2014). 
This raises the question as to whether NMDAR activation actually promotes myelin 
breakdown, and if so, why have many studies found that NMDAR blockade does not improve 





Evidence suggests that NMDAR expression moves from the oligodendrocyte to myelin during 
development, with a notably high expression of NMDAR sub-units on the inner loops of 
myelin which face the axolemma. The previous chapter demonstrated internodal vesicular 
glutamate release along myelinated axons. It is therefore reasonable to presume that axonal 
vesicular release under ischemic conditions will empty directly into the tight peri-axonal space 
between the internal myelin surface and the axolemma (20nm).  
Thus, the overall aim of this chapter is to examine the significance of excitotoxic myelin injury 
during ischemia. More specifically, I aim to resolve the controversy regarding the involvement 
of myelinic NMDA receptors. In addition, I hope to test the effect of a variety of sub-unit 








5.2.1: OGD-induced injury in the developing rat ON and CC 
 
Action potential failure underlies a variety of functional deficits in pre-term infants who suffer 
neonatal stroke. To access the effect of ischemia on developing WM, CAPs were recorded 
from the P10 rat ON and CC. WM tracts were subject to 60-minutes OGD (oxygen-glucose 
deprivation), followed by 60-90 minutes reperfusion. RON CAP recordings remained stable 
under control conditions for 135-minutes, showing no decrease in CAP amplitude 
(105.60±3.48%, n=10, Fig. 5.2a-c). In contrast, withdrawal of O2 and glucose led to a gradual 
decline in CAP amplitude over the course of 60 minutes, reaching 8.03±1.15% (n=18) before 
reperfusion. CAP amplitude only partially recovered following 60-minutes reperfusion, 
reaching 47.04±4.58% (n=18) of the initial, pre-OGD amplitude (p<0.0001, Fig. 5.2a-c).  
In addition to irreversible functional injury, structural axonal damage was also observed 
following OGD. RONs were collected after control and OGD experiments. In order to examine 
axon integrity, immunohistochemistry (IHC) was performed on RON sections using the axonal 
maker, NF-70. Confocal imaging of NF-staining revealed severely disrupted axon cylinders 
following OGD, characterised by axonal fragmentation and disorientation (Fig. 5.3b). In 
contrast, time-matched controls show little to no evidence of axon disruption (Fig. 5.3a). NF-
70 staining was quantified by measuring fluorescence intensity using Image-J software. 
Similar to CAP recordings, NF-70 reactivity in OGD-exposed nerves was significantly 
attenuated when compared to control nerves (OGD pixel intensity was 38.75±7.66% lower 
than control) (p=0.01, Fig. 5.3d).  
In an effort to access and compare the effect of OGD on the neonatal CC, CAP recordings from 
the ‘whole CC’ were carried out using an identical technique to that employed with the RON 
(Li, Velumian et al. 2016). The CC was dissected out from a 400µm thick coronal brain slice 
(see ‘Materials and Methods’ for details) and each end was gently nudged into the barrel of 
a glass electrode. While the overall amplitude recorded from the CC was generally smaller 
than the RON (presumably due to an imperfect, looser fit inside the barrel of the electrode 
which will decrease external resistance (Ro) (Stys, Ransom et al. 1991)), the biphasic CAP 
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shape remained. Under control conditions, CAP amplitude remained stable for 165 minutes 
(100.60±10.24%, n=3, Fig. 5.4). However, exposure to OGD resulted in a progressive decline 
in CAP amplitude to 0.46±0.34% (n=9) after 60 minutes. Following the restoration of normoxic 
conditions, CAP amplitude slowly recovered to 41.04±8.70% of its initial size after 90 minutes 
(n=9, p=0.0046, Fig. 5.4). When compared to time-matched OGD experiments on the RON, 
there was no significant difference in CAP recovery after 90 minutes (versus RON: 36.13±5.50% 
(n=8), p=0.67, Fig. 5.5a,c). However, the rate of CAP recovery following re-introduction of O2 
and glucose was significantly slower in the CC (p=0.029, Fig. 5.5a-b). This is the first direct 
comparison between two distinct developing WM tracts.  
Given that iGluR activation is known to mediate a large degree of irreversible functional 
damage in the P10 RON (Alix and Fern 2009), I decided to investigate the contribution of 
iGluR-mediated excitotoxic injury in the P10 CC. Replicating a known effective protocol (Alix 
and Fern 2009), the isolated CC was perfused with a combination of NBQX (20µM, 
AMPA/kainate receptor antagonist) and MK801 (10µM, NMDA receptor antagonist) for 20 
minutes before, during and for 40 minutes after OGD. However, the simultaneous blockade 
of AMPA/kainate and NMDA receptors did not improve CAP recovery to a level of significance 





















Fig. 5.2: Ischemia-induced functional injury in the early myelinating (P10) RON.   
 
a) Representative biphasic CAP traces recorded under control conditions and during exposure to 60 
minutes of OGD. (For all remaining representative CAP traces, the time points correspond to the CAP time-
course below (B); black = pre-OGD, grey = 60 minutes OGD and red = 60-90 minutes reperfusion). b) CAP 
time-course under control conditions and for OGD experiments. Note the reversible drop in CAP 
amplitude during OGD, followed by a partial recovery during reperfusion. c) Histogram comparing CAP 






Fig. 5.3: Ischemia-induced disruption of axon structural integrity in the early myelinating (P10) RON.   
 
a) Representative image of neurofilament-70 (NF-70) immunofluoresence in fixed P10 RON following a 
control experiment. Inset shows an example of NF-70 staining at a higher gain. Note the continuous 
unidirectional pattern of axon cylinders. b) Representative image of NF-70 immunofluoresence in fixed 
P10 RON following 60 minutes of OGD and 60 minutes reperfusion. Inset shows an example of NF-70 
staining at a higher gain. Note the disrupted pattern of staining characterised by disorientated axon 
cylinders and the loss of NF-70 fluorescence in several regions. c) No immunoreactivity is observed when 
NF-70 is omitted. d) Histogram comparing the relative NF-70 immunofluoresence intensity between 

















Fig. 5.4: Ischemia-induced functional injury in the early myelinating (P10) rat CC.   
 
a) Representative biphasic CAP traces recorded under control conditions and during exposure to 60 
minutes of OGD. b) CAP time-course under control conditions and for OGD experiments. Note the 
reversible drop in CAP amplitude during OGD, followed by a partial recovery during reperfusion. c) 



















Fig. 5.5: The P10 RON and CC display a similar degree of sensitivity to OGD. 
 
a) Overlay of the mean CAP time-course recorded from the CC and time-matched RON experiments. Note 
how CAP recovery after OGD is slower in the CC, yet the overall recovery is near identical. b) Histogram 
comparing CAP amplitude after 20 minutes of reperfusion. c) Histogram comparing CAP amplitude after 


















Fig. 5.6: Blockade of ionotropic glutamate receptors does not significantly reduce OGD-induced injury 
in the P10 CC. 
 
a) Representative CAP trace in the presence of AMPA/kainate receptor blocker, NBQX and NMDA 
receptor blocker, MK-801. b) CAP time-course in the presence of iGluR antagonists. The dotted trace 
represents the mean CAP time-course in OGD experiments without drug. c) Histogram showing the effect 




5.2.2 OGD-induced injury in the adult RON 
 
In adults, approximately 95% of strokes affect WM (Wang, Liu et al. 2016). Unlike the neonatal 
RON, the CAP waveform recorded from the adult RON is typically triphasic in shape (see Fig. 
5.7a for example). Therefore, the rectified area under the curve was recorded as a 
quantitative measure of axonal function. Under control conditions, CAP area showed no 
attenuation over a 165-minute period, slightly increasing by 13.90±6.72% of initial control 
area (n=4, Fig. 5.7c-e). In contrast, exposure to OGD led to a rapid drop in CAP area, followed 
by a complete block in AP conduction. Once CAP failure initiated, all three peaks initially fell 
in unison (Fig 5.7e). However, the first peak was typically the final peak to completely block 
out. CAP area was reduced to 50% of initial control recordings within 4.19±0.52 minutes of 
OGD (n=13). The mean CAP area after 60-minutes of OGD, followed by 90-minutes 
reperfusion, was irreversibly reduced to 15.12±1.71% of its original pre-OGD size (n=13, 
p<0.0001, Fig. 5.7a-e). CAP recovery typically stabilised within 37.81±4.10 minutes following 
the re-introduction of O2 and glucose. 
Following ON isolation, nerves were typically allowed to rest in the perfusion chamber under 
control conditions for 60 minutes before OGD was initiated. However, some experiments 
later in this chapter will require long drug pre-treatment periods of 2 hours. To investigate 
whether a longer resting period has any effect on OGD-sensitivity, several nerves were 
allowed to rest for 3 hours (i.e. 2 additional hours) in the chamber before exposure to OGD. 
However, there was no significant difference between the two groups (1 hour rest: 
15.97±2.28% (n=9) versus 3 hour rest; 13.11±2.31% (n=4), p=0.47, Fig. 5.7a). For this reason, 

















Fig. 5.7: Ischemia-induced functional injury in the fully-myelinated, adult RON.   
 
a) Representative triphasic CAP traces recorded under control conditions and during exposure to 60 minutes 
of OGD. b) CAP time-course under control conditions and for OGD experiments. Note the rapid drop in CAP 
area upon exposure to OGD, followed by low recovery during reperfusion. c) Histogram comparing CAP 
recovery after OGD against time-matched control experiments. d) CAP time-course for OGD experiments in 
which nerves were allowed to stabilise for either 1 or 3 hours in the perfusion chamber before recording. 
Inset; histogram comparing CAP recovery post-OGD. e) A single representative CAP trace showing the pattern 




5.2.3 AMPA/kainate receptor-mediated injury 
 
The adult RON is a well-established model WM tract and therefore, the injury mechanisms 
involved in WM anoxia/ischemia are relatively well-characterised (Stys 1998, Stys 2005). 
AMPA/kainate receptors are reported to mediate excitotoxic damage in adult WM by acting 
on the oligodendrocyte cell body (Li and Stys 2000, Tekkok and Goldberg 2001, McCarran and 
Goldberg 2007, Tekkok, Ye et al. 2007, Baltan, Besancon et al. 2008). In an effort to confirm 
the involvement of AMPA/kainate receptors in ischemic WM injury, experiments were 
performed in the presence of an known effective concentration of the broad-spectrum 
AMPA/kainate receptor antagonist, NBQX (20µM) (Alix and Fern 2009).  
Initially, RONs were perfused with NBQX under control conditions. Perfusion with NBQX had 
no effect on CAP area over a 120 minute recording period. Furthermore, there was no 
significant difference between NBQX-treated nerves after 50 minutes wash-out, when 
compared to time-matched controls (NBQX: 98.94±8.54% (n=3), versus 113.90±6.72% (n=4), 
p=0.164, Fig. 5.8). This data demonstrates that NBQX exerts no toxic effects under control 
conditions. When nerves were exposed to OGD in the presence of NBQX (20 minutes before, 
during and 40 minutes after OGD), CAP recovery was significantly higher than experiments 
without the drug, reaching 35.55±7.98% after 90 minutes reperfusion (n=4, p=0.027, Fig. 5.9a-
c), confirming the involvement of AMPA/kainate receptor activation during ischemia. 
Next, I investigated whether the anti-excitotoxic effect of NBQX is dependent on its lipid 
permeability. NBQX has a lipid partition co-efficient of 1.4 (logP) at 7.0pH. In contrast, a 
disodium derivative of the drug, NBQX-disodium salt (NBQX-Na), is much more lipophobic, 
with a lipid partition co-efficient of 0.17 (logP) at 7.0pH. To test whether a difference in 
lipophilicity affects CAP recovery, experiments were repeated using NBQX-Na (20µM). 
Despite the difference in lipid partitioning, there was no significant difference between the 
two species of NBQX, with CAP recovery reaching 27.67±4.00% (n=4, p=0.41, Fig. 5.9a-b). This 
is consistent with reports that AMPA/kainate receptors are located on the oligodendrocyte 
body, not in myelin. The results from both species of NBQX were pooled, giving an overall CAP 










Fig. 5.8: Blockade of AMPA/kainate receptors under control conditions does not adversely affect CAP 
conduction. 
 
a) Representative CAP trace in the presence of NBQX under normxic conditions in control aCSF. b) CAP 
time-course under control conditions including a 120-minute exposure to NBQX. c) Histogram showing 












Fig. 5.9: Blockade of AMPA/kainate receptors improves functional recovery following OGD.  
 
a) CAP time-course in the presence of either a lipid-soluble species of NBQX or a water-soluble species 
(Na-NBQX). Note; both AMPA/kainate receptor antagonists have a similar protective effect. b) Histogram 
comparing post-OGD CAP recovery in the presence of two NBQX species. c) Representative CAP trace in 
the presence of NBQX. d) CAP time-course in the presence of NBQX (pooled data). e) Histogram showing 




5.2.4 Myelinic NMDA-receptor involvement in ischemic WM injury 
 
Although adult WM expresses both AMPA/kainate and NMDA receptors, only AMPA/kainate 
receptors are thought to contribute to irreversible functional injury. Numerous studies have 
tested the effect of NMDA receptor inhibition during ischemia, but many have failed to find 
any significant improvement in functional recovery in mature myelinated WM (Li and Stys 
2000, Tekkok, Ye et al. 2007, Baltan 2009). This is somewhat surprising considering they are 
reportedly involved in mediating functional damage in pre-myelinated WM, injury to 
developing oligodendrocyte process and myelin sheath disruption during modelled ischemia 
(Káradóttir, Cavelier et al. 2005, Salter and Fern 2005, Micu, Jiang et al. 2006, Alix and Fern 
2009, Huria, Beeraka et al. 2015). Therefore, I aimed to further investigate the role of NMDA 
receptor activation during ischemia. 
To start the investigation, I initially examined CAP recovery in the presence of MK-801 (10µM), 
a broad-spectrum NMDAR antagonist. Following a previous protocol (Alix and Fern 2009, 
Baltan 2009), RONs were perfused with MK-801 for 20 minutes before, during and 40 minutes 
after OGD. While MK-801 did appear to have a mild protective tendency using this protocol, 
it did not significantly improve CAP recovery (25.94±6.31, n=3, p=0.72, Fig. 5.10). Experiments 
were repeated using 50µM MK-801. However, again this did not improve CAP recovery to a 
level of significance (30.58±4.87, n=4, p=0.27, Fig. 5.10). Consistent with previous findings, we 
found no significant protection using this protocol with either 10 or 50µM MK-801. However, 
it did appear to partially preserve CAP area which inspired further examination.  
Unlike AMPA/kainate receptors, which are located on the oligodendrocyte cell body, NMDA 
receptors are primarily expressed on the myelinating processes of oligodendrocytes 
(Káradóttir, Cavelier et al. 2005, Salter and Fern 2005) and within compact myelin sheath 
(Micu, Jiang et al. 2006, Micu, Plemel et al. 2016). Results from the previous chapter indicate 
that the peri-axonal space may be a significant site of excitotoxic injury during ischemia. Drug 
penetration through the myelin sheath is relatively slow and therefore, the interaction of MK-
801 with NMDA receptors may be limited if the pre-treatment exposure time is short (i.e. 20 
minutes). To access whether incomplete drug penetration was a limiting factor, we increased 
the length of the MK-801 pre-treatment period. RONs were perfused with MK-801 (50µM) 
for 90 minutes before, during and 40 minutes after O2-glucose withdrawal. Curiously, this pre-
221 
 
treatment protocol significantly improved post-OGD CAP recovery to 43.91±10.40% (n=4, 
p=0.002, Fig. 5.11b-d). Moreover, further increasing the length of drug pre-treatment to 120 
minutes dramatically improved CAP recovery, with CAP area reaching 62.02±4.80% after 
reperfusion (n=6, p<0.0001, Fig. 5.11a-d). This translates to a 410% improvement in functional 
recovery. A longer pre-treatment period of 165 minutes failed to confer additional protection 
(56.31±11.24%, n=4, p<0.0001, Fig. 5.11b-d). Thus, MK801-mediated protection increased 
with pre-treatment time up to 120 minutes, where it was maximally protective (Fig.5.11d). 
The data supports the hypothesis that drug penetration into myelin is a slow process. For all 
remaining experiments requiring the use of NMDA receptor modulators, 120 minute pre-
treatment periods were used. 
In order to confirm that MK801 does not have any potentially interfering effect on CAP 
shape/area, CAP area was monitored under control conditions during exposure to MK-801 
(50µM). Following a 120-minute pre-treatment period, CAP area was recorded for 125 
minutes in the continued presence of MK-801, followed by a 40 minute wash-out period. MK-
801 had no significant effect on CAP area under normoxic conditions (108.10±2.46%, n=3, 
(versus control; 113.90±6.72% (n=4)), p=0.39, Fig. 5.12). 
Considering NBQX also provided a significant degree of functional protection, experiments 
were performed in the presence of both MK-801 (50µM) and NBQX (20µM). RONs were pre-
treated with MK-801 for 120 minutes and NBQX for 20 minutes. The co-application of both 
antagonists resulted in a CAP recovery of 55.87±3.94 (n=4, p<0.0001). However, this was not 
significantly different to experiments with MK-801 alone, demonstrating that NBQX provides 
no additional protection (p=0.32, Fig. 5.13).  
ICH was also performed to access the axonal integrity of MK-801 treated nerves (120 minute 
pre-treatment protocol). Nerves were collected following control, OGD and MK-801 
experiments and post-fixed RON sections were stained with the axonal marker, NF-200. When 
compared to control slices (n=3), OGD-exposed nerves (n=4) were clearly disrupted, 
displaying a marked decrease in NF-200 fluorescence, axonal fragmentation and multiple 
regions of NF+ aggregations (see Fig. 5.14a-b). Interestingly, while MK-801 treated nerves 
(n=4 nerves) did appear to have numerous intact axons and much less NF+ aggregations, NF 
staining was still notably disrupted. Normalising NF-fluorescence data to OGD experiments 
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revealed that there was no significant improvement in NF-fluorescence intensity when nerves 
were treated with MK-801 (p=0.25, Fig. 5.14b). This is surprising considering NMDAR blockade 
preserves AP conduction.  
Next, myelin structural integrity was examined using the fluorescent myelin stain, fluromyelin 
red. When compared to control nerves (n=3), OGD caused a dramatic decrease in 
fluorescence intensity, accompanied by distinct regions of myelin breakdown (n=3). In 
contrast, MK-801 treated nerves (n=3) retained a high degree of fluorescence which was not 
significantly different to control nerves (p=0.0635). MK-801 treatment prevented the 
formation of regions of myelin breakdown during OGD, significantly improving fluoromyelin 
reactivity (p=0.005, Fig. 5.15). Together, this data suggests that NMDA receptor block 
prevents myelin breakdown down during ischemia, which preserves AP conduction.  
A recent study by Hamilton et al. (2016), reported that the toxic Ca2+ rise in myelin during 
ischemia, is a result of elevated [K+]e which indirectly gates  Ca2+-permeable TRP-A1 channels, 
expressed on the myelinating oligodendrocyte process. Furthermore, they suggest that the 
rise in [K+]e is primarily a result of NMDA receptor-mediated depolarisation. This raised the 
question of whether the functional and structural protection observed in the presence of MK-
801 (Fig. 5.11 and Fig. 5.15), is a consequence of reduced TRP-A1 channel activity. To access 
the possible involvement of TRP-A1 channels, I examined CAP recovery in the presence of A-
967079, a selective TRP-A1 receptor antagonist (Hamilton, Kolodziejczyk et al. 2016). To 
ensure sufficient penetration through the myelin sheath, adult RONs were pre-treated with 
TRP-A1 (10µM) for 120 minutes before exposure to OGD. However, A-967079 did not 
significantly improve functional recovery, with post-OGD CAP area reaching 24.35±6.61 (n=6, 
p=0.69, Fig. 5.16). This suggests the activation of myelinic NMDA receptors during ischemia, 















Fig. 5.10: A short pre-treatment period of NMDA receptor blockade does not significantly improve 
functional recovery following OGD. 
 
a) Representative CAP trace in the presence of NMDA receptor blocker, MK-801. b) CAP time-course in 
the presence either 10 or 50µM MK-801, including a 20 minute pre-treatment period. c) Histogram 
comparing CAP recovery in the presence of MK-801. Note; both concentrations of MK-801 do not 










Fig. 5.11: NMDA receptor blockade elevates functional recovery following long pre-treatment periods. 
 
a) Representative CAP trace in the presence of MK-801 following a 120 minute pre-treatment period 
before OGD. b) CAP time-course following different periods of MK-801 pre-treatment. Note how 
increasing the pre-treatment length improved functional recovery following OGD. c) Histogram 
comparing CAP recovery between a range of MK-801 pre-treatment periods. d) Data summary. ns p>0.05, 















Fig. 5.12: Blockade of NMDA receptors under control conditions does not adversely affect CAP 
conduction. 
 
a) Representative CAP trace in the presence of MK-801 under normxic conditions in control aCSF. b) CAP 
time-course under control conditions including a 120-minute exposure to MK-801. Note; before recording 
was initiated, nerves were also pre-treated with MK-801 for 120 minutes (total exposure to MK-801=240 
minutes). c) Histogram showing the effect of MK-801 on CAP area after 120 minutes exposure followed 

















Fig. 5.13: The combined block of NMDA and AMPA/kainate receptors does not provide additional 
protection when compared to MK-801 alone. 
 
a) Representative CAP trace in the presence of MK-801 and NBQX. b) CAP time-course following a 120 
minute pre-treatment period with MK-801 and a 20 minute pre-treatment with NBQX. Note the high 
degree of functional recovery post-OGD. However, MK-801 mediated protection is not potentiated by 
















Fig. 5.14: NMDA receptor blockade does not preserve axon structural integrity during OGD. 
 
a) Representative images of neurofilament-200 (NF-200) immunofluorescence in fixed adult RONs 
following a number of treatments. Note the formation of NF-200 aggregations (see arrows) and overall 
drop in staining intensity between control and OGD experiments. Surprisingly, NF-200 staining intensity 
did not improve following experiments with MK-801. Inset shows an example of staining at a higher gain. 
No immunoreactivity is observed when NF-200 is omitted. b) Histogram comparing the relative NF-200 









Fig. 5.15: NMDA receptor blockade prevents OGD-induced myelin disruption. 
 
a) Representative images of fluromyelin staining in fixed adult RONs following a number of treatments. 
Overall fluorescence intensity is reduced following OGD. In addition, numerous regions display a complete 
loss in fluorescence. MK-801 treatment restored fluorescence intensity. No auto-fluorescence is observed 
when fluromyelin is omitted. b) Histogram comparing the relative fluorescence intensity between all 















Fig. 5.16: Blockade of TRP-A1 channels does not improve recovery following OGD.  
 
a) Representative CAP trace in the presence of a selective TRP-A1 channel blocker, A967079. b)  CAP time-
course in the presence of A967079. Note; nerves were pre-treated with A967079 for 120 minutes before 




5.2.4 NR2C/D incorporating NMDA-receptors mediate ischemic 
myelin injury 
 
As discussed, NMDA receptors express different combinations of sub-units which strongly 
affect their physiological and pharmacological properties (Hollmann and Heinemann 1994, 
Parsons, Danysz et al. 1998). Previous studies have reported that myelinic NMDA receptors 
are composed of the obligatory NR1 subunit, and a combination of NR2C, NR2D and/or NR3 
subunits (Káradóttir, Cavelier et al. 2005, Salter and Fern 2005, Micu, Jiang et al. 2006, Piña-
Crespo, Talantova et al. 2010). Interestingly, NR2C/D incorporating NMDA receptors are only 
weakly blocked by Mg2+, and considered to be more sensitive to glutamate and glycine 
(Parsons, Danysz et al. 1998, Káradóttir, Cavelier et al. 2005, Micu, Jiang et al. 2006, Mosley, 
Acker et al. 2010).   
CIQ is a highly selective potentiator of NR2C/D subunit-containing receptors, which increase 
the frequency of channel opening without altering the EC50 value for glutamate (Mullasseril, 
Hansen et al. 2010). To test whether the enhanced activation of NR2C/D-expressing NMDA 
receptors is toxic under control conditions, nerves were perfused with CIQ (20µM) for 120 
minutes. However, exposure to CIQ had no significant effect on CAP area during this period 
(106.50±3.60%, n=3, p=0.11, Fig. 5.17a, note; recording was initiated after a 120 minute pre-
treatment with CIQ). Furthermore, exposure to OGD in the presence of CIQ, did not 
potentiate injury, with CAP area recovering to 18.28±8.61% (n=4), not significantly different 
to control OGD nerves (p=0.988, Fig. 5.17b-d). It is worth noting that although statistical 
significance was not achieved, AP conduction tended to block out at a quicker rate in the 
presence of CIQ (p=0.18).  
The endogenous neurosteroid, pregnenolone sulphate, strongly potentiates currents with 
NR2A/B-expressing NMDA receptors, having minimal effect on NR2C/D-expressing receptors  
(Káradóttir, Cavelier et al. 2005). In contrast, pregnanolone sulphate is a negative modulator 
of all NR2 receptor subunits, but is 4 times more potent at receptors expressing NR2C/D 
subunits (Malayev, Gibbs et al. 2002). Curiously, perfusion with pregnanolone hemisuccinate 
(3α5βHS; 100µM, (Weaver, Marek et al. 1997)), a synthetic analogue of the sulphated species, 
(for 120 minutes before, during and 40 minutes after OGD) had no significant effect on CAP 
recovery after 60 minutes OGD (17.32±5.02%, n=4, p=0.99, Fig. 5.18). This result is unlikely to 
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be due to any toxic effect of 3α5βHS as exposure under normoxic conditions did not appear 
to reduce CAP area (n=1, Fig. 5.18). Interestingly, previous studies show that 3α5βHS was only 
responsible for a maximal 20-47% reduction in NMDA-mediated currents in neuronal cultures 
(Weaver, Marek et al. 1997). Therefore, it is possible that 3α5βHS does not exert a strong 
enough inhibition of NMDA receptors to confer protection.  
To further test the involvement of NR2C/D containing receptors, experiments were repeated 
using a more potent NMDAR antagonist, PPDA. PPDA preferentially binds to NR2C/D-
containing receptors, displaying a 3 to 5 fold increase in affinity over NR2A/B-containing 
receptors (Feng, Tse et al. 2004). The application of PPDA (20µM) significantly improved post-
OGD recovery to 42.08±8.86% (n=5, p=0.0022, Fig. 5.19). Next, to test whether the 
accumulation of low concentrations of PPDA is sufficient to confer protection, experiments 
were repeated using 1µM PPDA. However, this protocol did not provide any significant 
protection following OGD (13.49±4.00%, n=3, p=0.99, Fig. 5.19b-c). Longer pre-treatment 
times with 1µM were not tested as this would presumably push the limits of nerve viability in 
the recording chamber. 
QNZ-46, an allosteric modulator of NMDA receptors, is currently the most selective inhibitor 
of NR2C/D-containing receptors, displaying a 50-fold selectivity over NR2A/B-containing 
receptors (Mosley, Acker et al. 2010). Furthermore, QNZ-46 inhibits in an activity-dependant 
manner (Hansen and Traynelis 2011). To test whether QNZ-46 is capable of preserving WM 
function following ischemia, CAP area was recorded in the presence of QNZ-46. Due to poor 
aqueous solubility at 100µM and 70µM, 50µM QNZ-46 was used during experiments. QNZ-46 
led to a significant increase in CAP recovery following OGD (43.44±4.50%, n=5, p=0.0013, Fig. 
5.20).  However, due to its poor aqueous solubility, we may be under-estimating its protective 
effect (Mosley, Acker et al. 2010). Experiments were repeated using 1µM QNZ-46, but similar 
to PPDA, low concentrations had no significant effect on CAP recovery (15.87±2.32%, n=3, 
p=0.99, Fig. 5.20).  
To examine myelin disruption during OGD, dual live-imaging of myelin (fluromyelin) and the 
cytoplasmic compartment of oligodendrocytes (using PLP-GFP mice) was monitored via 
spinning disk confocal microscopy. Examination of MONs revealed that myelin and 
oligodendrocyte processes are two distinct regions (Fig. 5.21a, see arrows). Thus, any 
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structural or morphological changes in fluorescent oligodendrocyte processes will not reflect 
myelin damage. Consistent with previous ultrastructural studies (Micu, Jiang et al. 2006, 
Hamilton, Kolodziejczyk et al. 2016), myelin decompaction was evident after 60 minutes of 
OGD, with myelin diameter increasing from 0.67±0.004µm (n=967 myelin strands/13 MONs) 
to 0.86±0.01µm (n=318 myelin strands/5 MONs, Fig.5.21b-d, p=0.0003). This was 
accompanied by oligodendrocyte somata swelling and the disruption of cell processes 
(oligodendrocyte injury was not quantified). Consistent with previous CAP recordings (see Fig. 
5.16), the TRP-A1 channel blocker, A-967079, had no effect on myelin injury, with myelin 
diameter increasing to 0.92±0.01µm after 60 minutes OGD (n=205 myelin strands/4 MONs, 
Fig5.21c-d, p<0.0001). In contrast, myelin decompaction was largly prevented in the presence 
of QNZ-46 (120-minute pre-treatment protocol). In QNZ-46 treated nerves, myelin diameter 
increased to 0.75±0.01µm following OGD, a significant reduction when compared to 
untreated nerves (n=216 myelin strands/4 MONs, p=0.02, Fig. 5.21c-d). This supports my 
previous findings that NMDAR activation mediates myelin breakdown. In contrast, 
oligodendrocyte cell injury appeared to be unaffected by QNZ-46, indicating that 
oligodendrocyte injury operates via an alternative mechanism, likely AMPA/kainate or TRP-

















Fig. 5.17: Potentiation of NR2C/D-containing NMDA receptors does not affect CAP conduction.  
 
a) CAP time-course under control conditions including a 120 minute exposure to a NR2C/D-containing NMDA 
receptor potentiator, CIQ. Inset; histogram comparing CAP area after 120 minutes perfusion with CIQ to initial 
starting CAP area in the absence of the drug. Note; CIQ has no effect on CAP area under control conditions. b) 
Representative CAP trace in the presence of CIQ for an OGD experiment. c)  CAP time-course in the presence of 
CIQ. Note; nerves were pre-treated with CIQ for 120 minutes before exposure to OGD. CIQ does not exacerbate 
















Fig. 5.18: Inhibition NMDA receptors with the neurosteroid, pregnanolone hemisuccinate, does not 
improve post-OGD functional recovery. 
 
a) Representative CAP trace in the presence of a negative modulator of NMDA receptors, pregnanolone 
hemisuccinate (PH). b) CAP time-course in the presence of PH. Note; nerves were pre-treated with PH for 
120 minutes before exposure to OGD. PH does not affect CAP conduction under control conditions. 
However, it does not protect during OGD. c)  Histogram comparing post-OGD recovery in PH to time-















Fig. 5.19: PPDA, a selective inhibitor of NR2C/D-containing NMDA receptors, improves functional 
recovery following OGD. 
 
a) Representative CAP trace in the presence of a negative modulator of NR2C/D-containing NMDA 
receptors, PPDA. b) CAP time-course in the presence of two different concentrations of PPDA. Note; 
nerves were pre-treated with PPDA for 120 minutes before exposure to OGD. 20µM PPDA dramatically 
increased CAP area after OGD, while 1µM PPDA failed to preserve CAP conduction. c) Histogram 














Fig. 5.20: QNZ-46, a selective inhibitor of NR2C/D-containing NMDA receptors, improves functional 
recovery following OGD. 
 
a) Representative CAP trace in the presence of a negative modulator of NR2C/D-containing NMDA 
receptors, QNZ-46. b) CAP time-course in the presence of two different concentrations of QNZ-46. Note; 
nerves were pre-treated with QNZ-46 for 120 minutes before exposure to OGD. 50µM PPDA dramatically 
increased CAP area after OGD, while 1µM QNZ-46 failed to preserve CAP conduction. c) Histogram 















Fig. 5.21: QNZ-46 prevents myelin decompaction during OGD.  
 
a) Oligodendrocyte cytoplasmic domain (PLP-GFP mouse; green) is distinct from myelin sheath (fluromyelin; 
red). See arrows. Inset shows an example of a stacked image of GFP-fluromyelin at a higher gain. b) 
Representative images of myelin and oligodendrocytes in live adult MONs, before and after 60 minutes of OGD 
followed by 60 minutes reperfusion (rep.). Note; QNZ-46 prevents myelin damage, but does not preserve 
oligodendrocytes. Nerves were pre-treated with QNZ-46 for 120 minutes before exposure to OGD. c) Histogram 
comparing myelin diameter before and after OGD. 60 minutes of OGD increases myelin sheath diameter. QNZ-
46 prevents myelin decompaction during OGD, but A967079 (TRP-A1 channel blocker) does not. d) Frequency 
distribution curve demonstrating how the OGD-evoked increase in myelin diameter is prevented by QNZ-46, 




5.2.5 QNZ-46 accumulation in myelin 
 
QNZ-46 is a derivative of 4-oxo-3(4H)quinazolinyl, containing the trans-stilbene 
pharmacophore (Mosley, Acker et al. 2010). It also contains the quinazolinone backbone 
which is known to exhibit strong fluorescence (Naleway, Fox et al. 1994) (see Fig. 2.11). 
Together, this gives QNZ-46 the structural properties of a fluorescent myelin stain. The 
fluorescent properties of QNZ-46 were confirmed with a lambda scan, which revealed a peak 
emission of 450nm (blue) in a lipid environment (excitation at 405nm) (see Fig. 2.11 in chapter 
2). 
This is highly advantageous as it allows for drug uptake to be monitored in real-time. Adult 
RONs were perfused with QNZ-46 (50µM) for a total of 120 minutes, followed by a 60 minute 
wash-out period. Nerves were transferred and imaged (in QNZ46-free aCSF) using a 
fluorescent microscope at various time-points through-out. Perfusion with the drug, led to a 
progressive increase in QNZ-46 relative-emission throughout the 120 minute treatment 
period, increasing by 152.40±18.03% (n=4, Fig. 5.22). Consistent with previous results, the 
data suggests that QNZ-46 slowly accumulates in myelin over time. Interestingly, QNZ-46 
fluorescence remained high following 60 minutes wash-out in control aCSF. There was no 
significant difference in QNZ-46 emission after wash-out when compared to the maximum 
emission during perfusion with the drug (120mins QNZ-46 versus 60 minutes wash-out, 
p=0.33), indicating that QNZ-46 partitions into the myelin sheath and is retained during wash-
out. 
To confirm the selective localisation of QNZ-46 in myelin, coronal rat brain slices were 
incubated (5°C) in QNZ-46 (50µM) and fluromyelin (1:20) for 120 minutes. Slices were 
subsequently transferred to a control aCSF solution (QNZ-56/fluromyelin- free) and imaged 
using laser scanning confocal microscopy. Consistent with our hypothesis, QNZ-46 
fluorescence localised in myelinated WM (corpus callosum) and was largely absent from 
neighbouring GM regions (Fig. 5.23a-b). Note the WM-GM boarder in Fig. 5.23b. High 
magnification images revealed vital QNZ-46 fluorescence in myelin-axon profiles, which co-






Fig. 5.22: QNZ-46 accumulates in the adult RON and is 
retained following wash-out. 
 
a) Representative live-images of QNZ-46 emission in 
the adult RON during perfusion with the drug for 120 
minutes. White dotted line outlines the RON. QNZ-46 
fluorescence intensity gradually increases over time 
and remains high following 60 minutes wash-out. b) 



















Fig. 5.23: QNZ-46 selectively accumulates in myelin sheath. 
 
a) Sample live-images of QNZ-46 emission (blue) in the adult rat CC and b) at the WM-GM border. Note; 
adult rat coronal brain slices were pre-incubated with QNZ-46 for 120 minutes. QNZ-46 fluorescence is 
high in WM regions, but absent in neighbouring GM. c) Sample image of vital QNZ-46/fluromyelin (FM; 
red) co-staining of myelinated axon profiles in the adult CC. QNZ-46 emission is high in myelin profiles. 






5.2.6 QNZ-46 acts as a persistent myelin shield and crosses the BBB 
in vivo  
 
The accumulation and subsequent retention of QNZ-46 in myelin may provide sufficient 
protection following its removal from the extracellular space. To test this hypothesis, RONs 
were pre-treated with QNZ-46 for 60 minutes, followed by a 60 minute wash-out period (in 
control aCSF) before exposure to OGD (see Fig. 5.24a). This pre-treatment protocol led to a 
significant improvement in CAP recovery, with CAP area reaching 33.26±4.62% following the 
re-introduction of oxygen and glucose (n=6, p=0.047, Fig. 5.24b-d). In contrast, replicating this 
protocol with NBQX (20µM), had no significant protective effect, with CAP area recovering to 
22.84±6.83% (n=4, p=0.83, Fig. 5.25), consistent with the expression of AMPA/kainate 
receptors on the oligodendrocyte cell body. Not only does this data complement our findings 
that QNZ-46 accumulates in myelin, but more importantly, it is the first drug to persistently 
provide protection in the CNS even when the drug is removed from the extracellular space.  
Drug permeability through the blood brain barrier (BBB) is one of the most important limiting 
factors in the development of pharmacological neurotherapeutics (Pardridge 2001, Pardridge 
2005). A recent study found that a similar compound (UBP141) effectively crossed the BBB 
following intraperitoneal (i.p.) injection in mice (Lozovaya, Gataullina et al. 2014). Therefore, 
we sought to determine whether QNZ-46 crosses the BBB in vivo. Assuming a total circulating 
blood volume of approximately 1170µl in an average 20g mouse, in silico modelling predicts 
an estimated concentration of ~50µM in the brain following a 200µl i.p. injection of QNZ-46 
(20mg/kg-1). In an effort to prevent crystallisation, QNZ-46 injections were dissolved in 50/50 
DMSO/20mM β-cyclodextrin and required gentle heating. C57Bl/6 wild-type mice were i.p. 
injected with either QNZ-46 or a vehicle 4 hours prior to animal sacrifice. Tissue was dissected 
into QNZ-46-free aCSF. QNZ-46 distribution was initially examined in coronal brain slices. 
Interestingly, vital QNZ-46 fluorescence displayed a similar distribution to that observed in 
the rat brain slices following bath loading (Fig. 5.26). QNZ-46 selectively localised in 
myelinated WM regions and was essentially absent from GM. Furthermore, QNZ-46 co-
localised with fluromyelin (following a brief incubation at 5°C for 30 minutes, Fig. 5.26). Again, 
this demonstrates myelin retention, but also provides direct evidence of BBB penetration.   
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QNZ-46 fluorescence was also observed in myelin strands within the MON following i.p. 
injection (Fig. 5.27a). CAPs were recorded from the ON of i.p. injected mice to access whether 
QNZ-46 accumulation is sufficient to confer protection. ONs from either vehicle control or 
QNZ-46 injected mice were dissected into and subsequently perfused with drug-free aCSF for 
60 minutes before O2-glucose withdrawal. CAP area recovered to 6.79±1.92% (n=4) in vehicle-
control injected mice. However, CAP recovery was significantly higher in QNZ-46 injected mice, 
with post-OGD CAP area increasing to 18.91±5.63% (n=5, p=0.048, Fig. 5.27b-d). The 
protective effect was not potentiated when QNZ-46 was added to the perfusing aCSF solution 





























Fig. 5.24: QNZ-46 provides persistent protection following wash-out.  
 
a) Schematic diagram of the QNZ-46 wash-off protocol. b) Representative CAP trace after QNZ-46 wash-
out. c) CAP time-course following QNZ-46 wash-off protocol. Post-OGD CAP area is elevated following 
treatment with QNZ-46. d) Histogram comparing post-OGD recovery after QNZ-46 wash-off treatment to 
















Fig. 5.25: NBQX does not improve post-OGD functional recovery following wash-out.  
 
a) Schematic diagram of the NBQX wash-off protocol. b) Representative CAP trace after NBQX wash-out. 
c) CAP time-course following NBQX wash-off protocol. Note; NBQX wash-off does not elevated post-OGD 
CAP area. d) Histogram comparing post-OGD recovery after NBQX wash-off treatment to time-matched 
















Fig. 5.26: QNZ-46 crosses the BBB and accumulates in central WM following I.P. injection in adult mice. 
 
a) Sample image of QNZ-46 emission (blue) in an adult mouse brain slice after an I.P. injection. Note the 
WM-GM border demonstrating QNZ-46 fluorescence in myelinated WM regions. QNZ-46 selectively 












Fig. 5.27: I.P. injected QNZ-46 accumulates in ON myelin and improves functional recovery after OGD. 
 
a) Sample image of QNZ-46 emission (blue) in MON myelin profiles (FM; fluromyelin; red) following I.P. 
injection. Merged image is recoloured for clarity. b) Representative CAP trace recorded from vehicle and 
QNZ-46 injected adult MONs. c) CAP time-course of I.P. injected mice with either vehicle or QNZ-46. QNZ-
46 improves post-OGD CAP recovery (black), but protection is not potentiated when QNZ-46 is included 
in the bath during OGD (red). d) Histogram showing the effect of QNZ-46 injection on functional recovery. 















Fig. 5.28: Adult RON data summary. 
 
Functional recovery after 60 minutes of OGD following a variety of pharmacological treatments. NMDA 











Excitotoxicty may be the single most important mechanism underlying ischemic WM damage. 
A common feature of WM ischemia is rapid myelin disruption which ultimately leads to action 
potential failure and functional deficits in patients. Results from the previous chapters 
indicate that the periaxonal space between the axon and inner layers of myelin sheath may 
be a significant site of excitotoxic injury. However, the exact mechanism(s) of ischemic myelin 
disruption is controversial. In this chapter, I show that the cytotoxic activation of NR2C/D-
containing myelinic NMDA receptors mediates the structural and functional injury of 
myelinated WM. Resolving prior conflicting results; the data also demonstrates that drug 
penetration through the myelin sheath is slow and thus, requires relatively long pre-
treatment periods. Furthermore, TRP-A1 antagonists do not confer functional protection.  
I have also identified a highly-selective, allosteric inhibitor of myelinic NR2C/D-containing 
NMDA receptors, QNZ-46. QNZ-46 has the characteristics of a fluorescent myelin stain which 
revealed its selective accumulation and retention in myelin over time. Furthermore, the 
systemic injection of QNZ-46 elevates the injury tolerance of WM, even when the drug is 
removed from the extracellular space. QNZ-46 is the first drug to exhibit persistent CNS 
protection. This feature combined with its ability to cross the BBB and its high selectivity for 
NR2C/D expressing receptors suggest that QNZ-46 may have significant clinical implications, 
not only for stroke patients, but also for a range of neurological disorders which involve 
myelin breakdown.  
 
5.3.2: OGD-induced injury in early myelinating WM 
  
Developing WM injury is the most common neuropathological correlate associated with the 
incurable condition, cerebral palsy. The neonatal rat ON and CC are regularly used to study 
ischemic injury in developing WM tracts (Follett, Rosenberg et al. 2000, Alix and Fern 2009). 
There is evidence to suggest that regional differences in sensitivity exist between different 
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regions of the CNS (Tekkok and Ransom 2004, Tekkok, Ye et al. 2007). Using a combination of 
electrophysiological and immunohistochemical techniques, a direct comparison was made 
between the two early myelinating WM tracts. In agreement with previous studies, 1 hour of 
OGD produced an irreversible decrease in CAP amplitude in the P10 RON (Alix and Fern 2009). 
In addition, disrupted axon structural integrity was also observed demonstrating that a 
relatively brief period of acute ischemia leads to both structural and functional injury. Thanks 
to the development of a novel technique which allows the recording of CAPs from the ‘whole’ 
CC (Li, Velumian et al. 2016), OGD-sensitivity in the P10 CC was also examined. Interestingly, 
CC excitability fell more rapidly during ischemia. Although CAP recovery following OGD was 
delayed in the CC, there was no significant difference in total functional recovery after 90 
minutes reperfusion, indicating that both WM tracts have a similar degree of sensitivity to 
ischemia. Tekkok and Ransom (2004) reported that the adult MON and CC react similarly to 
anoxia, with 120 minutes of anoxia producing an identical degree of irreversible injury. 
Consistent with these findings, my data demonstrates that developing WM tracts also display 
a remarkably similar response to energy deprivation. Further experiments are required to 
determine whether all WM tracts in the brain are equally sensitive to ischemia.   
As mentioned, previous studies have shown that the over-activation of iGluRs mediates a 
large component of irreversible functional injury in the P10 RON (Alix and Fern 2009, Alix, 
Zammit et al. 2012). I investigated whether excitotoxicity also contributes to injury in the P10 
CC. While the application of iGluR antagonists did appear to have a protective tendency, there 
was no significant improvement in functional recovery following OGD. This suggests that the 
injury mechanisms which operate in the CC are different to the RON. However, the high 
degree of variability in CAP recordings using this adapted methodological approach may have 
concealed the protective effect of such antagonists. This may be, in part, due to the varying 
distance between the mouth of the recording and stimulating electrode. For several 
experiments, a short recording distance between electrodes (1-2mm) was required to 
produce sufficiently large CAPs. This short conduction distance will inevitably expose only a 
short fragment of the tract to true OGD (since both electrodes are filled with control aCSF). 
Thus, this is likely to contribute to the varying degree of post-OGD recovery. Further 
experiments are required to conclusively determine whether excitotoxicity contributes to 
irreversible injury in the CC.  
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5.3.3: Excitotoxic injury in myelinated WM 
 
In agreement with previous studies, NBQX partially preserved WM function following 
ischemia (Tekkok and Goldberg 2001, McCarran and Goldberg 2007, Tekkok, Ye et al. 2007). 
This confirms that AMPA/kainate receptor activation contributes to excitotoxic WM injury in 
adult WM. Interestingly, a water-soluble derivative of NBQX, disodium-NBQX (Na-NBQX), was 
equally protective. In general, lipid membranes are permeable to liposoluble or non-polar 
compounds, such as NBQX. The similar degree of protection provided by both species of the 
drug suggests that liposolubility does not affect the actions of AMPA/kainate receptor 
antagonists. This is consistent with the expression of AMPA/kainate receptors on the surface 
of oligodendrocytes, not within compact myelin.  
NMDA receptor activation is reportedly involved in the ischemic breakdown of myelin. Yet 
surprisingly, there are no reports in the literature of NMDA-mediated functional injury in fully-
myelinated WM tracts. Consistent with these findings, short pre-treatment periods with an 
established NMDA-receptor antagonist (MK-801) failed to significantly preserve nerve 
function from ischemic injury. However, due to the expression of functional NMDA receptors 
within myelin, particularly along inner surface of myelin sheath, we reasoned that drug 
penetration into the periaxonal space may be slow. There are two potential routes by which 
NMDA receptor antagonists can access the periaxonal space. Firstly, the paranodal junction 
(PNJ) flanking each node is separated from the underlying axon by a narrow space of 
approximately 2-4nm (Rosenbluth 2009). This tight space is suggested to provide a route by 
which juxtaparanodal K+ channels can influence nodal activity, potentially regulating AP 
conduction (Rosenbluth 2009). Mierzwa et al. (2010) demonstrated that water-soluble, 
fluorescent dextran tracers (3 and 70kDa in size) are capable of penetrating the PNJ into the 
periaxonal space, diffusing symmetrically on both sides of the node of Ranvier. Both 3 and 
70kDa tracers were able to penetrate live and fixed nerves indicating that transport is via 
passive diffusion. However, the diffusion distance travelled in live nerves was only 4.4µm over 
a period of 135 minutes. Alternatively, lipid soluble compounds can directly penetrate 
through the myelin sheath. A previous study has shown that the association of MK-801 with 
an intact biological membrane (synaptoneurosome) takes less than 5 minutes (Moring, Niego 
et al. 1994). Similarly, dissociation from the membrane takes approximately 10 minutes. The 
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fast kinetics of the association/disassociation time constants is consistent with the quick 
onset and short acting nature of MK-801 in vivo (Vezzani, Serafini et al. 1989, Moring, Niego 
et al. 1994, Yang, Ren et al. 2016). However, myelin sheath is made up of multiple wraps of 
myelin (up to 14 layers in larger axons) which may significantly hinder the rate of drug 
penetration. Early studies found that C14 labelled compounds like phenobarbital (an anti-
epileptic drug) penetrate cerebral GM much more rapidly than WM regions in the adult cat 
(Roth and Barlow 1961). In contrast, WM is more readily penetrated in new-born kittens, 
which was due to the incomplete formation of myelin. Together, this suggests that myelin 
forms a significant barrier which reduces the rate of drug penetration, and thus, is comparable 
to the blood brain barrier.  
In order to facilitate sufficient drug penetration either through the PNJ or directly through the 
multi-layered myelin sheath, nerves were pre-treated with MK-801 for long periods. 
Intriguingly, increasing the duration of drug exposure dramatically increased functional 
recovery following ischemia. Maximum protection of >400% was observed following 120 
minutes pre-treatment the drug. This is consistent with the expression of NMDARs 
throughout compact myelin and that receptor activation during ischemia mediates ischemic 
myelin damage (Káradóttir, Cavelier et al. 2005, Micu, Jiang et al. 2006). Furthermore, it 
suggests that previous studies may have underestimated the involvement of NMDA receptor 
activation due incomplete drug penetration through the myelin sheath. Considering the 
average length of the MON internode is 134µm (Butt, Colquhoun et al. 1994) and that dextran 
traces diffuse only 4.44µm away from the node in 135 minutes (Mierzwa, Shroff et al. 2010), 
it is unlikely that drug diffusion through the PNJ accounts for such outstanding protection. 
Although MK-801 is much smaller (Mr=337) than the tracers used in that study, it is a 
positively charged molecule which will significantly hinder diffusion through the PNJ. 
Nonetheless, drug penetration through the multi-layered myelin sheath is likely the primary 
route of MK801 diffusion. Interestingly, simultaneous AMPA/kainate receptor blockade in the 
presence of MK-801 provided no additional protection during OGD, suggesting that 
preserving the oligodendrocyte-myelin unit is as equally protective as preventing myelin 
damage alone. Thus, this may be the maximum protection provided by iGluR antagonists.  
In agreement with previous reports, myelin degeneration was observed following OGD. 
However, myelin disruption was prevented in the presence of NMDA receptor blockers 
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(MK801; long pre-treatment), demonstrating that NMDAR activation during ischemia 
promotes myelin damage and that myelin preservation is sufficient to maintain functional 
WM. Interestingly, NMDAR blockade did not significantly preserve underlying axon integrity 
following OGD. Considering MK801 significantly improves AP conduction post-OGD, it is hard 
to believe that NMDAR blockade does not preserve axon structure. Changes in absolute 
NF200 fluorescence intensity may not be sufficient to accurately access structural changes in 
individual axons. As mentioned, MK801 treated nerves did appear to display a higher number 
of intact axon cylinders. An axon scoring system may provide a more comprehensive 
assessment of drug efficacy. 
Contrary to Hamilton et al. (2016), who found that Ca2+-permeable TRP channels mediate 
myelin disruption in cerebellar WM, the selective inhibition of TRP-A1 channels did not 
significantly improve functional recovery after OGD. Moreover, it did not prevent myelin 
decompaction in the adult MON. However, this study and others, often rely on either live-
imaging or patch-clamp recordings from oligodendrocyte processes (Káradóttir, Cavelier et al. 
2005, Hamilton, Kolodziejczyk et al. 2016). Dual imaging of myelin and the cytoplasmic 
domain of oligodendrocyte processes in the MON revealed that they are in fact, two distinct 
compartments. As a result, it is possible that the injury mechanisms which mediate ischemic 
myelin damage and oligodendrocyte injury are also distinct.  
 
5.3.4: NR2C/D-containing NMDA receptors mediate ischemic 
myelin damage  
 
Sub-unit selective antagonists of NMDA receptors have high clinical potential. As previously 
discussed, WM NMDA receptors have an unusual subunit composition, including NR2C/D 
and/or NR3A/B subunits. Curiously, a novel synthetic analogue of pregnanolone succinate 
(3α5βHS), a negative modulator of all NMDA receptor subunits, failed to preserve nerve 
function following OGD. However, work by Malayev et al. (2002) demonstrated that although 
pregnanolone succinate decreases the efficiency of NMDA activation, it does not completely 
inhibit NMDA mediated currents. Thus, it is possible that partial NMDA blockade is incapable 
of preventing myelin injury. In addition, CIQ, a positive modulator of NR2C/2D-expressing 
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receptors, failed to potentiate injury. With that said, CIQ operates by increasing the frequency 
of channel opening, which demonstrates that myelinic NMDA receptors are already 
maximally activated during ischemia. Consistent with the reported expression of NR2C/2D 
subunits in myelin, potent antagonists of NR2C/2D-expressing NMDA receptors, PPDA and 
QNZ-46, dramatically improved functional recovery following OGD, increasing CAP area to a 
surprisingly similar level, 42 and 43%, respectively. This translates to a ~240% improvement 
in functional recovery. Notably, this is considerably lower than the protection provided by the 
broad-spectrum NMDA antagonist, MK-801 (63%). Functional NR1/3-expressing NMDA 
receptors, which lack the NR2 subuint, are also expressed in ON myelin (Piña-Crespo, 
Talantova et al. 2010). NR1/3 receptors mediate a rise in Ca2+ myelin in response to NMDA 
receptor co-agonists, including glycine and D-serine (Piña-Crespo, Talantova et al. 2010). 
Moreover, they are insensitive to D-AP5, a glutamate site antagonist of NR2-expressing 
receptors (Piña-Crespo, Talantova et al. 2010). Therefore, NMDA mediated injury in myelin 
may arise from the over-activation of a combination of NMDA sub-types, including NR2C/D 
and NR3 subunits. Although selective antagonists of NR3A/B-containing receptors are not 
currently available, it would be interesting to test whether a combined block of both sub-
types would provide a similar degree of protection as broad-spectrum NMDA antagonists, 
such as MK801.  
The Ki values (inhibition constant) for PPDA are 0.55, 0.31, 0.125 and 0.096µM for 2A, B, C 
and D-containing receptors, respectively (Feng, Tse et al. 2004). Thus, PPDA displays a ~3-5 
fold preference for NR2C/2D-containing receptors. However, QNZ-46 has IC50 values of >300, 
229, 6 and 3µM for 2A, B, C and D-containing receptors, respectively (Mosley, Acker et al. 
2010), and therefore, displays a ~50-fold preference for NR2C/2D-containing receptors. QNZ-
46 is a member of a novel class of non-competitive antagonists which operates by a unique 
mechanism (Hansen and Traynelis 2011). QNZ-46 inhibition of NMDA receptors is use-
dependent, requiring the simultaneous binding of glutamate to the NR2 sub-unit. Hansen and 
Traynelis (2011) presented a model for the predicted mechanism of NMDAR inhibition by 
QNZ-46. The binding of glutamate to the NR2 subunit induces a conformational change which 
either enhances the availability of the QNZ-46 binding site, or changes the binding-site to a 
higher affinity conformation (see Fig. 5.29). The occupation of QNZ-46 increases the activation 
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energy required for the conformational change of each receptor subunit, and therefore, 





Fig. 5.29: Predicted hypothesis of QNZ-46 inhibition of NR2C/D-containing receptors. Taken from 
(Hansen and Traynelis 2011). 
 
 
The sub-unit selectivity and use-dependent nature of QNZ-46 represents a potentially 
powerful therapeutic advantage, capable of overcoming the side-effects associated with 
many non-selective antagonists. Live-imaging of myelin in PLP-GFAP adult mice revealed that 
treatment with QNZ-46 prevents the ischemia-induced decompaction of myelin sheath. This 
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indicates that the over-activation of NR2C/D-containing NMDA receptors mediates myelin 
breakdown during ischemia. As predicted, it did not appear to prevent the swelling and 
fragmentation of oligodendrocyte cell processes or soma, further indicating that injury occurs 
through distinct mechanisms.  
As discussed, QNZ-46 has the lipophilicity of a fluorescent myelin stain due to the trans-
stilbene pharmacophore and quinazolinone backbone (Wang, Popescu et al. 2010). The 
fluorescent properties of the drug were used to confirm the slow penetration of QNZ-46 into 
myelin over a 2 hour period. This is in agreement with the long pre-treatment time required 
for MK-801 to provide significant functional protection. Curiously, QNZ-46 emission remained 
high during wash-out, indicating that it accumulates in myelin over time and is retained 
following wash-out. Similarly, the localisation of QNZ-46 in myelin axon profiles and its 
absence from neighbouring GM regions further support the idea that QNZ-46 partitioning 
through myelin sheath is a slow process, but it also suggests that its retention during wash-
out may provide persistent protection. 60 minutes of treatment with QNZ-46 followed by 60 
minutes wash-out, significantly elevated functional recovery in the adult RON. This continued 
protection in the absence of the drug suggests that trapping of QNZ-46 in myelin sheath and 
integration with NMDA receptors, provides persistent functional protection over relatively 
long periods. Thus, myelin acts as a reservoir for NMDA-antagonists such as MK-801 and QNZ-
46. Consistent with the expression of AMPA/kainate receptors on oligodendrocyte cell bodies 
(Tekkok and Goldberg 2001, Salter and Fern 2005), and their absence in myelin, an identical 
protocol using NBQX did not preserve functional recovery.  
The BBB poses as a significant obstacle in the delivery of many drugs to the CNS. There are a 
number of transport mechanisms by which compounds can cross the BBB, including 
endocytosis, and active transports. However, transmembrane diffusion is the most common 
mechanism. Conversely, lipid solubility and molecular weight are important factors in BBB 
permeability (Banks 2009). A substantial fraction of molecules with a lipid/water partition 
coefficient greater than 0.03 readily penetrate the BBB (Oldendorf 1974). However, 
compounds which greatly surpass this lipid solubility can accumulate in the BBB and are 
subsequently sequestered by the capillary bed (Banks 2009). Similarly, high lipid solubility 
favours the accumulation of drugs in peripheral tissue, and thus, decreases the concentration 
of the drug which reaches the BBB. Therefore, the development of effective neuroprotective 
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agents must find a balance between sufficient solubility to permeate the BBB, yet not to the 
extent that decreases the availability of the drug presented at the BBB (Banks 2009). Another 
important factor in BBB permeability is molecular weight.  However, relatively large 
compounds (over 600Da) are known to penetrate the BBB (Banks 2009). In fact, cytokine-
induced neutrophil chemoattractant-1 (CINC1), a chemokine with a molecular weight of 
7,800Da, completely crosses the BBB following i.v. bolus injection (Pan and Kastin 2001). 
While QNZ-46 has a relatively low molecular weight of 443.41 (Tocris), its lipophilicity and 
accumulation in myelin raise the question of whether QNZ-46 crosses the BBB. Adult mice 
which were I.P. injected with QNZ-46 displayed widespread emission throughout WM regions 
of the CNS, including the corpus callosum and ON. This demonstrates that QNZ-46 readily 
crosses the BBB and selectively accumulates in myelin sheath. Furthermore, functional 
recovery was significantly elevated in I.P. injected mice, suggesting that the incorporation of 
QNZ-46 in myelin acts as a protective myelin shield. The lack of additional protection observed 
in I.P. injected mice which were also perfused with the drug following nerve dissection, 
suggests that myelin trapping following systemic QNZ-46 pre-treatment results in maximal 
protection. Thus, QNZ-46 elevates the injury tolerance of WM, even when the drug is 
removed from the extracellular space. The persistent protection provided by QNZ-46 has high 
clinical potential for patients who are at high risk of stroke, particularly those who are 
susceptible to recurrent stoke. In addition, QNZ-46 may prove to be beneficial in a range of 
pathological disorders which display myelin degradation, including multiple sclerosis.   
 
To summarise, I examined the involvement of myelinic NMDA receptors in ischemic WM 
injury. NMDA receptor antagonists provided exceptional protection when applied for 
sufficient time to penetrate myelin sheath. My results also show that NR2C/D-containing 
receptors mediate the ischemic decompaction of myelin. QNZ-46, a fluorescent NR2C/D 
NMDA receptor antagonist, elevates injury tolerance in myelinated WM tracts and provides 
































The goal of this thesis is to determine the mechanisms of glutamate release in central WM 
and to test the hypothesis that myelinic NMDA receptor activation mediates ischemic myelin 
injury. In this chapter, I will give a brief review of my findings, explain the proposed model of 




In chapter 3, I investigated the significance of vesicular glutamate release in adult WM. I 
showed that widespread depolarisation evokes a sharp rise in [Glut]e in the adult corpus 
callosum. Interestingly, the time-course and amplitude of glutamate release was independent 
of glutamate transporter activity, but was dramatically reduced by inhibition of vesicular 
glutamate loading. Similarity, depolarisation evoked rapid de-staining of the vesicular probe, 
FM4-64. Consistent with previous findings, this suggests that vesicular neurotransmitter 
exocytosis is evident within mature WM. However, this is the first direct evidence that 
vesicular glutamate release in WM can significantly elevate extracellular concentrations. In 
addition, I demonstrate the surprising extent of vesicular fusion along myelinated axons when 
compared to their companion astrocytes. Curiously, WM astrocytes show no evidence of 
vesicular docking suggesting that the robust rise in extracellular glutamate originates from 
axons. This is the first direct comparison of vesicular docking within different cellular 
compartments in mature WM. Considering there was no evidence of localised vesicular fusion 
at discrete sites along myelinated axons, vesicular glutamate release must occur underneath 
myelin sheath, elevating glutamate concentrations in the periaxonal space. These findings 
support the existence of an axo-myelin synapse in WM, providing a mechanism by which 
axons can signal to overlaying myelin. This novel synapse could represent an important 
physiological mechanism by which axonal activity regulates a variety of physiological 
functions including AP conduction velocity, myelin structure and/or metabolic support. 
Recent work by Micu et al. (2016) provides evidence that AP conduction induces a 
bafilomycin-a1 sensitive rise in myelinic Ca2+. Although electrical stimulation interfered with 
microelectrode biosensor recordings in my experiments, it would be interesting to test 
whether electrical activity evokes vesicular fusion in myelinated axons in situ. A possible way 
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of achieving this could be via monitoring axonal FM4-64 fluorescence in YFP+ axons following 
electrical stimulation. 
In chapter 4, I monitored [Glut]e under acute ischemic conditions and examined the potential 
mechanisms of ischemic glutamate release. I provide the first direct measurement of resting 
[Glut]e in several WM tracts, demonstrating that physiological concentrations are in the low 
micromolar range. Furthermore, I show that functional glutamate transports maintain low 
[Glut]e in most WM tracts. Following the onset of ischemia, [Glut]e increased within a matter 
of minutes and continued to do so throughout the duration of ischemia (with the exception 
of the adult MON). Pharmacological inhibition of a variety of potential release pathways, 
including glutamate transporters, VRACs, hemi-channels and the glutamate-cystine 
antiporter, failed to significantly reduced the rise in [Glut]e. A number of conditions and 
treatments aimed at preventing vesicular fusion dramatically reduced overall glutamate 
release. In addition, depleting WM tracts of their vesicular glutamate stores significantly 
elevated functional recovery following OGD. Similar to results in chapter 3, ischemia-evoked 
vesicular fusion occurred along the internode of myelinated axons. Together, the findings in 
this chapter provide a novel pathway of ischemia-induced glutamate release in WM. In 
addition, the data also indicates that the axo-myelin synapse may be a significant site of 
excitotoxic WM injury during energy deprivation. 
Following on from my findings in chapter 4, I examined the mechanism of ischemic myelin 
injury in chapter 5. I found that NMDA receptor-mediated injury in myelinated WM mediates 
a large component of irreversible functional injury. Resolving prior controversies, NMDA 
receptor blockade was only protective when antagonists were applied for long pre-treatment 
periods, providing sufficient time to penetrate the myelin sheath. Interestingly, I provide 
evidence that the gating of myelinic NMDA receptors during ischemia promotes myelin 
degradation and decompaction. In contrast, selective inhibitors of TRP-A1 channels did not 
preserve CAP area or prevent structural myelin damage during OGD. Negative modulators of 
NR2C/D-containing NMDA receptors dramatically improved functional recovery, consistent 
with the expression of NR2C and 2D subunits within compact myelin. Finally, I identified a 
highly selective NR2C/D-containing NMDA antagonist (QNZ-46) that also acts as a fluorescent 
myelin stain. QNZ-46 slowly accumulates in myelin over time, prevents myelin decompaction 
and elevates functional recovery following OGD. Interestingly, QNZ-46 is retained in myelin 
260 
 
following wash-out and provides persistent protection following the removal of the drug from 
the extracellular space. QNZ-46 selectively accumulates in myelinated central WM following 
systemic administration, providing direct evidence of BBB penetration and myelin retention. 
In addition, IP injected mice display an elevated injury tolerance during OGD, suggesting that 
QNZ-46 has exceptional clinical potential, not only for those at high risk of stroke, but also for 
a range of neurological disorders which involve myelin damage. 
 
6.2: A novel pathway of ischemic myelin injury 
 
The data presented in this thesis provides evidence of a novel pathway of myelin injury during 
ischemia. I found that vesicular exocytosis contributes to the ischemia-induced rise in [Glut]e. 
While the rise in [Glut]e may originate from unmyelinated axons which are directly exposed 
to the ECS, the data also provides evidence of vesicular fusion along myelinated axons i.e. at 
the axo-myelin synapse. In addition, the results presented in chapter 5 indicate that acute 
myelin injury during ischemia is primarily a result of the over-activation of NR2C/D containing 
NMDA receptors within myelin sheath. Together these findings suggest that ischemia initiates 
an unexpected cascade of events which ultimately leads to myelin disruption and AP failure.  
Under physiological conditions, myelinic NMDA receptors respond to activity-dependant 
vesicular glutamate release from axons. NMDA receptor activation leads to a rise in myelinic 
Ca2+ levels which may regulate a number of essential physiological processes (Fruhbeis, 
Frohlich et al. 2013, Micu, Plemel et al. 2016, Saab, Tzvetavona et al. 2016). [Glut]e is 
maintained in the low micromolar range due to the activity of glutamate transporters. 
However, under ischemic conditions, cellular ATP levels rapidly decline leading to ischemic 
depolarisation throughout WM. An early rise in axonal Ca2+ promotes the excessive fusion of 
glutamatergic vesicles with the internodal axolemma of myelinated (and unmyelinated) axons. 
This rapidly elevates glutamate concentrations in the confined periaxonal space separating 
the axolemma and inner loops of myelin. In turn, the accumulation of periaxonal glutamate 
activates a high density of functional NMDA receptors expressed in the overlaying myelin 
sheath. The over-activation of myelinic NMDA receptors during ischemia promotes the 
decompaction and degradation of myelin, an event which ultimately leads to a failure in 
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saltatory AP conduction. Notably, it is the irreversible loss in nerve excitability which underlies 
a range of functional deficits observed in patients who experience severe ischemia. This 
surprising injury pathway is distinct from the mechanisms which mediate injury to the 
cytoplasmic processes and soma of oligodendrocytes, which likely involve the activation of 
TRP-A1 and non-NMDA receptors, respectively (Tekkok and Goldberg 2001, Hamilton, 
Kolodziejczyk et al. 2016).  
The pathway elucidated here presents myelinic NMDA receptors as an attractive therapeutic 
target in the treatment of ischemic WM injury. The sub-unit selective NMDA receptor 
antagonist, QNZ-46, penetrates myelin and is retained in myelinated WM regions of the CNS 
following systemic injection of the drug. The incorporation of QNZ-46 in central myelin 
selectively inhibits myelinic NMDA receptor activation in a use-dependent manner, which 
prevents the over-activation of NMDA receptors during ischemia. As a result, QNZ-46 







Fig. 6.1: Schematic depiction of the proposed model of ischemic myelin injury. Compact myelin 
contains a high density of functional NR2C/D-containing NMDA receptors which are expressed 
throughout the myelin sheath. The underlying axon contains a number of glutamatergic vesicles. The 
axon and inner loops of myelin are separated by a confined region known as the peri-axonal space. 
Non-NMDA receptors are located on the oligodendrocyte cell soma, while TRP-A1 receptors are found 
on the cytoplasmic domain of the oligodendrocyte processes. (1) Under physiological conditions, 
[Glut]e are kept low. (2) Under ischemic conditions, glutamatergic vesicles fuse with the axolemma, 
releasing glutamate into the confined peri-axonal space. The accumulation of glutamate within the 
peri-axonal space over-activates myelinic NMDA receptors, which leads to myelin injury. (3) Treating 
nerves with QNZ-46 prevents the sustained activation of myelinic NMDA receptors, which 
subsequently prevents the excitotoxic degradation of myelin during ischemia.  
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6.3: Implications of QNZ-46 
 
NMDA receptor-mediated excitotoxity is implicated in a variety of neurological disorders 
including ischemia, Alzehimers’ disease, Parkinsons’ disease, chronic pain and multiple 
sclerosis (MS) (Cull-Candy, Brickley et al. 2001). Myelin-specific NMDA receptors provide a 
novel therapeutic target for a number of neurological disorders which affect myelin. QNZ-46 
in particular, displays a number of desirable characteristics associated with tolerable clinical 
neuroprotective agents. These features include brain accessibility, sub-unit selectivity, 
drugability and use-dependence. Thus, a relative sparing of physiological NMDA receptor 
activation is predicted which may overcome a variety of adverse effects. In addition, myelin 
accumulation and retention provide a suitable mechanism by which QNZ-46 provides 
persistent protect following the removal of the drug from the extracellular space, the first 
known drug to exhibit this unique characteristic. This may prove to be a major development 
in the treatment of chronic neurological disorders, such as neurodegenerative diseases and 
multiple sclerosis (MS). Similarly, it may elevate the injury tolerance of those who are at high 
risk of stroke, or susceptible to recurrent stroke.  
In vivo administration of an effective concentration of QNZ-46 in mice showed no evidence of 
acute adverse effects or behavioural alterations. While further investigations into the 
tolerability of QNZ-46 are required, initial findings suggest that its translational potential is 
exceptional. Considering the complexity of ischemic brain injury, it is unlikely that QNZ-46 
alone will provide a dramatic degree of protection clinically. However, the application of QNZ-
46 in conjunction with alternative pharmacological compounds targeting alternative cellular 
compartments (e.g. AMPA/kainate receptor inhibitors, TRP-A1 channel blockers, NCX 
inhibitors) may prove to be highly protective. QNZ-46 may represent a novel class of 






6.4: Concluding remarks 
 
The overall motivation behind this thesis is to contribute to a better understanding of the 
injury mechanisms involved in irreversible WM damage. The work presented here provides 
evidence of a novel injury pathway which is responsible for ischemic myelin disruption and 
irreversible functional injury. This discovery not only challenges the involvement of reverse 
glutamate transporters, but also raises the question of whether the axonal vesicular release 
injury pathway is also implicated in alternative neurological disorders. In addition, it supports 
recent reports of the axo-myelinic synapse which may play an important role in a number of 
physiological processes in central WM. Results on QNZ-46 provide an exciting new 
opportunity for further experiments into the actions, potential adverse effects and efficacy of 
the drug. Together, these findings will hopefully pave the way for further research and 
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